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SUMMARY 
Infants (<12 months) born to women with tuberculosis are at high risk of 
Mycobacterium tuberculosis (M. tuberculosis) exposure, infection and disease early in 
life. In settings with high prevalence of human immunodeficiency virus (HIV) and 
tuberculosis, tuberculosis disproportionately affects women of childbearing age. The 
aim of this dissertation was to comprehensively investigate prevention and treatment 
strategies for perinatal and infant tuberculosis in a high HIV-prevalence setting. 
Research objectives included: 1) defining clinical and epidemiological aspects of 
maternal-infant tuberculosis at a large referral hospital; 2) identifying barriers and 
solutions to isoniazid preventive therapy (IPT) delivery in tuberculosis-exposed 
newborns; and 3) obtaining rigorous pharmacokinetic data to guide the dosing of first-
line antituberculosis drugs in newborns and infants for the prevention and treatment 
of tuberculosis.  
In the first retrospective study, 70 newborns (42 HIV-exposed) were investigated for 
tuberculosis at Tygerberg Hospital, a large provincial referral hospital in Cape Town. 
Newborns were mainly screened for tuberculosis because of maternal tuberculosis. 
Isoniazid preventive therapy (IPT) was initiated in 36/50 (72%) newborns, because of 
maternal tuberculosis infectious risk and exposure of infants. Few of the newborns 
who received IPT were traceable at one-year, and of those traced, less than half 
completed IPT. 
To generate more rigorous clinical and epidemiological data on maternal-infant 
tuberculosis, a prospective cohort study was conducted in pregnant and postpartum 
women receiving tuberculosis treatment at Tygerberg Hospital. Over a one-year 
period, 74 pregnant and postpartum women, 53 (72%) HIV-infected, were 
consecutively enrolled. Nearly half of the women, 35 (47%) were diagnosed with 
tuberculosis only at delivery or postpartum, and a third of women with tuberculosis 
reported prior tuberculosis treatment. Tuberculosis-exposed newborns were often 
premature and of low birth weight (LBW; <2500 grams). All deaths occurred in HIV-
infected women (n=5) and all stillbirths (n=4) and newborn deaths (n=6) were from 
HIV-infected women. Favourable maternal tuberculosis treatment outcomes (cure and 
tuberculosis treatment completion) were documented only in 41/74 (55%) women, 
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while 33 (45%) had unfavourable treatment outcomes (death, treatment failure and 
loss to follow-up). These poor observed outcomes highlight the need for earlier 
diagnosis and treatment of tuberculosis during pregnancy, and close follow-up to 
ensure maternal tuberculosis treatment completion. Improved care for pregnant 
women with tuberculosis, with and without HIV infection, will likely reduce 
morbidity and mortality in mothers and tuberculosis-exposed newborns. Delayed 
maternal tuberculosis diagnosis led to IPT initiation in a large number of newborns. 
Forty-four newborns on IPT were followed to 6 months. A hospital-based 
tuberculosis linkage to care intervention, led to 29/44 (66%) newborns completing 
IPT without a study team intervention. A further 8 infants completed IPT after study-
team intervention. Appropriate tuberculosis referral and linkage to care from hospital 
to local tuberculosis clinic substantially improved IPT completion among 
tuberculosis-exposed newborns. 
More pharmacokinetic data regarding the appropriate use of antituberculosis drugs are 
required in neonates and infants, who undergo considerable physiological changes in 
the first year of life. An intensive isoniazid (INH) pharmacokinetic study was 
therefore designed and implemented in premature and LBW infants (n=20). 
Relatively high median INH peak concentrations of 5.63 μg/ml were achieved in 
LBW infants (at an INH dose of 10 mg/kg), compared to the adult proposed target 
value of > 3 μg/ml. INH exposures were higher with longer half-lives in smaller 
infants, and among genotypically determined N-acetyltransferase-2 (NAT2) slow 
acetylators, suggesting reduced clearance of INH. This first study of isoniazid use in 
LBW and premature neonates showed that the INH dose in premature and LBW 
infants should probably not exceed 10 mg/kg/day.  
The final study evaluated whether the revised higher 2009 World Health Organization 
(WHO)-recommended paediatric doses for rifampicin (RMP), INH, pyrazinamide 
(PZA) and ethambutol (EMB) achieved adequate drug concentrations in infants, 
compared to current adult pharmacokinetic target concentrations. All 39 infants 
enrolled achieved the minimum proposed adult target peak concentrations of > 3 
μg/ml for INH at a mean dose of 12.8 mg/kg (10.3 - 15.4 mg/kg), and the minimum 
adult target of  > 20 μg/ml for PZA at a mean dose of 33.3 mg/kg (28.5 – 38.5 
mg/kg). RMP administered at mean dose of 15.4 mg/kg (10.1 - 20.5 mg/kg) resulted 
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in very low RMP peak concentrations for both RMP formulations used during the 
study. None of the infants achieved the minimum proposed adult RMP target 
concentration of  > 8 μg/ml. Given the findings of this study, higher doses of RMP in 
infants should be considered especially given emerging data from adult RMP dose-
escalation studies showing better efficacy at higher doses with limited toxicity for 
short-term use. For EMB, only 1 of 16 infants achieved the recommended adult target 
concentration of  > 2 μg/ml when given at a mean dose of 20.2 mg/kg (15.4-24.1 
mg/kg). EMB dose-dependent ocular toxicity however poses a concern regarding the 
recommendation of higher EMB doses in infants where vision testing is challenging. 
This is the largest pharmacokinetic study of first-line antituberculosis drugs 
performed in infants to date, which has generated valuable pharmacokinetic data to 
inform the effective and safe dosing of first-line antituberculosis drugs in infants.  
 
Pregnant women in settings with a high burden of tuberculosis and HIV and their 
infants face a considerable burden of tuberculosis disease in HIV-endemic settings. 
Maternal-infant tuberculosis care can be improved by health systems strengthening 
interventions. Data generated from pharmacokinetic studies of antituberculosis drugs 
in tuberculosis-exposed infants will inform much needed dosing guidelines of first-
line antituberculosis drugs for newborns and infants, who have a high risk of 
tuberculosis and are prone to develop severe forms of tuberculosis. 
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OPSOMMING 
Babas (<12 maande) van vroue met tuberkulose het ’n hoë risiko vir Mikobacterium 
tuberculosis (M. tuberculosis) blootstelling na geboorte, wat kan lei tot infeksie en die 
ontwikkeling van tuberkulose siekte. In gebiede met ’n hoë voorkoms van menslike 
immuungebrek virus (MIV) word vroue van kinderdraende ouderdom tot ’n groot 
mate aangetas deur tuberkulose.  Die doel van hierdie verhandeling was om die 
voorkoming en behandelingstrategieë vir tuberkulose in die perinatale en baba 
tydperk omvattend te ondersoek binne die konteks van ‘n omgewing met ‘n hoë 
voorkoms van MIV. Navorsingsdoelwitte het die volgende ingesluit: 1) die 
definïering van kliniese en epidemiologiese aspekte van tuberkulose in moeders en 
babas by ’n groot verwysingshospitaal, 2) die identifisering van struikelblokke en 
oplossings vir die gebruik van isoniasied voorkomende behandeling in babas met 
blootstelling aan M. tuberculosis; en 3) die verkryging van betroubare 
farmakokinetiese data wat doseringsriglyne kan verskaf vir eerste-linie 
antituberkulose middels vir die voorkoming en behandeling van tuberkulose in 
pasgeborenes en babas.  
In die eerste studie is 70 pasgeborenes (waarvan 42 blootgestel was aan MIV) 
retrospektiewelik ondersoek vir tuberkulose by Tygerberg Hospitaal. Tygerberg 
Hospitaal is ‘n groot provinsiale verwysingshospitaal in Kaapstad.  Pasgeborenes was 
hoofsaaklik vir tuberkulose ondersoek as gevolg van moederlike tuberkulose. Vanweë 
potensiële tuberkulose blootstelling aan pasgeborenes en die risiko dat tuberkulose 
moeders nog aansteeklik was, is isoniasied voorkomende behandeling gegee in 36/50 
(72%) pasgeborenes. Min van die pasgeborenes wat isoniasied voorkomende 
behandeling ontvang het kon opgespoor word na een jaar, en minder as die helfte van 
die babas wat opgespoor is, het isoniasied voorkomende behandeling voltooi. 
’n Prospektiewe kohortstudie is onderneem in swanger en postpartum vroue op 
behandeling vir tuberkulose by Tygerberg Hospitaal. Die doel van hierdie studie was 
om meer omvattende kliniese en epidemiologiese inligting te versamel in moeders 
met tuberkulose en hulle babas. Gedurende die verloop van een jaar is 74 swanger en 
postpartum vroue, 53 (72%) met MIV-infeksie, ingesluit in die studie. Ongeveer die 
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helfte van die vroue, 35 (47%) was eers gediagnoseer met tuberkulose tydens 
verlossing of in die postpartum periode. ’n Derde van vroue met tuberkulose het ’n 
geskiedenis gehad van vorige tuberkulose behandeling. Tuberkulose-blootgestelde 
pasgeborenes was dikwels prematuur en/of gebore met ’n lae geboorte gewig (LGG; 
<2500 gram).  Alle moederlike sterftegevalle het voorgekom in moeders met MIV-
infeksie (n=5) en alle stilgeboortes (n=4) en babasterftes (n=6) was in babas van 
moeders met MIV-infeksie. Gunstige uitkomste van moederlike tuberkulose 
behandeling (genesing en voltooiïng van TB behandeling) was gedokumenteer in 
slegs 41/74 (55%) vroue, terwyl 33 (45%) ongunstige behandelingsuitkomste gehad 
het (sterfte, onsuksesvolle behandeling en verlore tydens opvolg).  Hierdie ongunstige 
uitkomste beklemtoon die behoefte aan ‘n vroeër diagnose en behandeling van 
tuberkulose tydens swangerskap, asook noukeurige opvolg gedurende tuberkulose 
behandeling ten einde voltooiïng te verseker. Verbeterde sorg vir swanger vroue met 
tuberkulose, ongeag van MIV-infeksie, behoort die morbiditeit en mortaliteit in 
moeders en hulle tuberkulose-blootgestelde pasgeborenes te verminder. Die laat 
diagnose van moederlike tuberkulose tydens swangerskap het daartoe aanleiding 
gegee dat ‘n groot aantal pasgeborenes isoniasied voorkomende behandeling benodig 
het.  Vier-en-veertig pasgeborens wat isoniasied voorkomende behandeling ontvang 
het, is vir ‘n tydperk van 6 maande opgevolg. ’n Hospitaal-gebaseerde strategie wat 
die koppeling van hospitaal na plaaslike TB klinieke ingesluit het, het aanleiding 
gegee tot die voltooiïng van isoniasied voorkomende behandeling in 29/44 (66%) 
pasgeborenes. Hierdie voltooiïng van isoniasied voorkomende behandeling is 
bewerkstellig sonder die ingryping van die studiespan. Na ingryping deur die 
studiespan het ‘n verdere 8 pasgeborenes isoniasied voorkomende behandeling 
voltooi. Toepaslike tuberkulose verwysing, wat die koppeling vanaf hospitaal na 
plaaslike TB klinieke verbeter het, het ‘n beduidende bydrae gelewer tot die 
voltooiïng van isoniasied voorkomende behandeling in pasgeborenes blootgestel aan 
M. tuberculosis.   
Verdere farmakokinetiese inligting word benodig vir effektiewe antituberkulose 
behandeling in pasgeborenes en babas wat aansienlike fisiologiese veranderinge in die 
eerste lewensjaar ondergaan. ’n Intensiewe isoniasied (INH) farmakokinetiese studie 
is beplan en uitgevoer in premature en LGG babas (n=20). LGG babas wat ‘n dosis 
van 10 mg/kg INH ontvang het, het relatiewe hoë mediane INH piek konsentrasies 
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van 5.63 μg/ml bereik, in vergelyking met die die voorgestelde teiken waarde vir 
volwassenes van > 3 μg/ml. INH konsentrasies was hoër met ‘n langer half-leeftyd in 
kleiner babas, asook in genotipies-vasgestelde N-asetieltransferase-2 (NAT-2) stadige 
asetileerders, wat daarop aandui dat daar verminderde INH opruiming was. Hierdie 
eerste studie van isoniasied in LGG en premature pasgeborenes het aangedui dat die 
dosering van INH na alle waarskynlikheid nie 10 mg/kg/dag behoort te oorskry nie. 
Die finale studie het die gewysigde hoër 2009 Wêreld Gesondheidsheidsorganisasie 
(WGO)-aanbevole pediatriese doserings vir rifampisien (RMP), INH, pirasinamied 
(PZA) en etambutol (EMB) ondersoek, om te bevestig of voldoende 
geneesmiddelkonsentrasies in babas bereik word, in vergelyking met die huidige 
teikenkonsentrasies in volwassenes. Al 39 babas op die studie het die minimum 
voorgestelde volwasse teikenkonsentrasies van > 3 μg/ml vir INH bereik met die 
toediening van ‘n gemiddelde dosering van 12.8 mg/kg (10.3 - 15.4 mg/kg), en die 
minimum volwasse teikenkonsentrasie van > 20 μg/ml vir PZA met die toediening 
van ‘n gemidddelde dosering van 33.3 mg/kg (28.5 - 38.5 mg/kg).  Rifampisien was 
toegedien teen ’n gemiddelde dosering van 15.4 mg/kg (10.1 - 20.5 mg/kg) en het 
baie lae RMP-konsentrasies tot gevolg gehad vir beide RMP formulerings wat in die 
studie gebruik is. Die voorgestelde volwasse RMP teikenkonsentrasie van > 8μg/ml is 
nie waargeneem in enige van die babas nie. Gegewe die bevindinge van hierdie studie 
behoort hoër doserings van RMP in babas oorweeg te word. Hoër RMP doserings is 
veral noodsaaklik in die lig van onlangse studies in volwassenes waar dit meer 
doeltreffend blyk te wees, en ook ‘n beperkte toksisiteit getoon het met korttermyn 
toediening. Vir EMB het slegs 1 uit 16 babas die vereiste aanbeveelde volwasse 
teiken konsentrasie van > 2 μg/ml bereik, met ‘n gemiddelde EMB toediening van 
20.2 mg/kg (15.4 - 24.1 mg/kg). ‘n Dosis-afhanklike risiko vir oog-toksisiteit met 
EMB is  rede tot kommer ingevolge die gebruik van hoër EMB dosisse in babas, 
aangesien die bepaling van sig moeilik is in babas. Hierdie is die grootste 
farmakokinetiese studie van eerste-linie antituberkulose geneesmiddels wat al in 
babas uitgevoer is en het waardevolle farmakokinetiese inligting verskaf wat bydra tot 
die effektiewe en veilige doserings van hierdie geneesmiddels in babas. 
Swanger vrouens, asook hulle babas, is baie vatbaar vir blootstelling aan M. 
tuberculosis infeksie en die ontwikkeling van tuberkulose in gebiede met ‘n hoë 
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voorkoms van tuberkulose en HIV. Die sorg van moeders en babas met tuberkulose  
kan verbeter word deur die versterking van bestaande gesondheidssisteem strukture. 
Inligting verskaf van farmakokinetika studies in eerste-linie antituberkulose 
geneesmiddels wat in pasgeborenes en babas met tuberkulose gedoen word, sal help 
om die nodige doseringsriglyne te verskaf vir babas, wat n hoë risiko het vir die 
ontwikkeling van tuberkulose, insluitende ernstige vorms van tuberkulose. 
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CHAPTER 1 
INTRODUCTION 
Epidemiology of tuberculosis and human immunodeficiency virus  
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium 
tuberculosis  (M. tuberculosis) and typically affects the lungs (pulmonary TB), but 
can affect any other site in the body (extrapulmonary TB). Of the 2-3 billion people 
globally estimated to be infected with M. tuberculosis, only a small proportion (5-
10%) will develop TB disease during their lifetime (1). TB and human 
immunodeficiency virus (HIV) control however remains a global challenge, 
especially in sub-Saharan Africa (2). HIV-infected individuals are at higher risk of 
developing TB disease (3). In 2014, the World Health Organization (WHO) estimated 
there to be 9.6 million new TB cases (3.2 million in women and 1 million in children) 
worldwide, of which 1.2 million (12%) were HIV-infected (1). Twenty-eight percent 
of the world’s TB cases were located in the African region in 2014 (1). During this 
period, the notification rate of TB in South Africa was 834 per 100 000 population 
and 61% of all TB cases were HIV-infected (1).  
Impact of TB/HIV on women of reproductive age 
TB and HIV among pregnant women is of great concern. Both TB and HIV 
disproportionately affect young adults (20-39 years), including women of 
childbearing age (4, 5). Women of reproductive age experience TB rates 1.5-2 times 
higher than men of the same age group in settings with high HIV prevalence (6). As 
most countries do not report the pregnancy status of female TB cases, it is unclear 
how many women with TB are pregnant. Sugarman et al. estimated that there were 
216 500 TB cases in pregnant women worldwide in 2011, of which the African region 
(89 400 cases; 41%) had the largest number (7). This number may be an 
underestimation of the true burden. The diagnosis of TB during pregnancy can be 
challenging, partly due to the non-specific nature of early TB symptoms in pregnancy 
(8) and lack of routine TB screening in pregnancy. Traditional symptom-based 
screening for TB does not perform well in HIV-infected pregnant women, with two 
recent studies reporting a sensitivity of between 28-54.5%, and a specificity of 84-
90.9% in this population (9, 10). HIV-infected women however, are at dramatically 
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increased risk of TB with reported TB prevalence during pregnancy ranging from 1-
11%, compared to the 0.06-0.53% documented in HIV-uninfected pregnant women 
(11). Two studies from Soweto, South Africa, indicated a high burden of TB amongst 
HIV-infected pregnant and postpartum women. The first, conducted amongst post-
partum HIV-infected South African women prior to the roll-out of combination 
antiretroviral therapy (cART), reported that 11% of HIV-infected women with a 
positive tuberculin skin test (TST) also had undiagnosed TB disease (12). The second 
study, conducted within the context of the routine Prevention of Mother to Child HIV 
Transmission (PMTCT) programme, showed that 2.16% (2 160 per 100 000 
population) of HIV-infected pregnant women had TB disease, identified through 
simple symptom-based TB screening (13). In the Western Cape province, South 
Africa, the peak TB notification rate amongst young adults (25-45 years) exceeded 1 
400 per 100 000 population in 2009 (14). At this time the antenatal HIV prevalence 
was 16.9% in women attending public antenatal clinics (15). However, the true 
burden of TB disease during pregnancy, and the attributable effect of HIV infection, 
remains undefined. 
Maternal and infant mortality related to TB/HIV 
TB/HIV co-infection poses a serious threat to women and their offspring. A 2.5 to 7-
fold increase in maternal mortality has been reported in TB/HIV co-infected mothers 
(16-18). With the emergence of the HIV epidemic in South Africa, a dramatic 
increase in the caseload of TB in pregnant women was observed in Durban during 
1996-1998, prior to the national roll-out of cART (19). TB became a leading cause of 
maternal mortality during this period, with rates of up to 323.3 per 100 000 deaths 
reported in HIV-infected pregnant women, compared to 148.6 per 100 000 live births 
in HIV-uninfected pregnant women (20). Since then, antiretroviral therapy (ART) 
uptake in HIV-infected pregnant women in South Africa has increased to 83%, as 
documented by a study conducted among 9803 HIV-infected pregnant women at 580 
nationally representative public health facilities in 2010 (21). However, non-
pregnancy related infections (mainly deaths in HIV-infected women complicated by 
TB and pneumonia) were still the single most common cause of maternal mortality 
between 2011-2013 in South Africa, and accounted for more than 35% of all South 
African maternal deaths (22). Adverse pregnancy outcomes for women with TB/HIV 
also include an increased risk of infant mortality, i.e. deaths in children less than one 
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year of age. A study from Pune, India, reported an almost 4-fold increase in infant 
mortality in the presence of maternal HIV-associated TB.  Women with incident TB 
and their infants had an adjusted 2.2- and 3.4-fold increased probability of death, 
respectively, compared to women-infant pairs without TB (23). Furthermore, between 
2003 to 2005 with limited cART availability, a mortality of 24% was observed in 
infants less than 3 months of age with culture-confirmed TB, with or without HIV in 
Cape Town, South Africa (24). 
Epidemiology of perinatal TB 
Congenital TB, a rare disease entity, occurs when M. tuberculosis is transmitted to the 
newborn, either haematogenously (in utero) from the mother to the foetus, or during 
the birth process, through ingestion/aspiration of infected amniotic fluid. Postnatal 
TB, which is more common, is acquired during the first weeks of life, mainly by 
inhalation of airborne TB bacilli from the mother or close contact with another 
infectious TB source case. Because of the difficulty in clinically distinguishing 
between true congenital TB and postnatal transmission, it has been proposed to 
combine these two disease entities, using the term “perinatal TB“ (25-27). In 
summary, perinatal TB manifests when M. tuberculosis is transmitted to a foetus or 
newborn infant early in life (27) and is extremely rare if the mother is effectively 
treated for TB during pregnancy (25). The burden of perinatal TB in South Africa is 
not well documented, however a 16% incidence of vertical TB transmission to infants 
was reported in a study of 82 HIV-infected and 25 non-infected pregnant mothers at a 
tertiary hospital in KwaZulu-Natal, South Africa (1997-1999), prior to the availability 
of PMTCT or cART in HIV-infected pregnant women (28). At Tygerberg Hospital 
(TBH) in the Western Cape province, routine surveillance data on all cases of culture-
confirmed childhood TB (<13 years of age) from March 2003 - February 2009, post 
cART rollout for HIV-infected pregnant women, found that 72 (8%) of 905 of 
culture-confirmed paediatric TB cases were younger than 3 months of age at 
diagnosis; at least 12 (1.3%) of these infants had confirmed congenital TB (27).  
TB/HIV related morbidity in neonates 
The increased frequency of prematurity (gestational age <37 weeks) and low birth 
weight (LBW; < 2500g) amongst infants contribute to the poor observed outcome of 
neonates born to mothers with TB, irrespective of maternal and infant HIV co-
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infection. Women with TB are twice as likely to have a premature and/or LBW infant 
(29). In a study from Tanzania, TB was associated with LBW amongst infants, and 
HIV-infected women were twice as likely to give birth to LBW infants compared to 
HIV-uninfected women (30). Maternal TB in HIV-infected women is also a risk 
factor for vertical HIV transmission. Gupta et al. have shown that infants born to 
HIV-infected mothers with TB had a 2.51-fold (95% CI, 1.05-6.02; p=0.04) increased 
adjusted odds of acquiring HIV infection compared to infants born to HIV-infected 
mothers without TB (31).  
Impact of maternal TB/HIV on infants 
Infants born to women living in high-burden TB and HIV settings are at high risk of 
exposure to M. tuberculosis and infection early in life, with a high subsequent risk of 
TB disease progression (Figure 1). In the absence of appropriate preventive therapy, 
up to 50% of infants infected with M. tuberculosis will develop disease, of which 
30% will develop progressive pulmonary or disseminated disease (32). In the Western 
Cape province, South Africa, more than 10% of infants born to HIV-infected women 
already had reported contact with a TB source case by 3-4 months of age in a trial 
which investigated the efficacy of isoniazid versus placebo in HIV-exposed and 
infected infants (33). Furthermore, a South African population-based study found that 
HIV-infected infants were 24-fold more likely to be diagnosed with culture-confirmed 
TB than their HIV-uninfected counterparts in the absence of cART access (34). These 
findings not only emphasize the high risk of M. tuberculosis exposure and disease 
progression early in life in TB/HIV endemic settings, but also the importance of TB 
preventive and curative therapy for the infected and diseased neonate and infant. 
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Figure 1. adapted from Don Enarson, The Union 
TB prevention through chemotherapy 
Post-exposure isoniazid preventive therapy (IPT) taken for 6-9 months has been 
shown to reduce the risk of progression to TB disease by 60-65% (35-37). Even 
though no benefit has been demonstrated for primary (pre-exposure) IPT against TB 
in HIV-exposed and infected children (38), six months of daily isoniazid (INH) 
remains the most widely accepted agent for post-exposure TB preventive therapy in 
children and is recommended by WHO (39). The delivery of post-exposure IPT in 
children is however, not prioritized by TB control programmes in countries with high 
burden of TB (40). Despite the WHO recommendation for contact investigation and 
treatment of M. tuberculosis exposure/infection in children < 5 years in countries with 
a high TB-burden (41), many countries including South Africa (42) face operational 
challenges in IPT implementation for young children (43-45). Studies in low- and 
middle-income settings have reported low but variable uptake of IPT among young 
child contacts. A clinic in Timor-Leste documented 18% IPT uptake (46), evidence 
from South India ranged from 19-33% in child contacts (47, 48), and in West Java, 
Indonesia, an IPT uptake of 50% have been reported (49). From the Western Cape, 
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South Africa, figures ranging from 5 – 40 % have been reported for unsupervised 
daily INH monotherapy in child contacts < 5 years of age (44, 45, 50, 51). Improved 
delivery of IPT should be prioritized in TB-exposed infants who have a high risk of 
disease progression and who are prone to develop serious forms of TB disease. Early 
recognition of infants requiring IPT, and optimal chemotherapeutic treatment are both 
essential for improved outcomes. There are limited data on the pharmacokinetic 
characteristics and safety profile of INH and other TB drugs in neonates and infants. 
Although IPT is the preferred choice of preventive therapy in TB-exposed newborns, 
current WHO and South African National TB programme (SANTP) dosing guidelines 
for INH are based on limited evidence in very young children. To our knowledge, 
only one newborn study has been published on elimination kinetics of INH, with data 
from only in two newborns, reporting an increased half-life of 19 hours in one infant, 
suggesting a reduced elimination rate of INH (52). No studies have focused on LBW 
infants, who are specifically relevant in the context of maternal TB/HIV co-infection. 
Therapeutic considerations of TB in neonates and infants 
INH, rifampicin (RMP) and pyrazinamide (PZA) with or without ethambutol (EMB), 
form the mainstay of treatment of drug-susceptible TB in children, which represents 
more than 90% of paediatric TB cases globally. First-line antituberculosis drugs are 
routinely recommended in children and infants with TB disease (39, 53). To ensure 
optimal curative treatment in infants, a sound understanding of the pharmacokinetic 
properties of the currently used antituberculosis drugs is required. Evidence on the 
optimal paediatric dosage and chemotherapeutic treatment for efficacy and safety in 
this group of children however remains lacking. Efficacy studies for antituberculosis 
drugs were traditionally performed in healthy adult volunteers and/or adults with TB 
disease where treatment response could be measured and bacteriological load 
documented. Treatment response indicators, i.e. reduction of bacterial load in sputum 
and/or culture negativity, have been used in adults typically with a high bacillary load 
to establish “adequate” pharmacokinetic target concentrations for antituberculosis 
drugs. These values were then extrapolated to children, where the frequently 
paucibacillary nature of paediatric TB, prohibited bacteriological, and thus 
pharmacodynamic monitoring. Furthermore, the optimal use and efficacy of first-line 
antituberculosis drugs may require further investigation, with existing data suggesting 
greater pharmacokinetic variability with INH and RMP than previously thought, and 
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efficacy that may be poorer than traditionally reported (54). Higher RMP dosing 
strategies (35 mg/kg/day for two weeks) in adults have achieved an up to ten-fold 
higher average plasma exposure with a greater estimated fall in bacterial load (55). 
These high RMP doses were safe and well tolerated for the given study duration, and 
had the objective to establish the maximal tolerable RMP dose in terms of safety and 
tolerability (55). It remains unclear what the  “adequate” pharmacokinetic 
antituberculosis drug target concentrations for adults and children with TB disease 
should be. The optimal dose required dose for infants requires further research.  
Unique developmental and physiological changes may influence the absorption, 
metabolism and excretion of specific drugs in young children (56), making it essential 
to characterize the pharmacokinetic profile of antituberculosis drugs in infants. 
Enzyme maturation, drug-drug interaction and increased drug clearance for body 
weight are all important factors determining drug exposure in young children (57). 
Limited pharmacokinetic data in young children is available for the first-line 
antituberculosis drugs. Furthermore, in 2009 the WHO recommended higher doses of 
first-line antituberculosis drugs for children (58).  
WHO antituberculosis dosing guidelines for children, 2006 versus 2009 (58) 
Drugs 2006 
mg/kg 
2009 
mg/kg 
Increase 
Isoniazid 5 (4-6) 10 (7-15)     100% 
Rifampicin 10 (8-12) 15 (10-20)    50% 
Pyrazinamide 25 (20-30) 35 (30-40)    40% 
These WHO recommendations are based on evidence from pharmacokinetic studies 
involving mainly older children, which showed that higher mg/kg dosing was 
necessary to achieve target adult drug concentrations, which were thought to be 
correlated with cure in adults. Few pharmacokinetic studies of TB drugs at the new 
recommended WHO doses have been performed in children < 2 years of age (59, 60) 
and none specifically in infants (< 12 months of age). Of the 20 children included in 
the study performed by Thee et al. amongst South African young children, only two 
children were < 3 months of age (personal communication: S Thee). The therapeutic 
and safety profiles of antituberculosis drugs given at these higher doses, therefore 
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currently remain largely unknown in both neonates (< 28 days of age) and infants. It 
is essential to obtain information regarding appropriate and safe dosing of 
antituberculosis drugs in this vulnerable paediatric group, where an adequate 
scientific knowledge base is necessary to guide dosing of TB regimens, and ultimately 
prevent and treat perinatal and infant TB.   
Purpose and scope of research 
Comprehensively characterizing the clinical burden and epidemiological features of 
maternal and infant TB, including outcomes, will inform prevention and treatment 
modalities for infants in the context of maternal HIV infection. This includes targeted 
delivery of post-exposure IPT in infants and investigating optimal methods for the 
programmatic implementation of IPT. Knowledge gained from comprehensively 
studying the epidemiological aspects of maternal-infant TB sets the scene against 
which the study of pharmacokinetic properties of antituberculosis drugs in infants 
becomes possible and relevant. Effective and safe antituberculosis drug therapy is 
important in the prevention and treatment of TB in neonates and infants. 
Representative pharmacokinetic data on INH, and other first-line antituberculosis 
drugs in neonates and infants, will be generated from rigorously designed intensive 
pharmacokinetic sampling studies. Together, this research will contribute 
significantly to our scientific understanding of maternal and infant TB in the context 
of HIV, with the ultimate aim of improved prevention and treatment of TB in infants. 
Overall objective 
In my thesis I comprehensively investigate strategies to prevent and treat perinatal 
and infant TB in the context of maternal HIV infection. 
Hypotheses 
The following complementary hypotheses were proposed to investigate strategies to 
control maternal and infant TB in the context of HIV. These hypotheses were tested in 
four studies, and each one is discussed in detail in the five relevant chapters: 
 Study 1: H1:  There is a considerable burden of maternal TB and TB-exposed
infants related to maternal HIV infection in a tertiary care setting in Cape
Town, South Africa.
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 Study 2: H2: The TB disease presentation and outcome in the HIV-infected
mother and its consequences for her infant differs from that observed in HIV-
uninfected mothers and their infants.
 Study 2: H3: The completion of IPT and curative TB treatment in TB-exposed
neonates is dependent on health system, socio-economic and maternal
determinants.
 Study 3: H4: The current WHO-recommended dose of INH of 10 mg/kg/day
achieves INH concentrations in TB-exposed neonates comparable to those
recommended for adults.
 Study 4: H5: The current dosing recommendations for first-line
antituberculosis drugs in the paediatric population achieve drug concentrations
in infants comparable to current recommended adult target values.
As part of the introductory chapters to the above studies, chapter 2.1 describes the 
burden, pathogenesis and clinical presentation of TB in neonates and infants. Chapter 
2.2 addresses the current knowledge on pharmacokinetic considerations for the use of 
first-line antituberculosis drugs in infants. In chapters 3-7, each of the above studies is 
presented as an introduction and key findings followed by published manuscripts. 
Chapter 8 summarizes the conclusions and future considerations. 
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CHAPTER 2.1 
MATERNAL AND INFANT TUBERCULOSIS: DISEASE BURDEN, 
PATHOGENESIS AND CLINICAL PRESENTATION 
Early tuberculosis (TB) diagnosis and effective treatment are of critical importance in 
pregnant women with TB, irrespective of maternal HIV status. The successful 
management of TB disease in pregnant women can prevent transmission of M. 
tuberculosis to the foetus and newborn, and improve outcomes for this population. 
Women of reproductive age are at high risk of developing TB in pregnancy in high-
burden TB and HIV settings (2, 28). HIV infection is also an important risk factor for 
progression from latent TB infection to TB disease (61). The improved availability 
and uptake of combination antiretroviral treatment (cART) may contribute towards 
reduced TB disease progression in HIV co-infected individuals (62), however the 
morbidity and mortality associated with both of these conditions in pregnant women 
and their infants remains high. A better understanding of the pathogenesis and clinical 
presentation of maternal-infant TB, with or without HIV infection, will assist in 
improved TB control for women and infants affected by TB. 
In the following section, different aspects of TB during pregnancy are addressed, 
including risk factors for developing TB disease. I briefly describe the role of the 
tuberculin skin test and the commercial interferon-gamma release assays in 
pregnancy, and the traditional symptom-based TB screening tool during pregnancy in 
HIV-infected women (9). TB diagnosis during pregnancy can be improved by 
obtaining a directed history, thorough clinical examination, with or without shielded 
chest radiology, and appropriate special investigations. Unfortunately, TB diagnosis 
remains difficult in pregnancy and is often delayed until the postpartum period. 
Findings from a recent large United Kingdom cohort showed that women in the early 
postpartum period were twice as likely to develop TB than non-pregnant women (63). 
All of these factors contribute to high TB exposure in newborns from TB and HIV 
endemic settings, with untreated maternal TB posing a significant infectious risk to 
the foetus and newborn.  
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Transmission modes for perinatal TB, from the antepartum period through the 
postpartum period, are discussed. I refer to how primary- and disseminated maternal 
TB is more likely to be associated with congenital TB, compared to pulmonary 
maternal TB that is more likely associated with postnatal TB acquisition. A clinical 
approach to the TB-exposed newborn, which is based both on the infectious risk 
posed by the mother with TB, and the “wellness” of the newborn is provided. A flow 
diagram illustrates the appropriate TB investigations to be performed in “well and 
high-risk” and “unwell” TB-exposed newborns, and includes prevention and 
treatment guidelines, as well as a specific management follow-up plan for the TB-
exposed newborn. As the symptoms and signs of early presentation of TB in infancy 
versus late presentation of TB in infancy often overlap, a detailed clinical and 
radiological overview is provided to highlight specific features of each. The last 
section of the chapter refers to the use of antituberculosis drugs in pregnancy and 
infants, and includes a section on infection control measures applicable to congregate 
neonatal settings, such as “kangaroo” care facilities. 
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HIGHLIGHTS OF THIS CHAPTER
•	Any	unwell	tuberculosis-exposed	infant,	regardless	of	the	mother’s	infectious	status,	needs	urgent	
evaluation	for	tuberculosis	disease.
•	Treatment	initiation	is	urgent	in	any	infant	with	tuberculosis.	If	an	infant	is	symptomatic,	start	
treatment	as	soon	as	appropriate	specimens	have	been	obtained	for	culture	and	determination	of
drug-susceptibility.
•	If	at	all	possible,	an	infant	with	tuberculosis	should	remain	in	close	contact	with	the	mother	and	every	
effort	made	to	enable	her	to	continue	breastfeeding.
•	Remain	vigilant	for	drug	toxicity	in	the	very	young	infant	where	enzyme	immaturity	and	varying	
body	constitution	may	affect	antituberculosis	and	antiretroviral	drug	exposure	and	toxicity.
•	Undiagnosed	infectious	tuberculosis	may	occur	in	any	health	facility,	but	it	is	particularly	dangerous	
in	congregate	neonatal	settings	such	as	“kangaroo”	care	units;	continual	vigilance	for	symptoms	and	
signs	of	tuberculosis	in	patients	and	staff	is	essential.
TUBERCULOSIS	IS	a	global	health	problem	and	
adversely	 affects	 both	 pregnant	 women	 and	 their	
offspring.	In	2013,	the	World	Health	Organization	
(WHO)	 estimated	 there	 were	 3.3  million	
new	 cases	 of	 tuberculosis	 in	 women,	 result-
ing	 in	 510,000	 deaths,	 of	 which	 180,000	 (35%)	
were	 in	 HIV-infected	 women.1	 Non-obstetric	
infection-related	 deaths,	 including	 tuberculosis,	
now	account	for	28%	of	maternal	deaths	worldwide.2	
Tuberculosis	in	pregnancy	is	associated	with	unfa-
vorable	 perinatal	 and	 infant	 outcomes.	 Increases	
in	 pre-eclampsia	 and	 vaginal	 bleeding	 have	 been	
observed,	 as	 well	 as	 a	 twofold	 risk	 of	 delivering	
premature	 and	 low	birthweight	 infants,	 and	 a	 six-
fold	increase	in	perinatal	infant	deaths.3,4	Table	13.1	
refers	to	definitions	for	maternal-infant	tuberculosis	
used	in	this	chapter.	Tuberculosis	 in	pregnant	and	
post-partum	 women,	 especially	 if	 untreated,	 can	
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result	 in	 transmission	 of	Mycobacterium tuberculo-
sis	to	the	fetus	and	newborn	(Figure	13.1).	In utero	
transmission,	 hematogenously	 via	 the	 placenta	 or	
aspiration,	 or	 ingestion	 of	 infected	 amniotic	 fluid	
before	or	during	birth,	results	in	congenital	tubercu-
losis;	respiratory	droplet	spread	from	an	infectious	
source	case,	usually	 the	mother,	 after	birth	 results	
in	 postnatal	 tuberculosis.	 Perinatal tuberculosis	 is	
the	preferred	term,	combining	the	entities	of	con-
genital	 (ante-	 and	 intra-partum	 transmission)	 and	
postnatal	(post-partum	transmission)	tuberculosis.
Tuberculosis	disease	progression	is	highest	in	the	
first	 year	 following	 infection,	 affecting	 particularly	
the	very	young,	when	immune	immaturity	is	present.	
Without	appropriate	treatment,	up	to	50%	of	infected	
infants	 will	 develop	 tuberculosis	 disease,	 30%	 of	
whom	will	 have	progressive	pulmonary	or	 dissemi-
nated	disease.5	In	Pune,	India,	a	fourfold	increase	in	
mortality	was	reported	among	infants	with	maternal	
HIV-associated	 tuberculosis,6	 while	 among	 South	
African	infants,	a	24%	mortality	was	observed	in	those	
aged	less	than	three	months	with	culture-confirmed	
tuberculosis.7	 The	 outcome	 of	 isolated	 pulmonary	
tuberculosis	 can	 be	 good	 in	 the	 young,	 however,	 if	
treatment	is	initiated	early.8	Increased	awareness	and	
early	 diagnosis	 and	 treatment	 are	 vital	 to	 improve	
outcomes	of	tuberculosis	in	infants.
A	high	index	of	suspicion	by	health	care	provid-
ers	 for	 tuberculosis	 in	pregnancy	 and	post-partum	
is	 imperative	 in	 order	 to	 identify	 and	 treat	 the	
disease	 early.	 Appropriate	 assessment	 of	 the	
tuberculosis-exposed	newborn	 is	 essential,	 consid-
ering	the	high	risk	of	progression	to	disease	follow-
ing	 infection.	 Signs	 and	 symptoms	 of	 tuberculosis	
in	the	newborn	and	infant	must	be	recognized	early	
and	 acted	upon	 rapidly.	 In	 infants,	 the	 time	 elaps-
ing	between	infection	and	disease	can	be	of	shorter	
duration	and	disease	presentation	more	acute	than	
in	 older	 children.	Optimal	 treatment	 in	 newborns	
and	 infants	 is	 essential	 for	 improved	outcomes.	 In	
high-burden	 tuberculosis/HIV	 settings,	 HIV	 test-
ing	should	be	offered	to	all	persons	with	suspected	
tuberculosis,	 including	 mothers	 and	 infants,	 and	
combination	antiretroviral	therapy	(ART)	initiated	
if	 indicated.	 Integrated	maternal	 and	 infant	 tuber-
culosis	care	strategies	are	key	to	control	this	disease	
and	 improve	 overall	 outcomes	 in	 these	 vulnerable	
populations.
TUBERCULOSIS IN PREGNANCY
The	 global	 burden	 of	 tuberculosis	 disease	 among	
pregnant	 women	 remains	 undefined,	 but	 216,500	
cases	 of	 tuberculosis	 were	 estimated	 world-
wide	 in	 2011.9	 Although	 relatively	 rare,	 a	 resur-
gence	 of	 tuberculosis	 in	 pregnancy	 has	 occurred	
as	 a	 result	 of	 the	 start	 of	 the	 HIV	 epidemic,	 the	
increase	 in	 drug-resistant	 tuberculosis,	 changes	 in	
socio-economic	 conditions,	 and	 increased	 migra-
tion.	data	from	selected	populations	show	a	preva-
lence	 of	 tuberculosis	 in	 pregnant	 women	 ranging	
from	 0.06–0.53%	 in	 HIV-uninfected	 women	 to	
1–11%	in	HIV-infected	women.10
Potential	 risk	 factors	 for	 developing	 tuberculo-
sis	 in	pregnancy	 include	HIV	 infection,	prior	close	
contact	with	a	case	of	contagious	 tuberculosis,	and	
a	 past	 history	 of	 tuberculosis.	A high	 index	 of	 sus-
picion	 for	 tuberculosis	 in	pregnancy	 is	also	needed	
for	 individuals	 emigrating	 from	 endemic	 regions	
to	 the	 developed	world.	 Current	WHO	 guidelines	
for	 tuberculosis	 infection-screening	 differ	 between	
tuberculosis	low-	and	high-burden	countries.	In	areas	
of	low	prevalence,	screening,	which	includes	a	tuber-
culin	 skin	 test	 (TST)	 or	 interferon-gamma-release	
assay	(IGRA),	is	recommended	for	high-risk	individ-
uals	only,	followed	by	treatment	of	infected	individu-
als	 after	 tuberculosis	 disease	 has	 been	 excluded.11	
In	 high-burden	 settings,	 routine	 screening	 is	 not	
During pregnancy At delivery After birth
Inhalation of
infected respiratory
droplets
Aspiration/ingestion
of infected amniotic
fluid or genital
secretions
Antepartum Intrapartum Postpartum
Haematogenous
via placenta and
umbilical vein
or aspiration/ingestion
of infected amniotic
fluid
FIGURE 13.1	 Transmission	modes	for	perinatal	tuberculosis.
13
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
1Tuberculosis in Neonates and Infants  •  233
recommended,	with	 the	 exception	of	HIV-infected	
individuals	 and	 children	below	5  years	 of	 age	with	
a	 known	 contact.11	 divergent	 results	 have	 been	
reported	 for	 the	 TST,	 with	 earlier	 studies	 suggest-
ing	diminished	tuberculin	sensitivity	in	pregnancy,12	
while	more	recent	studies	showed	no	difference.13,14	
In	 an	 Indian	 study	performed	 in	pregnant	women,	
an	 IGRA	resulted	 in	more	positive	 results	 than	 the	
TST;	of	the	401	women	included,	150	(37%)	had	a	
positive	IGRA,	compared	to	59	(14%)	positive	TST	
results	(p	<	0.005)	among	a	background	prevalence	
of	 tuberculosis	 infection	of	35–40%	 in	 the	popula-
tion.15	A potential	decrease	in	the	sensitivity	of	both	
TST	and	the	IGRAs	during	pregnancy	is	postulated	
to	 be	 caused	 by	 increasing	 levels	 of	 progesterone,	
favoring	a	Th2-type	immune	response,	and	suppress-
ing	the	cell-mediated	Th1	immune	response,	which	
must	be	intact	for	both	the	TST	and	the	IGRA	assays	
to	function	properly.16
Increased	awareness	for	diagnosing	tuberculosis	
in	pregnancy	is	required	during	the	ante-,	intra-,	and	
post-partum	 period,	 as	 symptoms	 are	 often	 vague	
and	 nonspecific.	 The	 recommended	 tuberculosis	
symptom-screening	tool	(cough,	fever,	night	sweats,	
and	weight	loss)	does	not	perform	well	in	pregnancy	
as	 poor	 weight	 gain	 is	 an	 unreliable	 predictor	 for	
the	disease	in	pregnant	women.	Confounding	mat-
ters	further	is	the	fact	that	additional	symptoms	of	
Table 13.1. Definitions for maternal-infant tuberculosis used in this chapter
Neonate	or	newborn First	28 days	of	life
Prematurity Born	at	less	than	37	weeks’	gestational	age
Low	birth	weight Birth	weight	of	less	than	2500	grams
Infant Less	than	12 months
Congenital	tuberculosis Newborn	presenting	with	tuberculosis	disease	at	birth	or	shortly	
thereafter.	Tuberculosis	infection	took	place	in utero	or	during	birth
Postnatal	tuberculosis Infection	occurs	post-partum	and	disease	presents	shortly	after	birth
Perinatal	tuberculosis Combined	congenital	and	postnatal	tuberculosis
Perinatal	period Period	around	birth	(5 months	before	and	1 month	after)
Close	contact Someone	sharing	an	enclosed	space	with	the	index	case	for	extended	
daily	periods*
Tuberculosis-exposed			
newborn
A	newborn	in	close	contact	with	someone	with	infectious	
tuberculosis,	normally	the	mother	or	another	caregiver
Tuberculosis	screening A	systematic	process	to	establish	the	diagnosis	or	its	exclusion	in	
someone	with	clinical	signs	and	symptoms	suggestive	of	tuberculosis	
disease
Tuberculosis	infection No	symptoms	or	signs	of	tuberculosis,	but	the	person	is	infected	
with	tubercle	bacilli,	following	exposure
Tuberculosis	disease Illness	that	occurs	in	someone	infected	with	M. tuberculosis,	
characterized	by	clinical	symptoms	and	signs,	with	or	without	
laboratory	or	radiological	evidence*
Treatment	for	tuberculosis	
infection
Treatment	offered	to	contacts	who	are	at	risk	of	developing	
tuberculosis	disease,	following	exposure	to	an	infectious	person,	in	
order	to	reduce	that	risk*
Tuberculosis	treatment A	2-month	intensive	phase	with	3	or	4	antituberculosis	drugs,	
followed	by	a	4-month	continuation	phase	with	2	drugs
*Adapted	from	the	WHO’s	Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children.	2nd	ed.	Geneva:
WHO; 2014.
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tuberculosis,	 like	 tiredness	 and	 fatigue,	 frequently	
occur	with	pregnancy,	potentially	leading	to	delayed	
diagnosis.	The	tuberculosis	symptom-screening	tool	
has	 high	 specificity	 of	 between	 84–90.9%,	 but	 its	
sensitivity	is	very	poor,	ranging	from	28–54.5%,	as	
shown	by	two	recent	studies	reporting	on	tubercu-
losis	screening	in	HIV-infected	pregnant	women.17,18	
despite	this	low	reported	sensitivity,	the	tuberculo-
sis	symptom-screening	tool	is	currently	the	best	one	
available	 when	 deciding	 upon	 further	 evaluation	
for	tuberculosis	in	a	pregnant	woman.	Noteworthy	
is	 the	finding	 from	a	recent	 large	United	Kingdom	
cohort	 that	 women	 in	 the	 early	 post-partum	
period	are	twice	as	likely	to	develop	tuberculosis	as	
non-pregnant	women.19	Health	care	providers	caring	
for	mothers	need	to	have	a	high	index	of	suspicion	
for	 tuberculosis	 in	 the	 puerperal	 period,	 a	 period	
of	extremely	high	risk	for	transmission	of	M. tuber-
culosis	 to	 the	 newborn.	 If	 any	 tuberculosis-related	
symptoms	are	present	in	a	pregnant	or	post-partum	
woman,	a	thorough	history,	a	clinical	examination,	
with	or	without	shielded	chest	radiology,	and	other	
special	 investigations	 to	 exclude	 tuberculosis	 dis-
ease	should	be	conducted.
The	clinical	presentation	of	 tuberculosis	 in	preg-
nancy	 varies	widely.	Women	 can	 be	 asymptomatic,	
or	 develop	 typical	 pulmonary	 tuberculosis	 (PTB),	
but	they	may	also	present	with	more	severe	forms	of	
tuberculosis,	including	disseminated	disease.	PTB	is	
the	most	common	form	of	disease,	but	extrapulmo-
nary	tuberculosis	(EPTB)	occurs	in	5–10%	of	preg-
nant	 women	 with	 tuberculosis.20	 However,	 EPTB	
has	 become	more	 frequent	 since	 the	 start	 the	HIV	
epidemic,	 presenting	 more	 commonly	 in	 immune-	
compromised	 individuals.	 The	 type	 of	 perinatal	
tuberculosis	in	the	fetus	or	newborn—congenital	or	
postnatal—depends	mainly	on	the	type	of	tuberculo-
sis	in	the	mother	(Figure	13.2).	In utero	and	at-birth	
transmission	(congenital)	are	more	likely	in	pregnant	
women	 with	 primary	 tuberculosis,	 presenting	 with	
pleural	effusion,	disseminated	disease	(miliary	tuber-
culosis	or	meningitis),	or	other	EPTB	that	has	a	bacil-
lemic	phase;	postnatal	transmission	is	more	likely	in	
post-partum	women	with	typical	cavitating	PTB.21,22	
Regardless	 of	 the	 mode	 or	 time	 of	 transmission,	
the	 approach	 to	 a	 tuberculosis-exposed	newborn	 is	
the same.
Tuberculosis-Exposed Newborn
A	 tuberculosis-exposed	newborn	 is	 a	 neonate	who	
has	been	in	direct	contact	with	a	tuberculosis	source	
case,	most	often	the	mother,	who	may	pose	an	infec-
tious	risk	irrespective	of	the	type	of	tuberculosis	or	
sputum	 acid-fast	 smear	 or	 mycobacterial	 culture	
results.	Previous	studies	have	shown	a	60–80%	risk	
of	transmission	to	infants	from	a	close	acid-fast	spu-
tum	 smear-positive	 contact,	 and	 30–40%	 from	 an	
acid-fast	 sputum	 smear-negative	 contact.23	 More	
pronounced	 adverse	perinatal	 outcomes	have	been	
reported	when	the	mother	has	advanced	pulmonary	
lesions	and	when	tuberculosis	is	either	treated	late	in	
pregnancy	or	incompletely	treated.24	In	South	Africa,	
a	high-burden	setting,	the	Southern	African	Society	
for	Paediatric	Infectious	diseases	(SASPId)	defined	
a	potentially	infectious	mother	as	someone	who	has	
received	less	than	two	months	of	effective	treatment	
for	 tuberculosis	 disease	 at	 the	 time	 of	 delivery,	 or	
whose	sputum	smear	has	not	yet	become	negative	or	
is	unknown	at	the	time	of	birth.25
Guidelines	 regarding	 the	 management	 of	
the	 tuberculosis-exposed	 newborn	 vary	 widely	
across	 different	 countries,	 with	 little	 evidence	 to	
support	 current	 practices.26	 The	 approach	 to	 a	
tuberculosis-exposed	 newborn	 depends	 largely	 on	
clinical	 circumstances	 and	 available	 resources.	 We	
therefore	propose	a	strategy	used	within	a	tuberculo-
sis	high-burden	setting,	based	on	clinical	experience	
Primary TB and
Disseminated TB
Other EPTB
Congenital TB
Postnatal TB
Pulmonary TB
FIGURE 13.2	 Types	of	maternal	tuberculosis	associated	with	perinatal	tuberculosis.
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and	expert	opinion,	realizing	that	this	may	not	suit	all	
settings,	and	cases	may	need	to	be	individualized.	In	
this	strategy,	two	issues	are	key	to	ensuring	appropri-
ate	management: (1) Establish	whether	the	newborn	
is	well	or	unwell;	(2) determine	whether	the	possible	
source	case	is	infectious.	The	risk	for	disease	progres-
sion	in	a	newborn	may	vary	following	infection	with	
M. tuberculosis	(see	Figure 13.3).
An	 unwell	 newborn	 is	 defined	 as	 a	
tuberculosis-exposed	 newborn	 with	 symptoms	
and	signs	suggestive	of	tuberculosis	disease,	which	
may	 include	 respiratory	 distress,	 hepatospleno-
megaly,	or	 fever.	Any	unwell	 tuberculosis-exposed	
newborn,	regardless	of	the	mother’s	infectious	sta-
tus,	needs	urgent	newborn	care,	as	well	as	evalua-
tion	 for	 tuberculosis	 disease.	 After	 stabilization	
of	 the	 newborn,	 testing	 should	 be	 conducted	 in	
the	 maternal-infant	 pair,	 including	 a	 tuberculosis	
symptom-screening	tool	given	to	the	mother,	chest	
radiography	 for	 the	mother,	 and	 a	 clinical	 exami-
nation	and	 tuberculosis-directed	 special	 investiga-
tions	for	the	newborn.	If tuberculosis in the newborn 
is suspected or present, appropriate treatment should 
be initiated immediately,	 as	 delay	 in	 treatment	will	
worsen	 prognosis.	 Once	 tuberculosis	 has	 been	
excluded	 in	 the	 newborn	 and	 mother,	 and	 the	
underlying	condition	treated	in	the	newborn,	regu-
lar	 follow-up	 visits	 should	 ensue	 to	 monitor	 the	
well-being	of	the	infant.
In	 the	case	of	a	well	 tuberculosis-exposed	new-
born	whose	mother	does	not	have	infectious	tuber-
culosis	disease	or	who	has	received	more	than	two	
months	of	appropriate	tuberculosis	treatment	and	is	
responding	well,	a	more	conservative	approach	may	
be	advised.	In	this	scenario,	no	treatment	is	indicated	
for	the	infant	while	the	child	remains	asymptomatic,	
but	 a	 BCG	 vaccine	 should	 be	 given	 where	 this	 is	
standard	practice.	Routine	management	and	regular	
follow-up	of	the	newborn	is	paramount	in	this	set-
ting.	The	infant	should	be	evaluated	for	symptoms	
and	signs	of	tuberculosis	at	each	well-child	visit,	and	
promptly	investigated	for	tuberculosis	if	indicated.
In	 the	 case	 of	 a	 mother	 with	 potentially	
contagious	 tuberculosis,	 the	 approach	 to	 a	
tuberculosis-exposed	newborn	at	risk	for	M. tuber-
culosis	 infection	 and	 disease	 progression	 becomes	
more	challenging,	and	the	strategy	in	Figure	13.4	is	
proposed.
“Unwell”	 (symptoms	 and	 signs	 sugges-
tive	 of	 tuberculosis)	 and	 “well	 and	 high-risk”	
tuberculosis-exposed	 newborns	 who	 are	 diag-
nosed	 with	 confirmed	 or	 probable	 tuberculosis	
disease	should	receive	at	least	six	months	of	treat-
ment	 with	 three	 or	 four	 antituberculosis	 drugs	
in	 the	 intensive	 phase,	 and	 two	 drugs	 during	 the	
continuation	phase.	Other	facets	of	care	are	impor-
tant,	 including	 regular	 follow-up,	 weight	 checks,	
and	 drug-dose	 adjustments	 according	 to	 weight	
gain.	A  “well	 and	high-risk”	 tuberculosis-exposed	
newborn	who	has	had	tuberculosis	excluded,	and	
a	 “well	 and	 low-risk”	 exposed	 newborn	 should	
receive	six	to	nine	months	of	isoniazid	for	possible	
tuberculosis	 infection.	 Monthly	 follow-up	 visits	
should	 be	 conducted	 for	 the	 duration	 of	 treat-
ment,	and	 isoniazid	dosage	adjusted	according	 to	
weight	gain.	At	each	visit,	screening	for	symptoms	
and	signs	suggestive	of	tuberculosis	should	be	per-
formed,	and	an	 infant	who	develops	these	should	
be	evaluated	for	tuberculosis	disease.	Some	guide-
lines	 recommend	 performing	 a	 TST	 toward	 the	
end	of	treatment—if	the	result	is	negative,	a	single	
dose	of	a	BCG	vaccine	is	given	when	it	is	standard	
practice,	 or	 where	 the	 risk	 of	 exposure	 to	 addi-
tional	cases	of	tuberculosis	is	high.27	BCG	vaccine	
protects	against	the	more	severe	types	of	dissemi-
nated	tuberculosis,	miliary	and	meningitis	disease,	
but	 is	 contraindicated	 in	HIV-infected	newborns.	
Careful	 follow-up	 of	 the	 tuberculosis-exposed	
newborn	 should	 continue	 for	 a	 period	of	 at	 least	
two years.
Where	 the	 health	 system	 makes	 use	 of	 “Road	
to	 Health”	 cards,	 it	 is	 essential	 that	 the	 diagnosis	
and	steps	 taken	 for	 treatment	and	management	be	
briefly noted.
High risk
Low risk
Unwell with TB symptoms and signs
Well, premature/low birth weight with or without HIV-exposure
Well, term gestation with or without HIV-exposure
FIGURE 13.3	 Risk	for	a	tuberculosis-exposed	newborn	to	develop	tuberculosis	disease.
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PERINATAL AND INFANT 
TUBERCULOSIS
Tuberculosis	 disease	 in	 the	 young	 is	 not	 a	 single	
entity;	 it	 represents	 a	 continuum	 of	 disease,	 with	
many	 overlapping	 symptoms	 and	 signs.	The	 term	
“perinatal	 tuberculosis”	 encompasses	 both	 con-
genital	 and	postnatal	 disease	 (Figure	 13.5),	where	
the	 exact	 time	 point	 and	 mode	 of	 infection	 with	
M.  tuberculosis	 is	 difficult	 to	 determine,	 and	 the	
clinical	 and	 radiological	 presentations	 overlap.	
Newborns	can	also	be	infected	with	M. tuberculosis	
later	in	infancy,	via	droplet	spread	from	an	infectious	
contact.	“Infant	tuberculosis”	refers	to	children	diag-
nosed	in	the	first	year	of	life.	Early	diagnosis	of	tuber-
culosis	may	be	difficult,	with	neonates	 and	 infants	
TB-exposed newborn
Well and low-risk Well and high-risk Unwell
– isoniazid for 6–9 months
Preventive TB therapy
– monthly follow-up visits
– check weight and adjust dose
– TB screening at each visit
• Investigate for TB, if any symptoms
and signs suggestive of TB
* Investigate for TB
according to available resources
– gastric aspirates
– chest radiology
– blood culture
– cerebrospinal fluid
– abdominal ultrasound
Preventive therapy finished
– BCG in high burden settings,
   if HIV negative
TB treatment
– 2 months intensive phase: 3/4 TB drugs
– 4 months continuation phase: 2 TB drugs
– months follow-up visits
– check weight and adjust dose
Not TB TB
– sputum smear or culture positive
– OR any type of TB and < 2 months on TB treatment
Infectious TB mother
FIGURE 13.4	 Approach	to	a	tuberculosis-exposed	newborn	from	a	potentially	infectious	mother.
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often	being	asymptomatic,	and	symptoms	and	signs	
only	becoming	apparent	in	the	late	neonatal	period	
and	early	infancy.	TST	and	IGRA	are	insensitive	for	
neonates	and	infants	and	are	more	often	negative	in	
these	children	than	in	older	children	with	tubercu-
losis	infection	or	disease.28	In	the	following	section,	
important	 differences	 between	 the	 earlier	 (mainly	
congenital)	and	later	(mainly	postnatal	and	infant)	
presentations	of	tuberculosis	are	highlighted.
Early Presentation of Tuberculosis 
in Infancy
True	 congenital	 tuberculosis	 is	 rare,	 with	 fewer	
than	 300	 cases	 reported	 in	 the	 literature	 prior	 to	
1994.22	 Since	 the	 recognition	 of	 HIV	 infection,	
and	 with	more	 women	 of	 childbearing	 age	 devel-
oping	 tuberculosis,	 an	 increase	 in	 vertical	 trans-
mission	 of	 M.  tuberculosis	 has	 been	 observed.	 In	
durban,	 South	 Africa,	 prior	 to	 the	 routine	 use	
of	 ART	 in	 HIV-pregnant	 women,	 a	 16%	 verti-
cal	 transmission	 rate	 of	M.  tuberculosis	 was	 docu-
mented	 in	 tuberculosis-exposed	 newborns,	 from	
both	 HIV-infected	 and	 HIV-uninfected	 pregnant	
women.29	 Maternal	 tuberculosis	 in	 HIV-infected	
women	 is	 also	 a	 risk	 factor	 for	 increased	 vertical	
HIV	transmission.30	The	revised	Cantwell’s	criteria	
from	 1994	 define	 true	 congenital	 tuberculosis	 as	
disease	diagnosed	 in	any	 infant	with	a	 tuberculous	
lesion	 and	 one	 or	 more	 of	 the	 following:  (i)  the	
lesion	being	present	 in	 the	first	week	of	 life;	 (ii)	 a	
primary	hepatic	complex	or	caseating	hepatic	gran-
uloma;	(iii)	infection	of	the	placenta	or	endometrial	
tuberculosis	in	the	mother;	or	(iv)	exclusion	of	the	
possibility	 of	 postnatal	 transmission	 by	 excluding	
tuberculosis	in	other	contacts.22
Symptoms	 and	 signs	of	 congenital	 tuberculosis	
may	be	present	at	birth,	but	they	often	occur	in	the	
first	weeks	of	 life,	and	mainly	 involve	the	 lung	and	
liver.	Combined	data	from	75	individual	congenital	
tuberculosis	 cases	 demonstrated	 a	 median	 age	 of	
presentation	 at	 2–3	 weeks	 and	 reported	 the	 fol-
lowing	 symptoms	 and	 signs:  respiratory	 distress	
(including	 tachypnea),	 hepatomegaly,	 splenomeg-
aly,	 fever	 (low-grade),	 prematurity,	 and	 low	 birth-
weight	occurred	in	more	than	40%	of	cases;	cough	
(acute	 or	 chronic),	 poor	 feeding,	 failure	 to	 thrive,	
abdominal	distention	(including	ascites)	in	25–40%	
cases;	and	irritability,	peripheral	lymphadenopathy,	
and	sepsis	syndrome	in	10–25%	of	cases.	Less	than	
10%	of	these	cases	presented	with	tuberculous	men-
ingitis,	 obstructive	 jaundice,	 skin	 lesions,	 otorrhea	
or	mastoiditis,	wheeze	or	stridor,	apnea	or	cyanosis	
attacks,	 facial	 nerve	 palsy,	 or	 shock.21	 Chest	 radi-
ography	was	available	for	53	of	the	75	infants,	with	
miliary	disease	(30%),	bronchopneumonia	(32%),	
and	lobar	opacification	(34%)	being	the	most	com-
mon	radiological	presentations.
A	 mycobacterial	 blood	 culture	 should	 be	 per-
formed	in	suspected	disseminated	tuberculosis	cases.	
Placental	histology	and	culture	and	post-partum	endo-
metrial	biopsy	may	be	of	value	 in	confirming	 tuber-
culosis	in	the	mother	and	congenital	infection	of	the	
neonate.	However,	finding	evidence	of	M. tuberculosis	
in	the	placenta	does	not	confirm	congenital	infection,	
nor	does	its	absence	rule	out	infection	of	the	neonate.	
Abdominal	ultrasound	should	be	performed	in	all	sus-
pected	cases	of	congenital	tuberculosis,	as	hypodense	
lesions	may	be	observed	in	both	the	liver	and	spleen	of	
the	infant.	In	a	review	of	170	congenital	tuberculosis	
cases	from	the	literature,	caseating	hepatic	granulomas	
were	found	in	15	infants	subjected	to	liver	biopsy,	and	
a	primary	hepatic	complex	was	found	in	two	infants,	
probably	pathognomic	of	congenital	infection.31
Late Presentation of Tuberculosis 
in Infancy
PTB,	 also	 referred	 to	 as	 “intrathoracic	 tuber-
culosis”	 that	 includes	 hilar	 and	 mediastinal	
Perinatal TB
Congenital TB
Postnatal TB
Infant TB
FIGURE 13.5	 Tuberculosis	disease	terminology	in	neonates	and	infants.
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lymphadeno	pathy,	 is	 present	 in	 up	 to	 90%	 of	
infants	with	tuberculosis: EPTB	occurs	in	15–30%	
of	 cases.8,21	 In	 a	 case	 series	of	47	 infants,	 the	most	
common	symptoms	and	signs	for	infant	tuberculo-
sis	 included	cough	(79%),	fever	(64%),	poor	feed-
ing	(43%),	 localized	rales	or	wheezing	(38%),	and	
decreased	 breath	 sounds.8	 These	 clinical	 features	
relate	to	the	pathophysiology	of	PTB	disease	in	the	
infant,	 which	 involves	 marked	 hilar	 and	mediasti-
nal	 lymphadenopathy.	 Enlarged	 glands	 can	 easily	
compress	the	airways	of	infants,	which	are	of	small	
caliber.	Partial	compression	of	the	large	airways	may	
present	 with	 stridor,	 whereas	 compression	 of	 the	
smaller	airways	leads	to	signs	of	air	trapping,	includ-
ing	 wheezing	 and	 focal	 decreased	 breath	 sounds.	
Progressive	 obstruction	 may	 cause	 a	 “ball-valve”	
effect,	which	can	 lead	 to	hyperinflation	of	parts	of	
the	lungs	or	even	an	entire	lung.	Complete	obstruc-
tion	 can	 result	 in	 collapse	 of	 certain	 sections	 of	
the	 lung.	Enlarged	lymph	nodes	are	also	known	to	
erode	 into	 the	 bronchus,	 spreading	 caseous	mate-
rial	to	the	lungs,	which	in	turn	may	create	segmental	
parenchymal	 lesions.	 A  parenchymal	 lesion	 in	 the	
lung	can	also	enlarge	and	cause	widespread	opaci-
fication	in	a	segment	or	lobe	of	the	lung,	presenting	
with	symptoms	and	signs	similar	to	pneumonia.	In	
the	 case	 series	 of	 47	 infants,	 44	 had	 parenchymal	
disease,	 and	one	 infant	had	hilar	 adenopathy	only.	
The	 majority	 of	 infants	 (86%)	 had	 radiologically	
confirmed	 segmental	 lesions	 associated	 with	 hilar	
adenopathy.8	 A  similar	 report	 showed	 radiological	
evidence	 of	 air-trapping	 (56%),	 lobar	 or	 segmen-
tal	 opacification	 (52%),	 lymphadenopathy	 (52%),	
and	large	airway	compression	(48%)	in	27	younger	
infants	with	PTB.32	Pleural	 effusions	do	not	occur	
commonly	in	infants,21	although	slight	thickening	of	
the	pleura	near	a	primary	focus	is	not	uncommon.
Gastric	aspirates	for	acid-fast	smear,	GeneXpert	
MTB/RIF,	and	culture	are	routinely	recommended	
when	 investigating	 young	 infants	 for	 tuberculosis	
disease.	Sputum	induction	may	also	be	successfully	
conducted	 in	 older	 infants.	 Although	 tuberculosis	
disease	in	children	is	paucibacillary	in	nature,	stud-
ies	have	 reported	 that	more	 than	70%	of	 clinically	
suspected	cases	in	infants	can	be	confirmed	by	cul-
ture.8,21,33	This	higher	microbiological	yield	may	be	
partially	 explained	 by	 the	 often-late	 diagnosis	 in	
the	young,	as	well	as	the	infants’	immature	immune	
system,	which	allow	for	uncontrolled	multiplication	
of	 the	 tubercle	 bacilli.21	 In	 a	 study	performed	 in	 a	
tuberculosis-endemic	region,	peripheral	lymphade-
nopathy,	 mainly	 cervical,	 occurred	 less	 frequently	
in	 infants	 than	 older	 children.34	 Prior	 to	 the	 uni-
versal	use	of	ART	 in	HIV-infected	 infants,	 axillary	
lymphadenopathy	was	 a	 frequent	 adverse	 event	 in	
HIV-infected	 infants	 receiving	BCG	vaccination	at	
birth.	Tuberculous	meningitis	 is	unusual	 in	 infants	
less	than	three	months	of	age,	probably	because	of	
the	time	needed	(several	weeks	or	months)	for	the	
spread	of	M. tuberculosis	infection	from	the	primary	
focus	to	the	brain	and	the	establishment	of	a	“Rich	
focus”	close	to	the	meninges.35
ANTITUBERCULOSIS DRUGS 
IN PREGNANCY AND INFANTS
This	section	highlights	specific	drug	issues	and	mat-
ters	related	to	pregnancy,	neonates,	and	infants.	The	
focus	is	on	first-line	drugs,	as	limited	data	are	avail-
able	 for	 second-line	drugs	within	 these	 vulnerable	
populations.
First-line Antituberculosis Drugs 
in Pregnancy
First-line	antituberculosis	drugs—isoniazid	(INH),	
rifampicin	 (RMP),	 ethambutol	 (EMB),	 and	 pyra-
zinamide	 (PZA)—are	 used	 in	 the	 treatment	 of	
drug-susceptible	 tuberculosis.	 They	 are	 safe	 and	
widely	 used	 in	 pregnancy,	 with	 no	 evidence	 asso-
ciating	them	with	increased	human	fetal	malforma-
tions.36	 Streptomycin	 and	 other	 injectable	 drugs,	
however,	are	contraindicated	in	pregnancy	because	
of	the	potential	risk	for	fetal	ototoxicity.37
INH	 as	 a	 single	 drug	 is	 recommended	 for	
the	 treatment	 of	 tuberculosis	 infection,	 both	 in	
low-burden	settings	and	for	HIV-infected	individuals	
in	high-burden	settings.	due	to	the	potential	risk	of	
INH	hepatotoxicity,	health	care	workers	are	hesitant	
to	administer	this	drug	in	pregnancy	or	the	immedi-
ate	post-partum	period,	 and	many	defer	 treatment	
until	 after	 delivery	 of	 the	 baby.	 Preexisting	 liver	
disease	and	the	use	of	other	hepatotoxic	drugs	may	
predispose	to	liver	injury	in	pregnant	women;	there-
fore,	 baseline	 transaminases	 should	 be	 performed	
prior	to	starting	treatment	with	INH.	Regular	moni-
toring	 of	 transaminases	 should	 be	 conducted	 in	
pregnant	women	taking	INH,	and	the	development	
of	symptoms	that	may	be	referrable	to	the	liver	or	an	
increase	of	serum	transaminases	of	3–5	times	more	
than	the	upper	limit	of	normal	in	an	asymptomatic	
pregnant	woman	 should	prompt	 immediate	 cessa-
tion	of	any	potentially	hepatotoxic	drug,	 including	
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INH.38,39	 A  large	 randomized	 international	 trial	 is	
underway	 with	 the	 aim	 of	 establishing	 the	 safety	
of	 antepartum-initiated	 INH	 versus	 deferred	 or	
post-partum	 initiated	 INH	 among	 HIV-infected	
women	in	tuberculosis	high-burden	settings.	Results	
from	this	study	will	guide	future	use	of	INH	during	
pregnancy	and	the	post-partum	period.	Pyridoxine	
supplementation	 is	 indicated	 in	most	 patients	 tak-
ing	INH,	including	pregnant	women,	to	prevent	the	
development	of	peripheral	neuropathy.
Recommended	first-line	 tuberculosis	 treatment	
regimens	for	pregnant	women	differ	between	coun-
tries,	with	many	recommending	the	standard	adult	
regimen	(two-month	intensive	phase	of	INH,	RMP,	
EMB,	 and	PZA,	 followed	by	 four	months	of	 INH	
and	RMP).40	In	the	United	States,	PZA	is	currently	
not	recommended	for	use	in	pregnancy	because	of	
lack	 of	 specific	 teratogenicity	 studies	 in	 animals,	
and	an	alternative	regimen	of	INH,	RMP,	and	EMB	
for	two	months,	followed	by	seven	months	of	INH	
and	RMP,	is	recommended.	RMP	induces	the	cyto-
chrome	P450	microsomal	hepatic	enzymes,	which	
play	 an	 important	 role	 in	 the	 metabolism	 of	 sev-
eral	 drugs,	 and	 can	 lead	 to	 lower	 drug-exposures	
of	 certain	 concomitant	 drugs.	 Because	 bleeding	
tendencies	 have	 been	 observed	 with	 RMP,	 giving	
prophylactic	vitamin	K	to	the	newborn	of	a	mother	
being	 treated	 for	 tuberculosis	 is	 of	 paramount	
importance	 to	 prevent	 hemorrhagic	 disease	 of	 the	
newborn.	 All	 of	 the	 first-line	 drugs	 cross	 the	 pla-
centa,	and	minimal	amounts	are	excreted	into	breast	
milk.	Breastfeeding	is	recommended	and	should	be	
encouraged	for	mothers	being	treated	for	tuberculo-
sis	who	are	no	longer	infectious.40
Second-line Antituberculosis 
Drugs in Pregnancy
Globally,	 the	 proportion	 of	 new	 cases	 with	
multidrug-resistant	 tuberculosis	 (MdR-TB),	 resis-
tant	to	INH	and	RMP,	was	3.5%	in	2013.1	Limited	
data	 are	 available	 for	 the	 use	 of	 second-line	 anti-
tuberculosis	 drugs	 in	 pregnancy,	 and	 it	 is	 largely	
unknown	to	what	extent	they	cross	the	placenta	or	
are	 excreted	 in	 the	 breast	 milk.	 Most	 second-line	
drugs	have	a	greater	incidence	of	adverse	effects	in	
the	 mother	 and/or	 an	 increased	 risk	 to	 the	 fetus	
in	 pregnancy.36	 Injectable	 drugs	 can	 cause	 neuro-
sensory	hearing	 loss	 in	 the	 fetus.	The	safety	of	 the	
fluoroquinolones	in	pregnancy	has	not	been	estab-
lished,	and	there	are	no	data	in	this	regard	for	newer	
drugs	 such	 as	 linezolid.	 However,	 untreated	 or	
poorly	treated	tuberculosis	in	the	pregnant	woman	
is	 associated	 with	 many	 poor	 fetal	 outcomes,	
including	prematurity	and	stillbirth.	The	benefits	of	
treating	 tuberculosis	 disease	 in	 pregnancy	 usually	
outweigh	the	risks	of	the	specific	drugs	for	the	fetus,	
but	the	advice	of	a	specialist	in	tuberculosis	should	
be	obtained	when	managing	drug-resistant	tubercu-
losis	in	pregnant women.
Antituberculosis Drugs in Infants 
with Tuberculosis Disease
INH,	 RMP,	 and	 PZA,	 with	 or	 without	 EMB,	
remain	 the	 cornerstones	 of	 first-line	 tuberculosis	
drug	regimens	 in	children	of	all	ages	(Table	13.2).	
The	 recommended	 standard	 regimen	 for	PTB	and	
peripheral	 lymphadenitis	 in	 the	 young	 consists	 of	
six	months	of	treatment;	three	or	four	drugs	(INH,	
RMP,	PZA,	 and	EMB)	 for	 two	months	 (intensive	
phase),	followed	by	two	drugs	(INH	and	RMP)	for	
the	following	four	months.27	Ethionamide	(ETH),	a	
second-line	drug,	is	sometimes	preferred	to	EMB	in	
the	very	young	because	of	good	CNS	penetration	in	
tuberculous	meningitis,	and	due	to	the	difficulty	in	
monitoring	 for	ocular	 toxicity	 that	 is	caused	rarely	
by	EMB	in	this	age	group.	However,	 in	a	 literature	
review	 of	 EMB	 in	 children,	 the	 drug	was	 stopped	
due	 to	 fears	 about	 possible	 ocular	 toxicity	 in	 only	
two	of	3,811	patients.41,42	A dose	of	15–20	mg/kg/
day	is	recommended	for	ETH use.43
In	 2009,	 the	WHO	 recommended	 higher	 doses	
of	 all	 first-line	 drugs	 for	 children	 than	 previously	
Table 13.2. Revised WHO-  
recommended tuberculosis 
drug-dosing guidelines for children27
F IRST-L INE 
ANTITUBERCULOSIS 
DRUGS
DAILY DOSE
INH 10	mg/kg	(range	
7–15	mg/kg)
RMP 15	mg/kg	(range	
10–20	mg/kg)
PZA 35	mg/kg	(range	
30–40	mg/kg)
EMB 20	mg/kg	(range	
15–25	mg/kg)
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recommended:  INH	 10	 mg	 versus	 5	 mg/kg/day,	
RMP	15	mg	versus	10	mg/kg/day,	PZA	35	mg	ver-
sus	25	mg/kg/day,	and	EMB	20	mg	versus	15	mg/
kg/day.44	 These	 recommendations	 were	 based	 on	
evidence	from	pharmacokinetic	(PK)	studies	involv-
ing	mainly	older	children,	which	showed	that	higher	
milligram-per-kilogram	dosing	is	necessary	to	achieve	
target	drug	concentrations	that	correlate	with	efficacy	
in	adults.	The	effect	of	these	higher	doses	on	young	
infants,	 with	 immature	 organ	 systems	 and	who	 are	
more	prone	to	drug	injury,	remains	largely	unknown.	
Limited	PK	and	safety	data	are	available	for	neonates	
and	 infants	 for	 first-line	 drugs,	 with	 none	 available	
for	 long-term	use	of	 second-line	drugs.	Fortunately,	
adverse	 reactions	 to	 first-line	 drugs	 are	 seen	 less	
frequently	 in	 infants	 and	 children	 than	 in	 adults.45	
A  transient	 increase	 in	 transaminases	 may	 occur	
with	the	hepatotoxic	drugs,	but	clinically	significant	
hepatitis	is	rare	and	documented	in	only	0.1%	of	chil-
dren.46	As	older	 children	generally	 tolerate	first-line	
drugs	 well,	 routine	 laboratory	monitoring	 of	 safety	
data	is	not	standard	of	care	in	the	otherwise	healthy	
older	child	receiving	first-line drugs.
However,	 caution	 about	 hepatotoxicity	 may	
be	 advised	 in	 neonates	 and	 infants	 with	 imma-
ture	 organ	 systems,	 and	many	 experts	 recommend	
biochemical	 monitoring	 in	 this	 age	 group.	 Young	
infants	 have	 unique	 developmental	 and	 physi-
ological	changes	that	may	influence	the	absorption,	
metabolism,	 and	 excretion	 of	 specific	 drugs.	 For	
INH,	 both	 N-acetyltransferase 2	 (NAT2)	 genotyp-
ing	and	enzyme	maturation	determine	 INH	serum	
concentration.	The	 rate	 of	 INH	 elimination	 shows	
genetic	 polymorphism,	 with	 individuals	 classified	
as	 homozygous	 fast	 (FF),	 heterozygous	 fast	 (FS),	
or	homozygous	slow	(SS)	acetylators,	depending	on	
their	 ability	 to	 eliminate	 this	drug.	despite	 genetic	
differences	 influencing	 the	 rate	 of	 elimination	 of	
INH,	evidence	suggests	that	NAT2	expression	phe-
notypically	matures	with	age	as	enzyme	maturation	
develops,	with	 faster	 acetylators	metabolizing	 INH	
more	rapidly	with	increasing	age.	The	exact	time	of	
enzyme	maturation	remains	unclear,	with	full	matu-
rity	of	the	enzymatic	pathways	responsible	for	INH	
metabolism	only	reached	at	an	estimated	2–4 years	
of	 age.47	 Genetically	 determined	 fast	 acetylators	
may	 therefore	 behave	 like	 slow	 acetylators	 in	 the	
very	 young	 with	 reduced	 clearance	 and	 relatively	
higher	serum	concentrations	of	INH.	In	a	study	con-
ducted	 in	 20	 low-birthweight	 infants	 receiving	 10	
mg/kg/day	of	 INH	(dosed	at	 the	 lower	end	of	 the	
WHO-recommended	dosing	guideline),	all	20	LBW	
infants	achieved	at	least	adult	INH	target	values,	and	
some	were	much	higher,	cautioning	against	the	use	
of	high-dose	INH	in	the	neonate	or	infant.48	Some	of	
the	 infants	were	monitored	with	periodic	measure-
ment	of	alanine	transaminases	(ALT);	most	results	
were	 normal,	 but	 one	 asymptomatic	 infant	 had	 a	
three	 times	 elevated	 value	 of	 ALT,	 which	 normal-
ized	at	six	months	of	age	with	continued	treatment.	
The	high	serum	concentrations	of	INH	achieved	in	
this	group	require	further	 investigation,	and	careful	
safety	monitoring	is	imperative	in	the	very young.
Rifampicin	 is	 a	 strong	 inducer	 of	 cytochrome	
CYP3A4,	 and	 since	 large	 numbers	 of	 medications	
are	CYP3A4	 substrates,	 RMP	use	 leads	 to	 reduced	
concentrations	and,	in	some	cases,	reduced	effective-
ness	of	other	drugs.	In	HIV	high-prevalence	settings,	
potential	 interactions	may	 occur	with	 specific	ART	
drugs,	 leading	 to	 decreased	 serum	 levels	 of	 these	
drugs	in	neonates	and	infants.	The	protease	inhibitor	
lopinavir/ritonavir	(LPV/r)	and	the	non-nucleoside	
reverse	 transcriptase	 inhibitor	 nevirapine	 (NVP),	
used	 in	prevention	of	mother	 to	child	transmission,	
have	been	documented	to	have	lower	serum	concen-
trations	in	the	presence	of	RMP	co-administration.49	
Overlapping	 toxicity	 of	 antituberculosis	 drugs	 and	
other	 concomitant	 drugs	 may	 increase	 the	 risk	 of	
adverse	 events.	 RMP	 is	 also	 known	 for	 its	 large	
inter-individual	 variation	 in	 serum	 concentrations,	
with	some	evidence	suggesting	lower	RMP	exposures	
in	the	young.50	Whether	higher	doses	of	RMP	should	
be	 considered	when	 treating	 disseminated	 tubercu-
losis	disease	(high	bacillary	 load),	HIV	co-infection	
(drug–drug	 interactions),	 and	 also	 within	 a	 back-
ground	of	rising	INH	resistance,	 remains	uncertain.	
Genotyping	 may	 influence	 RMP	 exposures,	 with	
recent	data	 indicating	 that	 a	 single-nucleotide	poly-
morphism	 (SNP)	 in	 SLCO1B1	 is	 associated	 with	
rifampicin	plasma	concentrations.
The	 treatment	 of	 neonatal	 and	 infant	 tubercu-
losis	 remains	a	challenge	due	 to	 the	paucity	of	PK	
and	safety	data	on	the	use	of	antituberculosis	drugs	
in	 this	 age	group.	Ongoing	PK	studies	will	 inform	
future	guidelines	for	the	optimal	dosing	of	first-	and	
second-line	drugs	in	the young.
INFECTION CONTROL
General Principles 
for Maternal-Infant Pairs
Mothers	 with	 tuberculosis	 disease	 and	 their	 new-
borns	 should	 preferably	 not	 be	 separated	 from	
21
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
1Tuberculosis in Neonates and Infants  •  241
each	 other.	 The	 mother	 with	 undiagnosed	 PTB	
or	 recently	 started	 PTB	 treatment	 poses	 the	
highest	 infectious	 risk	 to	 other	 people,	 includ-
ing	 her	 own	 baby.	 Transmission	 of	M.  tuberculosis	
depends	 the	 degree	 and	 duration	 of	 exposure	 to	
the	 infectious	 individual.	 Patients	 with	 acid-fast	
sputum	 smear-positive	 PTB	 are	 more	 likely	 to	
transmit	the	organism	than	sputum	smear-negative,	
culture-positive	 patients,	 although	 both	 carry	 an	
infectious	 risk.	 Breastfeeding	 should	 be	 encour-
aged,	 especially	 within	 resource-constrained	 set-
tings,	where	 it	may	be	essential	 for	 infant	 survival.	
The	 recent	 WHO	 guidelines	 recommend	 breast-
feeding,	irrespective	of	the	tuberculosis	status	of	the	
mother,27	while	the	American	Academy	of	Pediatrics	
recommends	 that	 women	 with	 tuberculosis	 who	
have	 been	 treated	 appropriately	 for	 two	 weeks	 or	
more	and	who	are	not	contagious	may	breastfeed.51	
It	is	evident	that	the	mother	should	start	appropriate	
treatment	 as	 soon	 as	 the	 diagnosis	 of	 tuberculosis	
disease	 is	made,	which	will	decrease	her	 infectious	
risk.	The	mother	should	wear	a	protective	mask	dur-
ing	 breastfeeding,	 and	 treatment	 for	 the	 newborn	
considered,	 depending	 on	 the	 likely	 contagious-
ness	of	the	mother.	The	risk	of	transmission	through	
breast	milk	is	negligible,	and	only	small	amounts	of	
antituberculosis	 drugs	 are	 excreted	 in	 breast	milk.	
Management	 of	 drug-resistant	 tuberculosis	 cases	
should	be	discussed	with	 a	 specialist	 familiar	with	
treating	these cases.
Isolation	 of	 potentially	 infectious	 tuberculo-
sis	 cases	 should	 be	 facilitated	within	 a	 health	 care	
facility,	 for	 both	 mother	 and	 newborn,	 to	 offer	
protection	 to	 fellow	patients	and	other	health	care	
providers.	 Good	 ventilation	 strategies	 within	 the	
isolation	facility	will	reduce	transmission	risk,	with	
negative-pressure	 ventilation	 the	 preferred	 option.	
PTB	patients	initiated	on	treatment	can	safely	leave	
isolation	once	the	following	criteria	are	met: at	least	
two	consecutive	sputum	acid-fast	smear	microscopy	
samples	negative	for	mycobacteria;	evidence	of	clin-
ical	 improvement;	 and	 adherence	 to	 an	 adequate	
treatment	regimen	for	two	weeks	or	more.52
Undiagnosed	 PTB	 may	 potentially	 occur	 in	
any	patient	or	health	 care	provider,	 and	 caution	 is	
advised,	 especially	 in	 resource-constrained	 con-
gregate	 settings	 where	 mothers	 share	 facilities;	
for	 example,	 during	 “kangaroo	mother	 care”	 prac-
tices	 (skin–skin	 contact	 and	 nursing	 of	 premature	
babies).	 Heyns	 et  al.53	 reported	 four	 infants	 that	
were	 infected	 and	 developed	 tuberculosis	 disease	
following	 exposure	 to	 a	 different	 mother	 with	
undiagnosed	 tuberculosis,	 illustrating	 that	 noso-
comial	 transmission	 of	 M.  tuberculosis	 may	 occur	
within	a	kangaroo	mother	care	unit.	In	tuberculosis	
high-burden	settings,	symptom	screening	is	advised	
for	all	rooming-in	mothers,	and	a	high	index	of	sus-
picion	 for	 tuberculosis	 is	 essential,	 including	 for	
health	care	providers.
In	 the	 unfortunate	 event	 of	 a	 new	
drug-susceptible	 PTB	 diagnosis	 within	 a	 neonatal	
care	setting,	immediate	steps	should	to	be	taken	to	
assist	 the	 index	 case	 and	 protect	 all	 exposed	 indi-
viduals.	If	babies	are	exposed	to	tuberculosis	in	the	
neonatal	care	setting,	appropriate	testing	and	treat-
ment	should	always	be	carried	out.	The	index	case	
should	be	started	on	appropriate	treatment	as	soon	
as	 possible,	 and	 remain	 home	 until	 noninfectious.	
Health	care	providers	are	known	to	be	at	higher	risk	
for	tuberculosis	disease	in	high-burden	settings.	In	a	
recent	study	from	South	Africa,	133	primary	health	
care	facilities	were	reviewed,	showing	an	incidence	
ratio	of	acid-fast	smear-positive	tuberculosis	in	pri-
mary	health	care	workers	of	more	than	double	that	
of	the	general	population.54	In	low-burden	settings,	
asymptomatic	 exposed	 individuals	may	 be	 offered	
TST	or	IGRA	assays,	and	if	results	are	positive	and	
conversion	 happened	 recently,	 treatment	 of	 tuber-
culosis	 infection	 is	 recommended.	 In	 high-burden	
settings,	 adults	 exposed	 to	 the	 index	 case	 usually	
will	be	followed	without	treatment.	After	a	detailed	
history	and	clinical	examination,	 regular	 follow-up	
should	 be	 conducted	 to	 identify	 suggestive	 symp-
toms	 and	 signs	 for	 tuberculosis	 disease.	However,	
it	 could	 be	 argued	 that	 health	 care	 providers	who	
care	for	neonates	and	infants	and	have	been	infected	
recently	 with	 M.  tuberculosis	 should	 always	 be	
offered	treatment	to	ensure	that	transmission	to	the	
young	patients	does	not	occur.	Treatment	of	tuber-
culosis	infection	is	recommended	for	HIV-infected	
individuals	in	all	settings.
Optimal	 management	 of	 tuberculosis-exposed	
maternal-infant	pairs	requires	integration	of	mater-
nal	and	infant	health	services,	which	relies	on	good	
communication	between	those	caring	for	the	preg-
nant	mother	and	those	responsible	for	the	newborn.
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CHAPTER 2.2 
PHARMACOLOGICAL CONSIDERATIONS OF FIRST-LINE 
ANTITUBERCULOSIS DRUGS IN INFANTS 
Changes in body composition, organ function, and enzyme maturation early in life all 
affect the absorption, distribution, metabolism and elimination of drugs (56, 57). 
These dynamic developmental changes influencing drug disposition occur mainly in 
infancy, resulting in a potential need for age- and weight-dependent dose adjustments. 
Cognizance should be taken of developmental changes over time, especially when 
long-term antituberculosis drug treatment is prescribed, to optimally guide effective 
and safe drug therapy in neonates and infants.  Adverse effects of first-line 
antituberculosis drugs generally occur less frequently in children than in adults (64-
67). As children generally tolerate these drugs well, routine laboratory monitoring of 
safety parameters is not standard of care in the otherwise healthy child receiving first-
line antituberculosis drugs in resource-limited settings. However, caution may be 
appropriate in the very young with immature organ systems, i.e. liver and kidney, 
which may be more prone to drug injury. Because of the reduced drug clearance in 
neonates and infants, blood concentrations are relatively higher, potentially leading to 
adverse events. To advance our understanding of first-line antituberculosis drugs, I 
summarized the mode of action for isoniazid (INH), rifampicin (RMP), pyrazinamide 
(PZA) and ethambutol (EMB), the currently proposed target pharmacokinetic 
parameters and the main safety considerations below. Additional considerations of 
drug disposition and developmental pharmacology, the role of N-acetyltransferase 2 
(NAT2) genotyping in INH metabolism, formulation considerations and potential 
drug-drug interactions to ensure dose optimization in infants are also addressed. 
The use of isoniazid, rifampicin, pyrazinamide and ethambutol in drug-
susceptible tuberculosis 
Isoniazid 
INH is the most bactericidal antituberculosis agent in use, with a high potency and a 
wide therapeutic margin (68). INH is a prodrug that needs to be converted to its active 
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form by the bacterial enzyme KatG, a catalase peroxidase. Following activation, INH 
inhibits the biosynthesis of mycolic acids in the mycobacterial cell wall. INH has little 
protein binding, is subject to first pass metabolism and is metabolised in the liver and 
intestine. INH has good early bactericidal activity (69), and prevents resistance in 
companion drugs in the intensive phase of treatment. The most important pathway for 
INH metabolism is dependent on trimodal NAT2 genotype, which influences the 
clearance rate of INH in the body. Faster acetylators acetylate INH more rapidly than 
slow acetylators, and may require higher drug doses to achieve optimal 
pharmacokinetic target concentrations. The time to maximum concentration (Cmax) for 
INH is reached within 1-3 hours irrespective of age, and the desirable 
pharmacokinetic target is a 2 hour plasma concentration of between 3 and 5 µg/ml 
based on adult studies (70). The main adverse events for INH, both of which are rare 
in children, are neurologic and hepatic toxicity (71). Children are less susceptible to 
developing peripheral neuropathy from INH (72, 73), which can be prevented and 
counteracted by administering pyridoxine supplementation. The more serious adverse 
event, hepatotoxicity resulting in liver failure, has occasionally been reported in 
children receiving INH at a dose of 10 mg/kg or less (74-76). Asymptomatic transient 
transaminase elevation occurs more frequently and has been reported in 5-10% of 
children on INH, with the highest rates documented in adolescents (77-79). In a recent 
study of 277 children receiving IPT, 113 (41%) had elevated transaminase levels, 
however, INH had to be discontinued in only four children (80). Special care should 
be taken when prescribing INH in the young, as a recent literature review reported an 
increased risk of hepatotoxicity with slow acetylator status, an increased INH dose, 
and when administered in combination with RMP (81).  
 
Rifampicin 
RMP is a bactericidal drug, of high potency and its sterilising activity on M. 
tuberculosis is by far the most important aspect of its function (82, 83). It acts on all 
populations of bacilli, including dormant bacilli, allowing for a shortening of duration 
of treatment (from 9-12 months previously to current “short-course” 6 months 
therapy). RMP inhibits DNA-dependent RNA polymerase of bacteria by binding its 
ß-unit and thereby preventing the translation of proteins (84). RMP is mainly 
metabolized by the liver, and induces its own metabolism leading to a progressively 
shortened half-life within the first 14 days of treatment (85). All rifamycins induce 
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hepatic and intestinal cytochrome CYP3A4, and since large numbers of medications 
are CYP3A4 substrates, the use of rifamycins lead to reduced concentrations of these 
medications, and thus, reduced efficacy. RMP formulations are known for their 
considerable intra- and inter-individual variability (85-88), which may partly be 
explained by differences in RMP bioavailability (89, 90). In a study including 20 
children, only 50% +/- 22% of a freshly prepared oral RMP suspension was absorbed 
compared to an intravenous dose (91).  Although the cause for this variability remains 
unclear, the following factors may impact on the bioavailability of RMP: raw material 
characteristics, changes in the crystalline nature of the RMP, excipients, degradation 
in the gastro-intestinal tract, and inherent variability in absorption and metabolism 
(92). RMP is the only hydrophobic drug of the first-line antituberculosis drugs, 
characterized by low solubility, easily adsorbed by pharmaceutical excipients, and 
showing a pH-dependent solubility that affects absorption (93). All of these factors 
highlight the need for stringent quality assurance of antituberculosis drugs and 
formulations in clinical care and research.  
RMP’s peak concentration occurs approximately 2 hours after dosing and a serum 
Cmax of ≥ 8 µg/ml has been proposed as a pharmacodynamic surrogate for RMP when 
treating M. tuberculosis (94). However, few adult and paediatric patients reach the 
recommended minimum RMP 2-hour concentration of 8 µg/ml (95, 96), with 
youngest children (0-2 years) at high risk of “sub-therapeutic” RMP concentrations 
(97-99). This proposed RMP target concentration of ≥ 8 µg/ml was derived from 
studies conducted in healthy adult volunteers and adults with TB disease (70, 96), in 
which pharmacokinetic and pharmacodynamic parameters may differ from children 
with TB disease. Dose recommendations for RMP in adults, at 8-12 mg/kg (a 
maximum of 600 mg/kg), which leads to an “adequate” RMP pharmacokinetic target 
concentration of 8 µg/ml, were largely chosen because of the high cost of RMP 
production at the time, and not because of maximal efficacy (100). This “adequate” 
RMP pharmacokinetic target concentration of 8 µg/ml is controversial, with adult 
studies with low RMP exposures associated with treatment failure and the emergence 
of drug resistance (101). A recent study from India also showed an association 
between a lower Cmax of RMP in HIV-infected and uninfected children, and death and 
treatment failures (102); higher RMP dosing strategies are currently being 
investigated in adults. The PanACEA consortium performed a study on higher-dose 
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RMP given as part of a multidrug TB treatment regimen in drug-susceptible TB for 
12 weeks in South African and Tanzanian TB patients. Higher doses of RMP showed 
a disproportionate plasma exposure increase with dose, (20 mg/kg resulted in a Cmax 
of 21.6 µg/ml and AUC of 113 h. µg/ml, and 35 mg/kg resulted in a Cmax of 35.2 
µg/ml and AUC of 235 h. µg/ml, respectively), and higher doses were safe and well 
tolerated over a 12-week period. Faster culture conversion in liquid media was 
obtained when RMP was dosed at 35 mg/kg as compared to the control regimen of 
RMP at 10 mg/kg/day (medians 62 and 49 days, adjusted hazard ratio 1.78 [95%CI 
1.22 - 2.58], p=0.003), suggesting an increased efficacy in the higher dosing group 
(55). How these RMP optimization studies translate into clinical practice and 
paediatric care, especially with regards to shortening of tuberculosis regimens, and 
achieving higher concentrations within cerebrospinal fluid with tuberculosis 
meningitis, still need to be determined.  
RMP is generally well tolerated by both adults and children with few major adverse 
events documented. Rash (0.8%), fever (0.5%), and nausea and vomiting (1.5%) have 
been reported (103), but severe hepatotoxicity is rare. Transient elevated 
transaminases do occur, and in a study of adult TB patients on 600 mg of RMP, mild 
hepatotoxicity occurred in about half of adult patients, but no one developed severe 
hepatotoxicity (104). Limited adverse event data are available in children using RMP 
alone. One small study performed in 25 children, reported no adverse events (79), and 
in a larger adolescent study (n=157), 41 (26%) mild adverse events occurred, however 
RMP use was discontinued in only one child, due to raised liver enzymes (105). In a 
literature review on antituberculosis drug-induced hepatotoxicity among children 
receiving multi-drug therapy for TB disease, liver enzymes were abnormal in 
380/3855 children (9.9%) and jaundice occurred in 75 children (0.83%) (81). It 
showed that pre-existing liver injury, as well as concomitant INH and/or PZA use 
(both of which are hepatotoxic drugs) might predispose to hepatotoxicity (81, 106). 
RMP hypersensitivity syndrome, an immunologic phenomenon characterized by a 
flu-like syndrome, and in severe cases, with hypotension, renal failure, and 
thrombocytopenia, occurs rarely and is almost exclusively seen with intermittent 
dosing of RMP (107), but has also been reported with prolonged use (103). Although 
RMP has shown a relatively safe drug profile in children, alanine aminotransferase 
monitoring is advised in neonates and infants on multiple antituberculosis hepatotoxic 
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drugs. Safety of RMP should be carefully monitored, especially when considering 
higher dosing strategies.  
Pyrazinamide 
PZA is of low bactericidal activity but has important sterilising action following 2-3 
months of treatment, especially when combined with RMP. It acts on slow-growing 
bacteria and is most useful in the initial phase of antituberculosis treatment. PZA is a 
nicotinamide analogue, a pro-drug that is converted by pyrazinamidase to the active 
form pyrazinoic acid in the bacterial cytoplasm (108). Absorption is generally good 
and maximum serum levels are achieved 1 hour after oral ingestion (87). Children 
achieve Cmax values of approximately 40 µg/ml when PZA is administered at a dose 
of 25 mg/kg, comparable to those of adults at similar weight-based doses (109). The 
half-life of 10 hours is long, making it suitable for once daily dosing. Effective PZA 
serum levels are not well defined, but current recommendations suggest that plasma 
concentrations of 20-60 µg/ml 1-2 hours post-dose, serve as a suitable 
pharmacokinetic target to achieve optimal effect (70). Limited evidence from a 
pharmacokinetic study in children < 2 years of age showed that comparable adult 
target concentrations were achieved at revised WHO-recommended doses (60).  
Despite PZA being the most hepatotoxic of the first-line antituberculosis drugs (110, 
111), hepatic failure and death attributed to PZA seldom occur (112). Evidence on 
dose dependent liver injury is conflicting (113), but a recent literature review 
suggested that PZA induced hepatotoxicity is idiosyncratic rather than dose-
dependent, and supports safe dosing with recommended doses of 30-40 mg/kg (114). 
Elevated transaminases occur infrequently with PZA use in children, and severe 
hepatotoxicity is very rare, mainly reported with use of multi-drug therapy for TB 
disease (115-118). Asymptomatic hyperuricaemia is frequently reported in adults 
(119), but rarely in children (120, 121). Symptoms of gout in children were mostly 
mild and elevated hyperuricaemia values returned to normal post PZA treatment (115, 
116, 120).  
Ethambutol 
EMB has a bacteriostatic function and is of low potency at the doses currently 
demanded by fear of toxicity (122); it does not contribute to the sterilisation of TB 
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lesions (123). Combining EMB with other companion antituberculosis drugs may aid 
in the prevention of drug resistance (122). EMB is thought to act on the mycobacterial 
cell wall, with slow and incomplete absorption occurs in adults and children (124) and 
the time to maximum serum concentration (Tmax) is between 2-4 hours. Tissue 
distribution of EMB is good, with the exception of the central nervous system. EMB 
drug concentrations are found to be lower in children than adults when using similar 
body weight doses (124-127), although none of these studies were performed in 
children less than 1 year of age. Effective therapeutic concentrations are defined as a 
Cmax ≥ 2 µg/ml and the majority of children should obtain this desirable serum level 
when EMB is administered at a dose of 20 mg/kg/day (122) This dose is now 
recommended for use in children by the WHO (58). The excretion of this drug is 
predominantly renal and impairment of kidney function is a relative contraindication 
for EMB use. The most concerning adverse effect from EMB is the dose-dependent 
ocular toxicity (122). Signs of toxicity include loss of visual acuity and colour vision 
or reduction in visual fields (71). This is of concern in young children owing to the 
difficulty in assessing ocular function and particular caution is warranted. However, 
in a literature review performed by Donald et al., EMB dosed at 15-30 mg/kg was 
stopped due to concerns about possible ocular toxicity in only 2 of 3811 children 
(128, 129). In a recent study, 3 of 11 children < 5 years of age developed reversible 
visual impairment secondary to 23, 25 and 27 mg/kg/day of EMB (130). More data on 
EMB optic neuritis is required in children, particular in the very young.  
Drug disposition and developmental pharmacology 
To achieve optimal pharmacokinetic target concentrations for first-line 
antituberculosis drugs, good drug bioavailability and drug stability is essential, as 
INH, RMP, PZA and EMB are all routinely administered orally. In neonates, small 
gastrointestinal tract surface area influences absorption of drugs. Slow gastric 
emptying and low intestinal motility also contribute to slower drug absorption, and 
thus a longer time to achieve maximal drug concentrations (56). The stability of some 
drugs are influenced by pH, with an increased absorption of acid-labile drugs 
observed in neonates with an elevated intra-gastric pH (131). In addition, evidence 
suggests that the maturation of drug-metabolizing enzymes and activity of efflux 
transporters in young children may alter the bioavailability of drugs (56) impacting 
directly on pharmacokinetic target concentrations achieved. Larger total body water 
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and extracellular compartments in neonates and young infants all influence drug 
distribution. Clearance increases rapidly with age in children, and the non-linear 
relationship that exists between body weight and drug clearance leads to a higher dose 
per kilogram body weight necessary to achieve similar pharmacokinetic 
concentrations (132). This may differ in neonates and infants with immature organ 
function and clearance processes, which cautions against routine use of high dose 
first-line antituberculosis drugs in this age group. Very limited pharmacokinetic data 
of first-line antituberculosis drugs is however available in the youngest age groups 
where drug exposures are the most difficult to predict. 
 
Role of NAT2-genotyping in the metabolism of isoniazid 
Pharmacogenetic factors have been shown to predict drug exposure in children 
receiving INH (59, 60, 133). The rate of INH elimination shows genetic 
polymorphism with individuals classified as homozygous fast (FF), heterozygous fast 
(FS) or homozygous slow (SS) acetylators depending on their ability to eliminate this 
drug (134). NAT2 genotyping and enzyme maturation in the young child may also 
impact on INH serum concentration in infants. Despite genetic differences influencing 
the rate of elimination of INH, evidence suggests that NAT2 expression 
phenotypically matures with age as enzyme maturation develops, with faster 
acetylators metabolizing INH more rapidly with increasing age. The exact time of 
enzyme maturation remains unclear, with full maturity of the enzymatic pathways 
responsible for INH metabolism reached at an estimated 2-4 years of age (133, 135). 
Knowledge of the existing genotype of the individual together with the phenotypical 
behaviour will assist in better defining the time point where enzymes fully mature. 
Changes in the maturity of liver enzymes and the pharmacogenetic determinant(s) of 
acetylating capacity may therefore all influence the dose of drug needed to achieve 
adequate blood levels and antimycobacterial action. Little is known about the role of 
enzyme maturation on INH target drug concentrations in infants. 
 
Impact of antituberculosis drug formulations on drug exposure 
Not many antituberculosis formulations are suitable for neonates and infants. This age 
group cannot swallow whole tablets, and the effect on bioavailability when crushing 
these tablets is poorly defined. Liquid suspensions also typically have unknown 
bioavailability, a short shelf life and may require refrigeration, which can be 
Stellenbosch University  https://scholar.sun.ac.za
32 
problematic and impractical to use in resource-limited settings. Antituberculosis drugs 
are not always palatable and pill burden and long treatment durations may be 
challenging in children. Paediatric dispersible fixed-dosed combination (FDC) 
antituberculosis drugs, adapted for the revised 2009 WHO recommended drug doses 
(58), were only launched in December 2015 by the TB Alliance. Only one FDC drug 
is available to date (Macleods Pharmaceuticals Ltd.; Mumbai, India), which is not yet 
licensed in South Africa. Limited pharmacokinetic studies of these new FDCs have 
been completed in children (136, 137), and none specifically in infants. 
Use of relevant concomitant medications in infants 
The impact of cART on antituberculosis drugs in infants, given as part of PMTCT, or 
as HIV treatment has not yet been well characterized. Lower serum antituberculosis 
drug concentrations have been shown in HIV-infected adults with TB (127, 138), 
which may be attributed to malabsorption caused by drug-drug interactions. Co-
administration of ART and other drugs given either as prevention or treatment to 
HIV-exposed infants may be potentially harmful to infants. Potential interactions may 
occur with specific ART leading to decreased serum levels of these drugs in infants. 
The protease inhibitor (PI), lopinavir/ritonavir (LPV/r) and the non-nucleoside reverse 
transcriptase inhibitor (NNRTI) nevirapine have both been documented to have lower 
serum drug concentrations in the presence of RMP co-administration (139). 
Overlapping toxicity and adverse events encountered with use of antituberculosis 
drugs and ART are common, including skin rashes, gastrointestinal intolerance, 
hepatotoxicity and peripheral neuropathy (139). An increased risk of adverse events 
has been reported in a Canadian study performed in adult TB patients, with HIV-
infected individuals reported to be 3.8 times more likely to develop an adverse event, 
compared to their HIV-uninfected counterparts (140). In adult studies, TB patients 
with advanced HIV infection commonly experienced peripheral neuropathy, other 
neurological complications, rashes and gastro-intestinal events (141). 
Hepatotoxicity is an adverse effect of many antituberculosis and antiretroviral drugs, 
with two adult studies reporting between 6-18% severe hepatotoxicity in TB patients 
in the cART era (141, 142). Very limited reports of adverse events on both 
antituberculosis and antiretroviral drugs are available for children, and more safety 
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data should be generated. This is especially true for infants in high HIV prevalence 
settings, where ART is widely used in the context of PMTCT.  
Conclusions 
Rigorously designed pharmacokinetic studies are important to generate representative 
data on the pharmacokinetic properties and safety of first-line antituberculosis drugs 
in children, including infants. Non-compartmental analysis will be used in the studies 
described in chapters 6 and 7 due to ease of interpretation and clinical relevance. The 
prevention and treatment of TB in infants remains a challenge, complicated by 
paucity of pharmacokinetic data on the use of first-line antituberculosis drugs at the 
currently recommended WHO doses. Data generated by the studies in chapters 6 and 
7 will establish whether comparable adult target levels can safely be achieved by 
using these recommended dosages for first-line antituberculosis drugs in infants. INH 
exposures in newborns will be evaluated in the presence of maternal HIV infection, a 
major consideration in settings with a high burden of TB and HIV. In addition NAT2 
genotyping will be described for all infants receiving INH. Potential interactions 
between antituberculosis and ART drugs are explored and safety data are 
systematically reported. 
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CHAPTER 3 
 
TUBERCULOSIS EXPOSURE AMONG NEWBORNS IN A HIGH BURDEN 
TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS SETTING 
 
Infants (<12 months) born to women with tuberculosis (TB) are at high risk of TB 
exposure, infection and disease. In high prevalence human immunodeficiency virus 
(HIV) settings, TB disproportionately affects women of childbearing age (2, 4). In 
Cape Town, South Africa, the peak TB notification rates exceeded 1400 per 100 000 
population among young adults (age 25-45 years) in some areas in 2009 (14), with a 
16.9% HIV prevalence amongst women attending public antenatal clinics (15). The 
burden of TB during pregnancy and related perinatal outcome has not been reported 
in this setting and remains largely unknown.  
 
The primary aim of this study was to describe the indications and current practices for 
routine TB screening in neonates (< 28 days of life) at Tygerberg Hospital (TBH). 
Secondary aims included determining clinical characteristics of TB-exposed neonates 
and their mothers, treatment decisions in neonates, and infant outcomes prior to 
hospital discharge. I conducted a retrospective folder review of neonates screened for 
TB in 2009. Potentially eligible neonates were comprehensively identified using a 
three-pronged surveillance strategy: 1) laboratory data for mycobacteriological 
information, 2) clinical records of TB-exposed neonates, as identified by attending 
clinicians; and 3) pharmacy records of neonates discharged on TB medications. 
 
Results 
A key finding of this study was that a large number of neonates (n=70) were routinely 
screened for TB at our hospital during a one-year period. The majority of these 
neonates were screened for TB because of confirmed (41; 59%) or suspected (9; 13%) 
maternal TB. Another 5 (7%) neonates were investigated because of a household TB 
contact, and 15 (21%) due to severe neonatal illness compatible with TB, but without 
any known TB exposure. Infants born to women with TB were often premature (< 37 
weeks gestational age) and of low birth weight (LBW: < 2500 grams). Of the 38 
women treated for TB, of whom 25 (66%) were HIV-infected, five women had 
disseminated TB and a quarter of the women with TB presented with pleural effusions 
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during pregnancy. Prospective data from pregnant and postpartum women with TB at 
the same facility are presented in chapter 4. Three women died postpartum with 
confirmed TB: 1 woman from pneumonia without any TB treatment being initiated, 1 
woman from pneumonia and drug-resistant TB, and one woman from post-partum 
haemorrhage two months into TB treatment. Vertical transmission of TB was 
bacteriologically confirmed in 3/50 (6%) neonates born to women with confirmed or 
suspected TB. HIV infection status was poorly documented in HIV-exposed infants. 
Thirty-six (72%) neonates born to 50 women with suspected and confirmed TB were 
initiated on isoniazid preventive therapy (IPT). Only a third of these infants were 
traceable 12 months later, and only 5/12 traceable infants completed six months of 
IPT, as per standard recommended WHO and South African National TB programme 
(SANTP) guidelines (39, 42).  
 
Limitations of this study were the use of routine retrospective hospital data and the 
possibility that not all neonates screened for TB may have been studied, despite using 
a three-pronged surveillance strategy. Notwithstanding these limitations this is the 
first study conducted in a TB and HIV endemic setting to investigate TB exposure 
and indications for TB screening in neonates. A large number of neonates were 
screened for TB due to suspected or confirmed maternal TB, and two-thirds of all 
neonates screened for TB (n=70) were born to HIV-infected women. A large 
proportion of neonates were started on IPT suggesting delayed TB diagnosis in 
pregnancy (with ongoing positive sputum status and risk of transmission of M. 
tuberculosis to the infant). TB treatment outcome data for maternal-infant pairs 
affected by TB, with or without HIV, were particularly limited. This study highlighted 
the need to perform a prospective study in pregnant women with TB and their 
neonates, to more comprehensively describe maternal TB and maternal and infants 
outcomes in a high burden setting.  
 
By collecting better quality data on the spectrum of TB disease during pregnancy, 
including outcome data, a better understanding of the TB disease burden in pregnant 
women could be developed and strategies designed to minimise adverse outcomes for 
both mother and neonate. This study also highlighted major operational gaps in IPT 
delivery to at-risk infants exposed to TB. By identifying barriers to completion of 
antituberculosis treatment (preventive and curative) in TB-exposed neonates, 
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strategies to achieve better control of maternal-infant TB can be designed. These 
research gaps will be addressed in chapters 4 and 5, respectively  (study 2 of this 
thesis), where maternal-infant TB pairs were followed prospectively.  
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B A C K G R O U N D :  Maternal and neonatal tuberculosis 
(TB) are under-recognised, particularly in settings with 
a high burden of human immunodeficiency virus (HIV) 
infection.
D E S I G N  A N D  S E T T I N G :  Retrospective audit of neonates 
routinely screened for TB in a South African hospital 
during 2009. Surveillance sources reviewed included 
routine clinical, laboratory and pharmacy records.
R E S U LT S :  Among 70 neonates (60% HIV-exposed) 
screened for TB, the median gestational age was 35.5 weeks 
(IQR 33–38), and the median birth weight was 2000 g 
(IQR 1530–2484). The neonates were grouped accord-
ing to a history of documented TB exposure: maternal 
TB in 41/70 (59%), suspected maternal TB in 9/70 
(13%), other documented household TB exposure in 
5/70 (7%), and no known TB exposure 15/70 (21%). Of 
the 50 neonates exposed to confirmed or suspected ma-
ternal TB, 36 (72%) were initiated on TB chemopro-
phylaxis, 5 (10%) received TB treatment and 9 (18%) 
received no intervention. Eight (8/50, 16%) were diag-
nosed with TB, all of whom were born to mothers with 
suspected or proven TB.
C O N C L U S I O N S :  Maternal TB, primarily among HIV-
infected women, was the main indication for TB screen-
ing of neonates. Routine TB screening of pregnant women 
and TB care in mothers and infants should be improved 
in settings with a high burden of TB and HIV. 
K E Y  W O R D S :  newborns; low birth weight; TB treat-
ment; IPT; outcome
IN 2009, the World Health Organization (WHO) 
reported that South Africa had more than 20% of 
the global human immunode! ciency virus (HIV) co-
infected tuberculosis (TB) cases,1 with 60% of all TB 
cases being HIV-infected.2 Women in their reproduc-
tive prime (age 15–29 years) are disproportionately 
affected by the dual TB-HIV epidemic.3 In a study 
performed in post-partum HIV-infected South Afri-
can women prior to the roll-out of combination anti-
retroviral therapy (cART), 11% of HIV-infected 
women with a positive tuberculin skin test had undi-
agnosed TB.4 
TB and HIV are associated with increased mater-
nal and infant mortality.5–7 Women with TB alone are 
twice as likely to have premature and low birth 
weight (LBW, <2500 g) infants than women without 
TB.8 A study from Tanzania found that TB contrib-
uted to 17% of prevalent LBW among infants, and 
HIV-infected women were twice as likely to give birth 
to LBW infants than non-HIV-infected women.9 Ma-
ternal TB in HIV-infected women is also a risk factor 
for vertical HIV transmission.10,11 
TB-HIV co-infection contributes signi! cantly to in-
fant mortality. A study from Pune, India, reported an 
almost four-fold increase in infant mortality with 
maternal HIV-associated TB. Women with incident 
TB and their infants had respectively an adjusted 2.2- 
and 3.4-fold increased probability of death compared 
to woman-infant pairs without TB.10 Infants born to 
HIV-infected women with TB are at high risk of de-
veloping disease, including disseminated and compli-
cated TB. In the absence of appropriate chemopro-
phylaxis, up to 50% of infants will develop TB, 30% 
of whom will have progressive pulmonary or dissem-
inated disease, following exposure and infection.12 
Data regarding the presentation and outcome of TB-
exposed neonates are limited, particularly in settings 
with a high burden of TB and HIV.
Our aim was to describe the spectrum and out-
come of routine neonatal TB screening at a tertiary 
referral hospital in a setting with a high burden of TB 
and HIV. We describe indications for TB screening, 
sources of TB exposure, and the clinical presentation, 
management and outcome of mother-infant pairs. 
S U M M A R Y
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METHODS
Design and setting
This was a retrospective, descriptive study of neo-
nates routinely screened for TB at Tygerberg Hospi-
tal (TBH), a tertiary referral hospital in Cape Town, 
Western Cape Province, South Africa. TBH manages 
up to 6000 high-risk deliveries per year, serving ap-
proximately 30% of all provincial referrals. Neo natal 
wards have 112 beds, including 8 neonatal intensive 
care beds and 33 high-care beds. In this resource-
limited health care setting, there were 4470 admis-
sions to the neonatal wards in 2009; more than 20% 
of all neonates delivered were LBW. During the study 
period, no standard maternal or neonatal TB screen-
ing protocol was in place. 
During 2009, the peak TB noti! cation rate in Cape 
Town was among young adults (age 25–45 years), 
exceeding 1400 per 100 000.13 Childhood TB (age 0–
14 years) contributed 17.3% of the total provincial 
disease burden, with a noti! cation rate of 620/100 000 
in 2008 (unpublished data, Western Cape Depart-
ment of Health). The provincial maternal HIV preva-
lence for this period was 16.9% among public ante-
natal clinic attendees.14 Pregnant woman with a CD4 
count < 250 × 106/l quali! ed for cART, consisting of 
zidovudine (ZDV), lamivudine and nevirapine (NVP); 
for women with higher CD4 counts, prevention of 
maternal-to-child transmission (PMTCT) therapy in-
cluded antenatal ZDV and a single dose of NVP at 
the onset of labour.
Sources and type of data 
Based on the limited documentation of TB screening 
practice among newborns in TBH, we reviewed and 
included several sources of routine surveillance data 
to comprehensively identify neonates screened for TB. 
These included 1) laboratory data: all samples rou-
tinely collected from neonates (age <28 days) sub-
mitted to the routine hospital National Health Labo-
ratory Service (NHLS) for mycobacterial investigation 
during the study period; 2) clinical records: all neo-
nates with TB exposure or suspected TB disease as 
documented by attending clinicians in the neonatal 
wards; and 3) pharmacy records: the routine hospital 
pharmacy database was reviewed and all records of 
neonates discharged on any TB medications were 
retrieved. 
Thereafter, neonatal and maternal hospital folders, 
chest radiographs (CXR; where available) and addi-
tional laboratory records were reviewed to collect 
available clinical and demographic data on mother-
infant pairs. A standard data collection tool was de-
signed to extract folder data. The following neonatal 
data were collected: estimated gestational age, birth 
weight, HIV exposure (maternal HIV infection sta-
tus), clinical characteristics, including radiological in-
vestigations, TB exposure status and source and type 
of exposure, laboratory investigations, including myco-
bacterial investigation (culture, smear and drug suscep-
tibility testing), placental investigations, treatments, 
including TB preventive therapy and treatment and 
outcome at discharge from hospital. Maternal data 
included age, gravidity, parity, HIV status, CD4 count 
and cART, CXR, TB treatment history, information 
regarding current TB investigations including bacte-
riology, and the observed spectrum of TB disease. 
Case definitions
A case of neonatal TB was de! ned as clinical presen-
tation compatible with disease in conjunction with 
isolation of Mycobacterium tuberculosis from gas-
tric/tracheal aspirate, or clinically diagnosed TB; in 
the latter, a decision was made to treat together with 
infectious disease specialists, based on the presence of 
maternal TB with radiological or other clinical evi-
dence in the neonate suggestive of TB in the absence 
of culture con! rmation in the neonate.
A case of maternal TB was classi! ed as a mother 
already on anti-tuberculosis treatment or started on 
anti-tuberculosis treatment during the labour admis-
sion, after either bacteriological con! rmation or clin-
ical ! ndings compatible with TB (suggestive symptoms 
and CXR). If there was a strong clinical suspicion of 
TB during hospitalisation, but inadequate proof to 
make the diagnosis of TB, women were classi! ed as 
having suspected maternal TB. Women found to have 
a subsequent positive M. tuberculosis culture were 
re-classi! ed as having maternal TB following review 
of the available data.
Neonates received chemoprophylaxis according 
to standard WHO and South African National TB 
Programme (SANTP) guidelines.15 All neonates in 
close contact with a TB case were eligible for chemo-
prophylaxis, consisting of daily isoniazid (INH) ther-
apy (10 mg/kg/day) for 6 months. Anti-tuberculosis 
treatment in neonates comprised a 2-month inten-
sive phase of daily INH (10 mg/kg), rifampicin (RMP; 
10 mg/kg), pyrazinamide (25 mg/kg) ± ethionamide 
(ETH; 20 mg/kg), followed by a 4-month continua-
tion phase of INH and RMP at the same dose. ETH 
was the drug of choice in cases with extensive disease 
(instead of ethambutol) due to the dif! culty in evalu-
ating visual acuity in neonates.
Maternal and neonatal mortality during hospitali-
sation was documented. In January 2011, all surviv-
ing mothers/care givers, excluding infant deaths dur-
ing hospitalisation, were contacted by telephone to 
establish outcome. A standard questionnaire was ad-
ministered to all contactable participants. Three at-
tempts were made before participants were classi! ed 
as lost to follow-up. 
Approval for the study was obtained from the 
Health Research Ethics Committee of Stellenbosch 
University and TBH (N09/12/354). Waiver of in-
formed consent was granted. 
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Statistical analysis
Due to the descriptive nature of the study and the 
limited sample size, our analysis was not hypothesis 
driven. This study was not designed or powered to 
investigate the association between HIV infection and 
TB exposure in neonates. Our analysis was therefore 
mainly descriptive. Categorical variables were reported 
as actual numbers and proportions, and continuous 
variables as medians and interquartile ranges (IQRs). 
We ascertained the number of neonates screened for 
TB, and described the clinical characteristics of moth-
ers and neonates.
RESULTS
During the period under review, 74/4470 (2%) neo-
natal admissions were screened for TB, of which four 
were excluded due to inappropriate investigation 
(clinical condition not deemed to be TB-related). The 
Figure illustrates the three surveillance sources used 
to identify the study sample, the contribution of each 
source and the reported indications for TB screening 
among neonates. Only 10 patients were identi! ed us-
ing all three surveillance strategies. The majority of 
the neonates were screened for TB due to a history of 
maternal TB (41/70, 59%) or suspected maternal TB 
(9/70, 13%). Of the remaining 20 neonates, 5/70 
(7%) were investigated because of another household 
TB source case and 15/70 (21%) due to severe neo-
natal illness without known TB exposure. No infor-
mation on maternal TB was documented for these 
20 neonates, and only one of these quali! ed for TB 
prophylaxis based on local guidelines. 
The cohort of 70 neonates included four sets of 
twins. The median gestational age was 35.5 weeks 
(IQR 33–38), median birth weight was 2000 g (IQR 
Figure Flow diagram of TB screening and TB exposure in neonates born during 2009 at Tygerberg Hospital. * Excluded due to in-
appropriate investigations for TB: swabs from eyes (n = 3) and joints (n = 1). † Mother started on anti-tuberculosis treatment dur-
ing delivery admission to hospital or positive M. tuberculosis culture that was taken during delivery admission to hospital. ‡ Anti-
t uberculosis treatment was not initiated in 4 neonates: 1 died due to nosocomial sepsis, 1 died due to congenital abnormalities, 
1 was thought to have a low infection risk (mother in last month of anti-tuberculosis treatment), and 1 was discharged into the care 
of the aunt following the death of the mother. § TB case = neonate treated for TB. TB = tuberculosis.
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1530–2484), and sex was equally distributed. The 
majority (60%) of the neonates were HIV-exposed, 
and the median CD4 count of the HIV-infected moth-
ers was 176 × 106/l (IQR 90–328).
Data summarised in Table 1 include CXR ! ndings, 
bacteriology and treatment decisions for all 41 neo-
nates with proven maternal TB exposure. Neonates 
born to the 50 mothers with con! rmed or suspected 
maternal TB yielded eight (16%) cases of neonatal 
TB, of which six were born to HIV-infected mothers. 
Of the 50 neonates exposed to con! rmed or suspected 
maternal TB, 36 (72%) were initiated on chemo-
prophylaxis, 5 (10%) received anti-tuberculosis treat-
ment and 9 (18%) received no TB chemotherapy.
Clinical characteristics of the 38 women with TB 
are documented in Table 2. The spectrum of maternal 
TB was classi! ed as pulmonary TB, extra-pulmonary 
TB or both.2 A large proportion of all women with 
TB (17/38, 45%) were diagnosed with TB during 
the intrapartum period or shortly postpartum, with 
three infants developing con! rmed or presumed TB. 
A high proportion of HIV-infected women with TB 
had pleural effusions (8/25, 32%) or disseminated 
TB (5/25, 20%).
Clinical data on the cases of con! rmed and pre-
sumed neonatal TB are shown in Table 3, while data 
on maternal and neonatal mortality are summarised 
in Table 4. Overall neonatal mortality during hospi-
tal admission was 7/70 (10%); maternal mortality 
was 3/66 (5%). All maternal deaths were associated 
with TB, while TB might have contributed to one 
neonatal death. Telephonic follow-up to establish 
outcome in the cohort of 70 neonates could only be 
obtained in 29/70 (41%) infants. Of the 2/5 traceable 
neonates who were initiated on anti-tuberculosis 
treatment, both were reported to be well and to have 
completed 6 months of TB treatment. Of the 13/37 
(35%) traceable neonates who were started on TB 
chemoprophylaxis, one was subsequently started on 
anti-tuberculosis treatment; only 5/12 patients (42%) 
completed 6 months of INH.
Table 1 Clinical characteristics of neonates exposed to 
mothers treated for TB (n = 41)*
Neonates n (%)
Gestation, weeks, median [IQR] 36 [33–38]
Birth weight, g, median [IQR] 1950 [1537–2283]
Male sex 16 (39)
HIV-exposed 27 (66)
Chest radiography
Non-specific changes 24 (58)
Hyaline membrane disease 4 (10)
Transient tachypnoea of newborn 2 (5)
Pneumonia 4 (10)
Acute respiratory distress syndrome 1 (2)
Not performed 6 (15)
TB bacteriology (neonate)
Smear-positive 0
Culture-positive 2 (5)†
Anti-tuberculosis treatment initiated 
Anti-tuberculosis treatment 5 (12)
TB prophylaxis 32 (78)
No treatment‡ 4 (10)
Possible maternal TB transmission 7§
Mortality at discharge from hospital 3 (7)
* Includes three sets of twins.
† Another neonate was M. tuberculosis-positive, but the mother was only 
suspected to have TB and was not treated for TB.
‡ Anti-tuberculosis treatment was not initiated in 4 neonates: 1 died from 
nosocomial sepsis, 1 from congenital abnormalities, 1 was thought to have a 
low infection risk (mother in her last month of anti-tuberculosis treatment) 
and 1 was discharged into the care of the aunt due to the death of the 
mother.
§ One additional neonate with possible maternal TB transmission was identi-
fied from the group of mothers with suspected TB (eight neonates in total 
were considered to be neonatal TB cases).
TB = tuberculosis; IQR = interquartile range; HIV = human immunodeficiency 
virus.
Table 2 Clinical characteristics of mothers treated 
for TB (n = 38)*
n (%)
Age, years, median [IQR] 27 [23–31]
HIV-infected 25 (66)
Absolute CD4 count (HIV-infected women),
median [IQR] 138 [76–250]
Time of TB diagnosis
Ante partum 
Intra/post partum 
21 (55)
17 (45)
Confirmed vs. probable maternal TB†
Confirmed 
Probable 
22 (58)
16 (42)
CXR
Pleural effusion
Cavities
Lymphadenopathy
Bronchopneumonia
Miliary TB
Non-specific changes
Not performed 
9 (24) 
2 (5)
2 (5)
3 (8)
3 (8)
7 (18)
12 (32)
TB disease classification‡
PTB only 
EPTB only
Both PTB and EPTB
All disseminated TB§
22 (58)
7 (18)
9 (24)
5 (13)
Bacteriology
Smear-positive only¶
Culture-positive only 
Smear- and culture-positive
Negative smear and culture
No evidence of bacteriological 
investigation 
1 (3)
10 (26)
11 (29)
8 (21)
8 (21)
Mortality at discharge from hospital 3 (8)
* Includes three sets of twins.
† Confirmed maternal TB = bacteriological confirmation by smear or culture 
for M. tuberculosis; probable maternal TB = clinical diagnoses of TB and 
treatment initiation without available laboratory proof of bacteriological 
confirmation.
‡ PTB = sputum AFB-positive, M. tuberculosis on sputum culture, started 
based on suggestive CXR findings; EPTB = TB involving abdominal and su-
perficial skin lymph nodes.
§ Disseminated TB in mothers: 3 miliary, 1 blood culture and 1 placenta Ziehl-
Nielsen-positive.
¶ Culture not performed.
TB = tuberculosis; IQR = interquartile range; HIV = human immuno-
deficiency virus; CXR = chest radiography; PTB = pulmonary TB; EPTB = 
e xtra-pulmonary TB; AFB = acid-fast bacilli.
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DISCUSSION
This is the ! rst study investigating neonatal TB expo-
sure in the Western Cape Province, South Africa, a 
setting with high burdens of TB and HIV. The major-
ity of neonates in this hospital setting were routinely 
investigated for TB due to maternal or suspected ma-
ternal TB. In addition, two thirds of the women with 
TB were also HIV-infected, indicating the high bur-
den of co-infection in this setting. Almost half of all 
the women treated for TB were diagnosed only dur-
ing the intra- and postpartum period, illustrating the 
lack of appropriate routine antenatal TB screening, 
the importance of in-hospital screening and the po-
tential risk of nosocomial transmission in hospital 
settings such as ours. 
Of the 50 neonates screened for TB due to con-
! rmed or suspected maternal TB, a high proportion 
(8/50, 16%) were diagnosed with TB; 3/50 (6%) had 
con! rmed TB (assumed maternal source of infection) 
and 5/50 (10%) suspected transmitted TB. Those 
treated for presumed congenital TB (one set of twins) 
were judged to be at particularly high risk for TB in-
fection, although no con! rmatory bacteriological ev-
idence was available. The mothers of all infants had 
con! rmed TB, and three were HIV-infected. The neo-
nates were premature, had LBW and clinical signs of 
pneumonia and respiratory distress syndrome. A sin-
gle additional South African study from KwaZulu-
Natal (1997–1999)16 had previously reported a 16% 
incidence of vertical TB transmission in a setting with 
30% maternal HIV prevalence prior to the availabil-
ity of cART. Our data highlight the risk of congenital 
TB, particularly in the context of a high burden of 
maternal HIV. 
The presentation of congenital TB may be varied 
and dif! cult to diagnose. Mortality is typically high, 
at 22–50%.17,18 It is therefore imperative to maintain 
a high index of suspicion for TB among pregnant or 
postpartum women and their infants in settings with 
a high TB burden. TB screening during the antenatal 
and postnatal period is currently not adequately im-
plemented in high-burden settings, for example in 
PMTCT programmes. Our results con! rm that al-
most half of the women with TB were only diagnosed 
when admitted to hospital in the intra- and post-
partum period. Mothers were frequently only investi-
gated for TB when they had suggestive symptoms 
after hospitalisation for the delivery of their babies, 
by which time there was substantial risk of morbidity 
to both mother and infant. Furthermore, two thirds 
of the women with con! rmed TB were also HIV-
i nfected, with a tendency towards paucibacillary dis-
ease, indicating the need for rigorous screening using 
other tools in addition to sputum smear microscopy. 
In our study, the infants were mostly LBW and 
premature, consistent with studies from India, where 
infants born to mothers with TB had signi! cantly Ta
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lower weight and a two-fold increased risk of pre-
maturity. These effects were more prevalent when 
anti-tuberculosis treatment was commenced late in 
pregnancy, where poor maternal drug adherence was 
present and when the mother was sputum smear-
positive for M. tuberculosis.8 These data further em-
phasise the importance of earlier maternal TB case de-
tection. The high maternal mortality (5%) in women 
with TB is of concern; the delayed TB diagnosis in 
the majority of these women may be a contributing 
factor.
Women with TB were mostly young and HIV-
i nfected. The TB disease spectrum among mothers 
varied. Noteworthy observations were that pleural 
effusions occurred in nearly a quarter and dissemi-
nated TB in 5/25 (20%) HIV-infected mothers. It is 
possible that the risk of transmitting M. tuberculosis 
in utero is higher in pregnant mothers with recent 
M. tuberculosis infection or primary TB, e.g., those 
presenting with pleural effusion or with disseminated 
TB (miliary TB or tuberculous meningitis), which has 
a bacillaemic phase.17,19 In support of this hypothesis, 
of the eight neonatal TB cases (one set of twins), two 
mothers had tuberculous pleural effusions and three 
had disseminated TB disease. In a review of 75 cases 
of congenital TB with information on maternal TB 
available in 65 (43 with CXR results), 12/43 (28%) 
had pleural effusions, 8/43 (19%) had miliary TB and 
6/43 (14%) central nervous system disease.20 
Gupta et al. recently documented that infants born 
to HIV-infected mothers with TB had a 2.5-fold (95% 
con! dence interval [CI] 1.05–6.02, P = 0.04) in-
creased odds of being HIV-infected compared to in-
fants born to non-HIV-infected mothers, adjusting 
for maternal and infant factors.10 Despite the incom-
plete data on infant HIV polymerase chain reaction 
(PCR) testing (available for only 19/41 HIV-exposed 
infants in the present study), the number of HIV-
i nfected infants was high compared to routine re-
ported provincial HIV vertical transmission rates (3–
5%). We found that 5/19 (26%) infants tested for 
HIV were PCR-positive: 3 from the con! rmed mater-
nal TB group and 2 from mothers with suspected TB. 
However, these results should be interpreted with 
caution: selection bias might have occurred, as more 
severely ill infants were potentially more likely to be 
tested for HIV.
Although the attrition for neonates screened for TB 
was high, an alarmingly small number of infants were 
referred for TB chemoprophylaxis, and 5/12 (42%) 
completed 6 months’ chemoprophylaxis. This high-
lights the remaining operational challenges in linking 
hospital community care and improving adherence 
to INH preventive therapy in this highly vulnerable 
age group.
This study has several limitations, including the 
use of routine retrospective hospital data and the pos-
sible incomplete documentation of neonates screened 
for TB despite using a multisource surveillance strat-
egy. As no existing maternal TB screening protocol 
was in place, the entry point for our study was in-
fants screened for TB and not infants eligible for TB 
screening, leading to the potential omission of some 
infants. Data routinely recorded in folders were of 
varying quality, and outcome data were particularly 
limited, including those on completion of chemopro-
phylaxis and anti-tuberculosis treatment in this mo-
bile and impoverished urban study population. 
In a setting with high TB and HIV burdens, both 
routine antenatal TB and HIV screening are imperative. 
Table 4 Data on neonatal and maternal in-hospital mortality
HIV-exposed
Maternal 
TB status
Bacteriological evidence 
of TB in neonate 
Treated 
for TB
Age at 
death Attributed cause of death
Neonatal deaths (n = 7/70, 10%)
Yes (PCR not performed) Suspected None No 7 days Prematurity and Klebsiella 
pneumoniae septicaemia
Yes (PCR not performed) Confirmed 
(pleural effusion)
M. tuberculosis-positive No* 1 day Congenital abnormalities 
(Pierre Robin syndrome)
Yes (PCR-positive) Confirmed None Yes 6 months Stage 4 HIV and septicaemia
No Suspected M. tuberculosis-positive No* 16 days Acinetobacter baumanni 
septicaemia
Yes (PCR-negative) Not TB None No 51 days Congenital brain abnormality
Yes (PCR not performed) Not TB None No 16 days Respiratory syncytial virus 
pneumonia
No Not TB None No 24 days Group B streptococcus infection
Maternal deaths (n = 3/66, 5%)
Negative Yes, confirmed M. tuberculosis-positive None 10 days Pneumonia
Positive Yes, confirmed M. tuberculosis-positive 
(INH- and RMP-resistant)
None 2 days Miliary TB (multilobar 
pneumonia requiring 
ventilation)
Negative Yes, confirmed M. tuberculosis-positive 2 months  1 day Post-partum haemorrhage
* Infant died before gastric aspirate result became available.
HIV = human immunodeficiency virus; TB = tuberculosis; PCR = polymerase chain reaction for HIV; INH = isoniazid; RMP = rifampicin.
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Screening for TB diagnosis and prevention clearly lags 
behind that of HIV within PMTCT programmes. 
Where several HIV-infected mothers received cART, 
few were screened antenatally for TB. Early detec-
tion of both diseases will aid in the appropriate and 
earlier treatment of the mother and infant, reducing 
adverse outcomes, including neonatal TB, prematu-
rity and LBW. Our data indicate the need for prospec-
tive studies and interventions for improved maternal 
and infant TB screening and management in high-
burden settings.
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TB  exposure  in  neonates i
C O N T E X T E  :   La tuberculose (TB) maternelle et néona-
tale n’est pas suffisamment reconnue dans les contextes 
où le fardeau du virus de l’immunodéficience humaine 
(VIH) est élevé. 
S C H É M A  E T  D I S P O S I T I O N  :   Il s’agit d’un audit rétro-
spectif des nouveau-nés dépistés en routine pour TB 
dans un hôpital d’Afrique du Sud pendant l’année 2009. 
Comme sources de surveillance, on a utilisé les dossiers 
de routine en matière de clinique, de laboratoire et de 
pharmacie.
R É S U LTAT S  :   On a dépisté 70 nouveau-nés pour TB 
(60% exposés au VIH). L’âge gestationnel médian a été 
de 35,5 semaines (IQR 33–38) et le poids médian à la 
naissance de 2000 g (IQR 1.530–2.484). Les nouveau-
nés ont été regroupés en fonction de leurs antécédents 
documentés d’exposition à la TB : TB maternelle chez 
41/70 (59%) ; suspicion de TB maternelle chez 9/70 
(13%) ; autres expositions documentées au niveau du 
ménage chez 5/70 (7%) ; et aucune exposition connue à 
la TB chez 15/70 (21%). Sur les 50 nouveau-nés expo-
sés à une TB maternelle confirmée ou suspectée, 36 
(72%) ont été mis sous chimioprophylaxie de la TB, 5 
(10%) ont reçu un traitement de la TB et chez 9 (18%), 
il n’y a eu aucune intervention. Le diagnostic de TB a 
été porté chez 8/50 nouveau-nés (16%), tous nés de 
mères atteintes d’une TB suspectée ou démontrée. 
C O N C L U S I O N S  :   La TB maternelle, principalement chez 
les femmes infectées par le VIH, a constitué l’indication 
principale du dépistage chez les nouveau-nés. Un dé-
pistage de routine de la TB chez les femmes enceintes et 
les soins de TB chez les mères et chez les nourrissons 
devraient être améliorés dans les contextes où le fardeau 
de TB et de VIH est élevé.
M A R C O  D E  R E F E R E N C I A :   La tuberculosis (TB) materna 
y la TB neonatal suelen pasar desapercibidas, sobre 
todo en los entornos con una alta carga de morbilidad 
por la infección causada por el virus de la inmunodefi-
ciencia humana (VIH).
M É T O D O :   Evaluar la detección sistemática de la TB en 
los recién nacidos en un hospital en Sudáfrica en el 2009. 
Las fuentes de datos de vigilancia analizadas fueron los 
registros corrientes clínicos, de laboratorio y de farma-
cia del hospital. 
R E S U LTA D O S :  Se practicó el cribado para TB a 70 re-
cién nacidos (60% expuestos al VIH). La mediana de la 
edad gestacional fue 35,5 semanas (IQR 33 a 38) con 
una mediana del peso al nacer de 2000 g (IQR 1530 a 
2484). Los recién nacidos se categorizaron en función 
del antecedente de exposición a la TB de la siguiente 
manera: TB materna en 41/70 (59%), presunción clí-
nica de TB materna en 9 (13%), otra exposición directa 
documentada en 5 (7%) y sin exposición a la TB en 
15/70 recién nacidos (21%). De los 50 neonatos ex-
puestos a una TB materna presunta o confirmada, se 
inició la quimioprofilaxis tuberculosa en 36 (72%), 5 
(10%) recibieron tratamiento antituberculoso y en 9 
(18%) no se aplicó ninguna intervención. Se estableció 
el diagnóstico de TB en ocho recién nacidos (8/50, 
16%), cuyas madres presentaban ya sea una presunción 
clínica o un diagnóstico confirmado de la enfermedad.
C O N C L U S I Ó N :  La TB materna, sobre todo en las mu-
jeres con infección por el VIH, constituye la principal in-
dicación de detección de la TB en el recién nacido. Es 
importante mejorar la detección sistemática de la TB en 
las mujeres embarazadas y la atención de la TB de las 
madres y los lactantes en los entornos con una alta carga 
de morbilidad por TB e infección por el VIH.
R É S U M É
R E S U M E N
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CHAPTER 4 
 
CLINICAL DISEASE PRESENTATION AND TREATMENT OUTCOMES OF 
PREGNANT WOMEN WITH TB AT A REFERRAL HOSPITAL 
 
It became evident that exposure to M. tuberculosis was common and a serious clinical 
concern among neonates routinely admitted to a large provincial referral hospital in 
the Western Cape Province, Tygerberg Hospital (TBH) (143). Maternal TB was the 
main indication for completing TB screening in neonates, of which the majority was 
born to HIV-infected women. Isoniazid preventive therapy (IPT) was indicated in a 
large proportion of neonates because mothers were judged to pose an infectious risk 
of TB to their newborn infants (143). This delayed maternal TB diagnosis, together 
with the high number of poorly characterized and very ill pregnant women with TB 
who were often co-infected with HIV, were points of concern. No standard recording 
and reporting of TB during pregnancy was routinely required by the national TB 
programme during the time this research was conducted, and the burden of TB in 
pregnant and postpartum women at a facility such as TBH was therefore unknown. 
TB during pregnancy is associated with high morbidity and mortality in both mothers 
and infants (20, 23, 28, 29). It was therefore thought to be important to describe the 
epidemiology and clinical presentation of maternal-infant TB at TBH, and collect data 
on infant outcomes and maternal TB treatment outcomes.  
 
A prospective cohort study was conducted among pregnant and postpartum women 
routinely admitted to the obstetric services at TBH during 2011. HIV-infected and 
uninfected women, identified to be on TB treatment were consecutively enrolled from 
January 2011 through December 2011. All pregnant women on TB treatment and 
those initiated on TB treatment by their routine clinicians were eligible for inclusion. 
During the study period, 8471 women were admitted to the TBH obstetric services, 
where 5864 high-risk deliveries were managed during 2011. Low birth weight (LBW; 
<2500 g) infants constituted 2179 (37%) of all live births during this period (144). 
Baseline maternal and infant data were extracted from hospital records, and maternal 
TB treatment outcomes were assessed at TB treatment completion. Paper-based TB 
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treatment clinic registers and the national electronic TB registry (ETR.net) were used 
to determine maternal TB treatment outcomes. Standard World Health Organization 
(WHO) TB treatment outcome definitions were applied to classify maternal TB 
disease outcome: cured, treatment completed, treatment failure, loss to follow-up and 
death (145). Cured or treatment completed were considered as favourable TB 
treatment outcomes, while treatment failure, loss to follow-up or death were classified 
as unfavourable. Analysis was mainly descriptive; in addition, a multivariable 
regression model was used to identify predictors associated with unfavourable 
maternal TB treatment outcome. 
Results from this study showed that a large number (n=74) of pregnant and 
postpartum women with TB were admitted to routine obstetric services at TBH during 
a single year. Of the 74 women with TB, 35 (47%) women were diagnosed only after 
hospital admission for labour, and 22 (30%) reported a previous TB treatment 
episode. Fifty-three (72%) of 74 women were HIV-infected and 31/53 (58%) HIV-
infected women had a CD4 count of < 200 cells/mm3. Only HIV-infected women had 
manifestations of severe extrapulmonary (EPTB), including TB meningitis, TB spine, 
TB pericarditis, abdominal TB and bacteremia. Despite free, accessible antiretroviral 
therapy (ART) in the public sector, only 34/53 (64%) HIV-infected pregnant women 
had received any form of prevention of mother-to-child transmission (PMTCT) 
therapy or combination ART (cART). All five maternal deaths were amongst HIV-
infected women. The four stillbirths and 6 newborn deaths all occurred amongst 
infants born to HIV-infected women. Similar high rates of maternal and newborn 
mortality have previously been observed in pregnant and postpartum women with TB 
and HIV in earlier studies from India and KwaZulu-Natal, South Africa, where access 
to cART was not yet widely available (20, 23). 
Maternal TB treatment outcomes were poor in general, with 41/74 (55%) women only 
having favourable TB treatment outcomes. There was a high proportion of premature 
(49/75; 65%) and LBW infants (44/75; 59%) born to women with TB (2 sets of twins; 
1 foetus died in utero). Women with unfavourable TB outcomes were 3.83 times 
more likely to deliver a LBW infant (95% confidence interval 1.40 – 10.53, p=0.009), 
suggesting additional challenges for infant care in women with LBW infants beyond 
their own personal healthcare. 
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In conclusion, this study found a large number of women with TB routinely admitted 
and treated for TB at a large provincial referral hospital during 2011. The diagnosis of 
maternal TB was delayed with almost half of women initiated on treatment after 
hospital admission for labour. Maternal HIV infection was associated with high 
maternal and newborn mortality. Maternal TB treatment outcomes were poor. Health 
system strengthening is required to increase routine antenatal TB screening in settings 
with high burden of TB and HIV. Early TB diagnosis and treatment of pregnant 
women with TB, and PMTCT or cART in HIV co-infected women, will likely 
improve both maternal health and perinatal outcomes. Careful clinical management 
and follow-up is required for pregnant women with TB to ensure better treatment 
outcomes.  
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Abstract
Background
Tuberculosis during pregnancy and treatment outcomes are poorly defined in high preva-
lence tuberculosis and HIV settings.
Methods
A prospective cohort study of pregnant and postpartum women identified to be routinely on
antituberculosis treatment was conducted at Tygerberg Hospital, Cape Town, South Africa,
from January 2011 through December 2011. Maternal tuberculosis disease spectrum and
tuberculosis-exposed newborns were characterized by maternal HIV status. Maternal
tuberculosis treatment outcomes were documented and a multivariable regression model
identified predictors of unfavourable tuberculosis treatment outcomes. Infant outcomes
were also described.
Results
Seventy-four women with tuberculosis, 53 (72%) HIV-infected, were consecutively
enrolled; 35 (47%) were diagnosed at delivery or postpartum and 22 (30%) of women
reported previous antituberculosis treatment. HIV-infected women were 5.67 times more
likely to have extrapulmonary tuberculosis (95% CI 1.18–27.25, p = 0.03). All 5 maternal
deaths were amongst HIV-infected women. Birth outcomes were available for 75 newborns
(2 sets of twins, missing data for 1 stillbirth). Of the 75 newborns, 49 (65%) were premature
and 44 (59%) were low birth weight (LBW; <2500 grams). All 6 infants who died and the 4
stillbirths were born to HIV-infected women. Unfavourable tuberculosis treatment outcomes
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were documented in 33/74 (45%) women. Unfavourable maternal tuberculosis outcome
was associated with delivery of LBW infants (OR 3.83; 95% CI 1.40–10.53, p = 0.009).
Conclusions
A large number of pregnant women with tuberculosis presented at a provincial referral hos-
pital. All maternal and infant deaths occurred in HIV-infected women and their newborns.
Maternal tuberculosis treatment outcomes were poor.
Introduction
Tuberculosis (TB) during pregnancy and maternal TB treatment outcomes are poorly defined
in settings with high burden of TB and human immunodeficiencyvirus (HIV). TB and HIV
infection are both associated with increasedmorbidity and mortality in pregnant women and
their infants [1–4]. TheWorld Health Organization (WHO) estimated that there were 9.6 mil-
lion new TB cases globally in 2014, of which 1.2 million (12%) were HIV-infected, 74% from
the African region [5]. Of these incident TB cases, 3.2 million occurred in women, with 480,
000 estimated TB deaths [5].
It is unclear how many of these women were pregnant, as most countries do not report the
pregnancy status of female TB cases.Women of reproductive age are disproportionately
affected by TB in high HIV prevalence settings [6–7]. HIV-infected women are at increased
risk of TB with a prevalence of TB in pregnant women ranging from 1–11%, compared to
0.06–0.53% in HIV-uninfected women [8]. Immunological changes during pregnancymay
predispose to the susceptibility of new infection and the activation of latent TB infection [8].
Whether this increased risk of TB in HIV-infected women is further increased by being preg-
nant, remains unknown. In South Africa, where 61% of all reported TB cases were HIV-
infected in 2014 [5], non-pregnancy related infections (mainly deaths in HIV-infected women
complicated by TB and pneumonia) are the single most common cause of maternal mortality,
accounting for more than 35% of all maternal deaths [9]. TB in pregnant women also adversely
impacts on perinatal and infant outcomes. A two-fold risk of delivering premature (<37 weeks
gestational age) and low birth weight (LBW; <2500 grams) infants, and a six-fold increase in
perinatal deaths have been reported in women with TB [10]. Limited data are available for TB
treatment outcomes in pregnant women with TB, despite both pregnancy and TB linked to
poor outcomes [11].
The aim of this study was to describe the clinical presentation of TB in HIV-infected and
HIV-uninfected pregnant women and their perinatal outcomes at a large provincial referral
hospital in Cape Town. Maternal TB treatment outcomes were assessed at the end of antituber-
culosis treatment. Predictors of unfavourable TB treatment outcomes in pregnant women were
identified and reported.
Methods
Study design and setting
We conducted a prospective cohort study in HIV-infected and HIV-uninfected pregnant
women with TB routinely admitted to the obstetric services at Tygerberg Hospital (TBH),
Cape Town, South Africa, from January 2011 through December 2011. TBH is a large second-
ary and tertiary provincial referral hospital in theWestern Cape Province serving
TB in Pregnancy and Treatment Outcomes
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approximately one-third of the provincial population. During 2011, 8471 women were admit-
ted to the obstetric services at TBH, which managed 5864 high-risk deliveries. Obstetric service
admissions included women with antepartum (prior to delivery) complications, women in
labour (intrapartum), and women with postpartum complications (until 6 weeks post delivery).
LBW infants constituted 2179 (37%) of all live births during this period [12]. In 2009, Cape
Town had a mid-year population of 3,443,010 (3,241,508 HIV-uninfected and 201,502 HIV-
infected individuals), and 29,478 newly notified TB cases were recorded in the electronic TB
registry (ETR.net) [13]. Pregnant and postpartumwomen identified to be on routine antituber-
culosis treatment at TBH were consecutively enrolled and baseline information was obtained
frommothers and their newborns.
Pregnant women with tuberculosis
Antenatal TB screening was not routinely recommended or implemented by the South African
National TB programme (NTP) during the study period, despite the fact that all HIV-infected
persons were recommended to have had routine TB screening [14]. TB screening in pregnant
women at TBH consisted of identifying any of the following symptoms: presence of chronic
cough (>2 weeks), night sweats, fever, and loss of weight or failure to gain weight during preg-
nancy. If any of these were present, investigations were performed, including sputum/other
samples for microscopy for acid-fast bacilli (AFB) and mycobacterial culture, and shielded
chest radiography in the case of suspected pulmonary TB (PTB) [14]. For women with sus-
pected extrapulmonary TB (EPTB), directed special investigations were performed as clinically
indicated. The type of TB was classified according to the anatomical site of disease using stan-
dard WHO definitions: PTB only involved the lung parenchyma or the tracheobronchial tree;
EPTB involved organs other than the lungs, i.e. pleura, lymph nodes, pericardium, bones,
meninges or positive blood cultures forMycobacterium tuberculosis; both PTB and EPTB
involved a PTB case complicated by pleural effusion [15]. For the purpose of the study, severe
EPTBmanifestations were defined as EPTB not isolated to only peripheral lymph nodes or
pleural effusions, i.e. TB meningitis,M. tuberculosis positive on blood culture, abdominal TB,
TB spine and TB pericarditis. Standard WHO TB case definitions were applied: both a bacteri-
ologically confirmedTB case (a biological specimen that is positive by smear, microscopy, cul-
ture or Xpert MTB/RIF) or a clinically diagnosis of TB (no bacteriological confirmation but
diagnosed as TB disease with a decision to treat by a routine clinician) were classified as mater-
nal TB cases [15]. The standard antituberculosis treatment regimen for drug-susceptibleTB,
also in pregnant women, included a 2-month intensive phase of isoniazid (INH), rifampicin
(RMP), pyrazinamide (PZA) and ethambutol, followed by a 4-month continuation phase of
INH and RMP [14]. Antituberculosis treatment was individualised based onWHO treatment
guidance. Drug-resistant antituberculosis treatment regimens consisted of at least four effective
drugs and the total antituberculosis treatment duration was maintained for a minimum of 18
months [16]. No injectable agents were used in pregnant women with drug-resistant TB due to
the risk of foetal toxicity [14].
TB-exposed newborns
If any mother with TB was judged to pose a risk of transmittingM. tuberculosis to her newborn
(i.e. mother on antituberculosis treatment for< 2 months or not yet sputum smear or culture
converted), infants were investigated for TB disease. Infant screening included clinical exami-
nation, gastric aspirates/other sample for culture forM. tuberculosis, chest radiography and
other imaging/investigations as clinically indicated. Antituberculosis treatment was started in
infants if TB was suspected or confirmed. In disease-free infants, where the mother might still
TB in Pregnancy and Treatment Outcomes
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be infectious, 10 mg/kg/day of isoniazid preventive therapy (IPT) for six months was given in
infants born to drug-susceptibleTB mothers, while infants born to mothers with drug-resistant
TB received tailored preventive therapy regimen according to the mother’s drug susceptibility
test result. Infants born to mothers with TB who were no longer judged to be infectious did not
receive antituberculosis treatment, but were closely followed as part of routine care. Infant TB
outcomes were available for TB-exposed infants at 6 months of age in a subset of infants
enrolled on a complementary study of IPT delivery [17].
HIV infection in women and newborns
Maternal HIV testing included two confirmatory enzyme-linked immunosorbent assays
(ELISA) for HIV antibodies, routinely performed in all pregnant women with an unknown
HIV status upon hospital admission. The prevention of mother-to-child HIV transmission
(PMTCT) policy at the time included lifelong combination antiretroviral therapy (cART) for
all HIV-infected pregnant women with a CD4 count350 cells/mm3 and limited ART from 14
weeks onwards during pregnancy for HIV-infected women with CD4 count>350 cells/mm3
[18]. HIV-infected pregnant women on cART received the following drugs, tenofovir (TDF),
lamivudine (3TC)/emtracitabine (FTC) plus nevirapine (NVP). Limited ART regimens
included antepartum (just before delivery) zidovudine (AZT), intrapartum (during delivery)
NVP and AZT, and a single dose of TDF and FTC postpartum. Daily NVP for 6 weeks was
administered as newbornpreventive therapy for HIV, or daily NVP was given until discontinu-
ation of breastfeeding for mothers not on cART. HIV polymerase chain reaction (PCR) testing
was routinely performed at 6 weeks of age in HIV-exposed infants and earlier if clinically indi-
cated. All HIV-infected infants were fast-tracked for cART initiation [19]. HIV PCR results for
infants were extracted from the provincial laboratory database 6 months post-delivery.
Maternal TB treatment outcomes
Maternal TB treatment outcomes were assessed at the end of antituberculosis treatment, which
was routinely administered by TB services. Facility-based TB treatment clinic treatment regis-
ters (from local clinics) were reviewed and verified against the national electronic TB registry.
Standard WHO TB treatment outcome definitions were applied to classify maternal TB disease
outcomes: cured, treatment completed, treatment failure, lost to follow-up or death [15].
Cured or treatment completion was considered favourable TB treatment outcomes, while treat-
ment failure, lost to follow-up (LTFU) or death were classified as unfavourable TB treatment
outcomes. Maternal mortality was defined using the International Classification of Diseases
revised version 10, which included late maternal deaths between 42 days and one-year post
abortion,miscarriage or delivery [20].
Data collection
Written informed consent was obtained from eligible women with TB. Baseline information
was extracted frommaternal and infant hospital folders using a standard data collection tool.
Maternal data included age, ethnicity (black versus mixed race), haemoglobin at admission,
previous antituberculosis treatment, the presence of patient-reported TB symptoms (cough of
any duration, night sweats, perceived weight loss, chest pain or shortness of breath, fever, tired-
ness or malaise), the timing of TB diagnosis (ante- versus intra- or postpartum), type of TB
(PTB, EPTB or both), TB treatment regimen, and microbiology results including AFB smear-
microscopy, culture, and drug susceptibility testing where available. All chest radiographs were
read by two independent readers, using the modifiedTimika radiology score [21], which esti-
mates the extent of active PTB seen on a posteroanterior chest radiograph according to
TB in Pregnancy and Treatment Outcomes
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percentage of lung involvement and the presence/absence of cavities [22]. In HIV-infected
women CD4 count during pregnancy and ART delivery were documented. Perinatal outcomes
included gestational age, birth weight, birth type (singleton versus twin status), and death (still-
birth defined as death of a foetus after 28 weeks gestation). All antituberculosis treatment deci-
sions in newborns and deaths prior to hospital discharge were recorded.Maternal TB
treatment outcomes were assessed at antituberculosis treatment completion.
Data analysis
Maternal TB and infant characteristics, including infant outcomes, were evaluated by maternal
HIV status using summary statistics, odds ratios (OR) and 95% confidence intervals (CI).
Bivariate associations between categorical variables were evaluated using the Chi-square or
Fisher’s exact tests and continuous variables by t-test or Wilcoxon sign-rank-sum test for nor-
mally and non-normally distributed data, respectively. A p-value<0.05 was used to determine
statistical significance. In addition, a multivariable regression model was used to identify
whether any covariates were associated with unfavourable maternal TB treatment outcome.
Any covariate with a univariable logistic regression p-value<0.1 was included in the final
model. Maternal HIV status was considered clinically relevant and was included in the final
model regardless of its univariable p-value.
The study was approved by the StellenboschUniversity Health Research Ethics Committee
(N10/08/279), and the Ethics Advisory Group of the International Union Against Tuberculosis
and Lung Disease (944/10), Paris, France.
Results
Characteristics of pregnancy-associated TB
Seventy-four pregnant and postpartumwomen were identified to be on antituberculosis treat-
ment at TBH (Fig 1). Sixty-one (82%) of 74 women delivered at TBH and 13/74 (18%) women
were transferred in post-delivery. Of the 74 women with TB, 39 (53%) were started on antitu-
berculosis treatment prior to the delivery (3.6 months median duration of TB treatment) and
35 (47%) women were initiated on TB treatment upon hospital admission for delivery or
within 6 weeks post-delivery. On admission to the obstetric services, symptoms suggestive of
TB were documented in 31/74 (42%) women: 28/31 (90%) reported cough of any duration, 11/
31 (35%) night sweats, 11/31 (35%) perceived weight loss, 11/31 (35%) chest pain or shortness
of breath, 6/31 (19%) reported fever and 2/31 (6%) complained of tiredness and malaise.
Table 1 describes the maternal TB characteristics by HIV status. Fifty-three (72%) of 74
women on antituberculosis treatment were HIV-infected (median CD4 count 155 cells/mm3;
range 11–565 cells/mm3); 29/53 (55%) were on cART at time of delivery (median time on
cART 2 months; IQR: 1–5 months), 5/53 (9%) on PMTCT, 10/53 (19%) received no ART, and
9/53 (17%) had no documentation of ART. Age, ethnicity and EPTB only were associated with
maternal HIV status. All severe EPTBmanifestations occurred in HIV-infected women. Six
(14%) of 42 women in whom TB was bacteriologically confirmedhad drug-resistant TB; 4
were HIV-infected and 4 overall had unfavourable treatment outcome (Table 2).
Maternal TB treatment outcomes
Forty-one (55%) of 74 women with TB had favourable TB treatment outcomes and 33 (45%)
women had unfavourable treatment outcomes (Fig 1). Of the 26/74 (35%) women who were
LTFU, 13 were LTFU before entering the clinic TB registry and 13 women were classified as
LTFU at the time of TB treatment completion. HIV status was not associated with
TB in Pregnancy and Treatment Outcomes
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unfavourable maternal TB treatment outcome (OR 1.1, 95% CI 0.4–3.1, p = 0.85), but all 5
women who died were HIV co-infected.Deaths amongst pregnant women are described in
Table 3. All five maternal deaths (3 during hospital delivery admission and 2 after discharge
from hospital) were classified as TB-related by routine attending clinicians, but no autopsies
were performed.
Characteristics and outcomes of TB-exposed infants
Table 4 summarizes the characteristics and hospital outcomes of infants by maternal HIV sta-
tus (n = 76; 2 sets of twins). Gestational age and birth weight was unknown for 1 stillbirth.
Forty-nine of 75 (65%) infants were premature and 44/75 (59%) infants were LBW. No dif-
ferences in the gestational age and birth weight were observedbetweenHIV-exposed and HIV-
unexposed infants. All ten deaths (4 stillbirths, and 6 newborndeaths) were in infants born to
HIV-infected women; the causes of infant deaths are listed in Table 4. Treatment decisions
were made for all 72 live-born TB-exposed infants (4 stillbirths); 11 (15%) were given no anti-
tuberculosis treatment by routine attending clinicians (3 newborndeaths, 8 born to women
judged not to be infectious); 57 (79%) were initiated on IPT (all born to women judged to pose
significantM.tuberculosis transmission risk), and 4 (6%) were started on antituberculosis treat-
ment (3 completed 6 months of antituberculosis treatment and 1 died).M.tuberculosis was
confirmed in 2/72 (3%) TB-exposed infants; both infants had congenital TB and both were
born to HIV-infected women.
Of the 57 infants initiated on IPT, outcome data were available in 39 (68%) infants at 6
months following hospital discharge: 24/39 (62%) completed IPT, 13/39 (33%) did not com-
plete IPT, and 2/39 (5%) died (17). HIV PCR tests were performed in 45 (82%) of 55 HIV-
exposed newborns;HIV PCR testing was not done in 10 infants (4 stillbirths, 4 newborn
deaths, and in 2 newbornswho were LTFU). Of the 45 newbornswho had HIV testing, 42
Fig 1. Pregnant and postpartum women on tuberculosis treatment and their outcomes (n = 74).
doi:10.1371/journal.pone.0164249.g001
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(93%) had a negative test result and 3 (7%) were HIV PCR positive. All 3 HIV-infected infants
were initiated on cART and were alive and well at six months of age.
Table 1. Maternal tuberculosis characteristics by HIV status (n = 74).
All pregnant women Maternal HIV status OR (95% CI) p-value
HIV-infected (n = 53) HIV-uninfected (n = 21)
Age in years, mean (SD) 29.8 (6) 31.1 (6) 26.7 (6) 1.16 (1.04–1.30) 0.006
Black ethnicity (%) 1 48 (65) 42 (80) 6 (29) 9.55 (3.00–30.34) <0.001
Haemoglobin in g/dL, mean (SD) [n = 70] 9.8 (1.7) 9.6 (1.8) 10.1 (1.5) 0.86 (0.64–1.18) 0.352
Previous TB treatment (%) 22 (30) 16 (30) 6 (29) 1.08 (0.35–3.29) 0.891
Timing of TB diagnosis
Antepartum (%) 39 (53) 27 (51) 12 (57) -Ref-
Intra- or postpartum (%) 35 (47) 26 (49) 9 (43) 1.28 (0.46–3.55) 0.630
TB case definitions
Bacteriologically confirmed (%) 50 (68) 33 (62) 17 (80) 0.39 (0.11–1.32) 0.129
Clinically diagnosed (%) 24 (32) 20 (38) 4 (20) Ref
TB disease type
PTB only (%) 47 (63) 30 (56) 17 (80) Ref
EPTB only (%) 22 (30) 20 (38) 2 (10) 5.67 (1.18–27.25) 0.030
Both PTB and EPTB (%) 5 (7) 3 (6) 2 (10) 0.85 (0.13–5.60) 0.866
EPTB disease manifestation [n = 27] 2
Severe EPTB
TB meningitis (%) 8 (29) 8 (15) 0 (0)
Blood culture positive for M. tuberculosis (%) 1 (4) 1 (2) 0 (0)
Abdominal TB (%) 1 (4) 1 (2) 0 (0)
TB spine (%) 1 (4) 1 (2) 0 (0)
TB pericarditis (%) 1 (4) 1 (2) 0 (0)
Non severe EPTB (%)
Peripheral lymph nodes (%) 2 (7) 2 (4) 0 (0)
Pleural effusions (%) 13 (48) 9 (17) 4 (19)
Microbiological results
Smear positive (%) [n = 73]3 28 (38) 18 (34) 10 (50) 0.44 (0.16–1.24) 0.121
Culture positive (%) 42 (57) 28 (53) 14 (67) 0.56 (0.19–1.61) 0.282
Chest radiographic features [n = 52] 4 52 (70) 39 (74) 13 (62)
Percentage affected lungs, median (IQR) 14 (8–32) 14 (8–33) 14 (8–28) 0.99 (0.96–1.02) 0.382
Presence of cavities (%) 9 (17) 6 (15) 3 (23) 0.61 (0.13–2.87) 0.528
Final score, median (IQR) 15 (8–38) 19 (8–38) 14 (8–28) 0.99 (0.97–1.01) 0.346
TB treatment regimen
First-line TB treatment (%) 68 (92) 49 (93) 19 (91) 1.29 (0.22–7.63) 0.779
Second-line TB treatment (%) 6 (8) 4 (7) 2 (9)
Maternal mortality (%) 5 (7) 5 (9) 0 (0.0) — 0.313
OR, odds ratio; SD, standard deviation; TB, tuberculosis; Ref, reference; PTB, pulmonary TB; EPTB, extrapulmonary TB; IQR, interquartile range.
1 Women were of black ethnicity or mixed race
2 M. tuberculosis was cultured in 15/27 (56%) EPTB women; on cerebrospinal fluid in 3, on bone biospy in 1, on pericardial fluid in 1, on blood culture in 1,
on lymph node tissue in 3 (1 abdominal TB and 2 peripheral lymphadenopathy), and on pleural fluid in 6.
3 Xpert MTB/RIF was positive and culture positive for M. tuberculosis in the sputum of 1 women. The positive Xpert MTB/RIF result was excluded from the
smear positive analysis.
4 Chest radiographic features were only available for 52 pregnant women with any TB disease type.
doi:10.1371/journal.pone.0164249.t001
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Predictors of unfavourable maternal TB treatment outcomes
In univariable logistic regression, delivery of a LBW infant was associated with unfavourable
maternal TB treatment outcome (p = 0.009). Maternal HIV status, maternal age, haemoglobin
upon hospital admission, the presence of any EPTB, bacteriologically confirmed tuberculosis,
and intra- and postpartumTB diagnosis were not associated with an unfavourable treatment
outcome (Table 5). In multivariable regression, adjusting for maternal HIV infection, women
delivering LBW infants were 3.83 times more likely to have an unfavourable TB treatment
Table 2. Characteristics and outcomes of pregnant women with confirmed drug-resistant tuberculosis (n = 6).
Maternal characteristics Outcomes
TB presentation TB treatment regimen HIV features Perinatal and infant 1 Maternal TB
• Pulmonary TB2
• M. tb (INH and RMP
resistant) cultured from
sputum within 13 d
• 38 y,
• Mixed race
• 3 m of OFX,ETO,PZA,EMB,TRD
prior to delivery;
• 9 m interruption post- delivery,
and presented again with M.tb
sputum (INH, RMP, ETH and OFX
resistant)
• CD4 24 cells/mm3
• Previously diagnosed with HIV
infection, 3 m prior to delivery
(TDF, 3TC, NVP)
▪ Male,
▪ 1940 g,
▪ 38 w GA
▪ Alive at 9 m and completed 6 m
of high dose INH, in place of
safety.
▪ PCR HIV negative
Unfavourable
(LTF)
▪ Pulmonary TB2
▪ M. tb (INH and RMP
resistant) cultured from
sputum within 22 d
▪ 28 y,
▪ African
▪ 8 m of OFX, ETO, PZA,EMB,
TRD and 5 m of TB treatment
interruption prior to delivery.
▪ Mom was re-initiated on TB
treatment post-delivery—adhered
for 3 m, and then re-located
• CD4 410 cells/mm3
• Previously diagnosed with HIV
infection, but defaulted ART 5 m
prior to delivery PMTCT at
delivery
▪ Male,
▪ 3100 g,
▪ 40 w GA
▪ Alive at 3 m and completed 3 m
of high dose INH, then LTF.
▪ PCR HIV negative
Unfavourable
(LTF)
• TB meningitis and miliary TB
• M. tb (INH and RMP
resistant) cultured from CSF
within 18 d,
• 29 y,
• Mixed race
• 11 days of INH,RMP,PZA,EMB
• M.tb culture results only became
available after the mother had died
• CD4 87 cells/mm3
• Previously diagnosed with HIV
infection, but defaulted ART 3 m
prior to delivery
▪ Foetus died in utero Unfavourable
(died)
• Pulmonary TB 2
• M. tb (INH and RMP
resistant) cultured from
sputum within 22 d
• 30 y,
• African
• 18 m of OFX,ETO,PZA,EMB,
TRD
• 14 m prior to delivery, and 4 m
post-delivery
• CD4 154 cells/mm3
• Previously diagnosed with HIV
infection 14 m prior to delivery
(ZDV, 3TC, EFV)
▪ Female,
▪ 2690 g,
▪ 40 w GA
▪ Alive at discharge from hospital.
No TB medication indicated
▪ PCR HIV negative
Favourable
(cured)
• Pulmonary TB
• M. tb (INH and RMP
resistant) cultured from
sputum within 22 d
• 38 y,
• Mixed race
• 24 m of OFX,ETO,PZA,EMB,
TRD
• 9 m prior to delivery, and 15 m
post-delivery
• HIV uninfected ▪ Male,
▪ 2920 g,
▪ 38 w GA
▪ Alive at discharged from
hospital.
▪ No TB medication indicated
Favourable
(cured)
Pulmonary TB
• sM. tb (INH, RMP, ETH, OFX
and AMK resistant) cultured
from sputum within 24 d
• 30 y,
• African
• 1 m of OFX,ETO,PZA,EMB,TRD
• Prior to delivery, followed by 8 m
of extensively drug-resistant TB
treatment 3
• HIV uninfected ▪ Female,
▪ 3625 g,
▪ 40 w GA
▪ Alive at 1 month and completed
1 month of high dose INH—then
LTF (re-located with grandmother)
Unfavourable
(LTF)
TB, tuberculosis; M. tb, Mycobacterium tuberculosis; INH, isoniazid; RMP, rifampicin; d, days; y, years; m, months; OFX, ofloxacin; ETO, ethionamide;
PZA, pyrazinamide; EMB, ethambutol; TRD, terizidone; TDF, tenofovir; 3TC, lamivudine; NVP, nevirapine, g, grams; ZDV, zidovudine; EFV, efavirenz; w,
weeks; GA, gestational age; ART, antiretroviral therapy; PCR, polymerase chain reaction; PMTCT, Prevention of mother-to-child-HIV transmission; CSF,
cerebrospinal fluid
1 No fetal abnormalities were detected at birth
2 Previously treated for drug-susceptible TB
3 Mother was subsequently discharged from TB hospital and lost to follow-up
doi:10.1371/journal.pone.0164249.t002
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outcome (95% CI 1.40–10.53, p = 0.009), compared to women delivering infants
weighing> 2500 grams.
Discussion
This study represents one of the largest prospective cohorts of HIV-infected and uninfected
pregnant and postpartumwomen with TB, including reporting of maternal TB treatment out-
comes. TBH is a provincial referral hospital that manages high-risk and complicated deliveries
and serves communities with high burdens of TB and HIV. Of the 74 women with TB, nearly
half were only diagnosed at delivery or in the postpartum period, and almost a third of women
reported prior tuberculosis treatment. More than two-thirds of women on antituberculosis
treatment were HIV-infected, the majority were severely immune suppressed, and many pre-
sented with severe manifestations of EPTB. All deaths occurred in HIV-infected women. All
stillbirths and newbornswho died were born to HIV-infected women. Maternal TB treatment
outcomes were poor with unfavourable TB treatment outcomes in 33/74 (45%) of women. Pre-
maturity and LBW status were common amongst infants. LBW deliveries were associated with
unfavourable maternal TB treatment outcomes.
The challenges of diagnosing TB during pregnancy may lead to under-recognition of TB in
pregnant women. Early TB symptoms are often non-specific [23], and overlap with pregnancy
Table 3. Deaths amongst pregnant women with tuberculosis and infant outcomes (n = 5).
Maternal characteristics Outcomes
TB presentation TB treatment regimen
duration prior to delivery
HIV features at delivery Perinatal and infant Maternal
death
▪ Pulmonary TB
▪ Respiratory failure (Sputum
negative for M. tb)
▪ 31 y and African
▪ Hb 11.4 g/dL
▪ 1 w
▪ RMP,INH,PZA and EMB
▪ Pneumocystis jiroveci
pneumonia
▪ CD4 16 cells/mm3.
▪ Newly diagnosed with
HIV
▪ No prior cART
▪ Male, 1290 g, 29 weeks GA
▪ Alive at 3 m and on TB preventive
therapy
▪ PCR HIV negative
▪ 2 d after
delivery
▪ Abdominal TB
▪ M. tb (INH and RMP susceptible)
cultured from lymph node within 6 d.
▪ Adenosine deaminase of 185 IU/L
on ascitic fluid
▪ 24 y and African
▪ Hb 9.8 g/dL
▪ 1 d
▪ RMP,INH,PZA and EMB
▪ Kaposi sarcoma
▪ CD4 50 cells/mm3
▪ Diagnosed with HIV 2
m prior to delivery
▪ cART initiated at time of
HIVdiagnosis
▪ Female, 2030 g, 35 weeks GA
▪ M. tb cultured from gastric aspirate
(x2). Alive at 6 m and completed TB
treatment
▪ PCR HIV negative
▪ 96 d after
delivery
▪ Bacteraemia
▪ M. tb (INH and RMP susceptible)
cultured from blood within 28 d
▪ 27 y and African
▪ Hb 7.8 g/dL
▪ Less than 1 m
▪ RMP,INH,PZA and EMB
▪ CD4 102 cells/mm3
▪ Newly diagnosed with
HIV
▪ cART inititated < 1 m
prior to delivery
▪ Male, 980 g, 30 weeks GA
▪ Died on day of birth—cause of death:
prematurity and hyaline membrane
disease
▪ PCR HIV negative
▪ On day of
delivery
▪ TB meningitis and miliary TB
▪ M. tb (INH and RMP resistant)
cultured from CSF within 18 d
▪ 29 y and of mixed race
▪ Hb 8.2 g/dL
▪ 11 d
▪ RMP,INH,PZA and EMB
▪ CD4 87 cells/mm3
▪ Newly diagnosed with
HIV
▪ No prior cART
▪ Foetus died in utero ▪ 11 d after
admission
▪ TB meningitis
▪ Tuberculoma on CT scan
▪ 27 y and of mixed race
▪ Hb 7.3 g/dL
▪ 1 d
▪ RMP,INH,PZA and EMB
▪ CD4 37 cells/mm3
▪ Newly HIV diagnosed
▪ No prior cART
▪ Male, 1260 g, 30 weeks GA
▪ Alive at 6 m and completed TB
treatment
▪ PCR HIV negative
▪ 54 d after
delivery
M. tb, M. tuberculosis; y, years; RMP, rifampicin; INH, isoniaizd; PZA, pyrazinamide; EMB, ethambutol; cART, combination antiretroviral therapy; g, grams;
w, weeks; GA, gestational age; PCR, polymerase chain reaction; d, days; Hb, haemoglobin; m, months; CSF, cerebrospinal fluid; CT, computerized
tomography
doi:10.1371/journal.pone.0164249.t003
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symptoms [11]. Poor performance of TB symptom-screening tools has been noted in two
recent studies in HIV-infected pregnant women, reporting a sensitivity of 28% and 54%,
respectively [24–25]. A third of women from our cohort reported previous TB treatment,
highlighting the possible importance of documentation of previous treatment as a risk factor
for maternal TB. Consideration of previous TB may therefore be useful as an additional part of
currentWHO TB screening algorithms in pregnant women. Furthermore, TB diagnosis in
pregnant women was often delayed. Almost half of the women in our cohort were only diag-
nosed with TB upon hospital admission for labour and up to 6 weeks post-delivery. Delayed
TB diagnosis can be explained both by the difficulty in diagnosing TB during pregnancy and
the increased risk of TB in the post-partum period.A large epidemiological study from the
United Kingdom that was conducted in 192,801 women (a total of 264,136 pregnancies)
recently found that early postpartumwomen were twice as likely to develop TB as non-preg-
nant women [26]. Delayed TB diagnosis in 47% of our cohort likely contributed to the
Table 4. Characteristics and outcome of TB-exposed infants at hospital discharge, by infant HIV exposure status (N = 76).
All infants Infant HIV Status OR (95% CI) p-value
HIV-exposed (n = 55) HIV-unexposed (n = 21)
Gestational age in weeks, median (IQR) [n = 75] 1 36 (31–38) 36 (31–38) 37 (33–38) 0.99 (0.87–1.13) 0.851
Premature (%) [n = 75] 1 49 (65) 38 (70) 11 (52) 2.16 (0.77–6.09) 0.146
Birth weight in grams, median (IQR) [n = 75] 1 2120 (1386–2920) 2080 (1350–2930) 2230 (1900–2885) 1.0 (1.00–1.00) 0.563
Low birth weight, <2500 grams (%) [n = 75] 1 44 (59) 32 (59) 12 (57) 1.09 (0.39–3.03) 0.867
Birth type
Singletons (%) 72 (95) 51 (93) 21 (100) — 0.571
Number of twin babies (%) 4 (5) 4 (7) 0 (0)
TB treatment decision in live born infants [n = 72]
No TB treatment (%) 11 (15) 7 (14) 4 (19) Ref
TB preventive therapy (%) 57 (79) 41 (80) 16 (76) 1.46 (0.38–5.69) 0.582
TB treatment (%) 2 4 (6) 3 (6) 1 (5) 1.71 (0.13–22.51) 0.682
Deaths 10 (13) 10 (18) 0 (0.0) — 0.054
Stillbirths (%) 4 (5) 4 (7) 0 (0.0)
Newborn deaths (%) 3 6 (8) 6 (11) 0 (0.0)
OR, odds ratio; CI, confidence interval; IQR, interquartile range; Ref, reference; AFB, acid fast bacilli
1 Unknown gestational age and birth weight for one fetus who was still in utero when mother died.
2 M. tuberculosis cultured from 2 gastric aspirates in 1 infant, 1 symptomatic ventilated infant had AFB on tracheal aspirate, 1 infant had miliary TB, and 1
infant had suggestive chest radiography.
3 Respiratory distress syndrome in 2, necrotising enterocolitis in 1, presumed nosocomial sepsis in 1, vein of Galen malformation in 1, and duodenal web in
1.
doi:10.1371/journal.pone.0164249.t004
Table 5. Predictors of unfavourable maternal tuberculosis treatment outcome (n = 74).
Univariable OR (95% CI) p-value Multivariable OR (95% CI) p-value
Maternal HIV infection 1.10 (0.40–3.06) 0,850 1.06 (0.36–3.10) 0.921
Low birth weight infant (<2500g) 3.83 (1.40–10.53) 0,009 3.83 (1.40–10.53) 0.009
Any extrapulmonary TB 1.59 (0.61–4.12) 0,342
Maternal age 0.99 (0.92–1.07) 0,837
Intra- and postpartum TB diagnosis 1.69 (0.67–4.27) 0,264
Haemoglobin prior to delivery 0.87 (0.66–1.15) 0,319
Bacteriologically confirmed TB 1.54 (0.57–4.16) 0,396
doi:10.1371/journal.pone.0164249.t005
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pronounced maternal morbidity and mortality. Untreated maternal TB carries a significant
risk of TB exposure to infants and risk of TB in infants, and led to IPT being initiated in three-
quarters of TB-exposed infants.
More than two-thirds (72%) of women with TB were HIV-infected, which is comparable to
the 2009 national data with an HIV prevalence of 61% in all notified TB cases [5]. Despite wide
access to maternal ART, only 64% ART uptake was documented in pregnant women with TB
in our study. Only HIV-infected women had severe EPTBmanifestations, including TBmenin-
gitis, TB spine, TB pericarditis, abdominal TB and bacteraemia. Increased EPTBmanifestations
in HIV-infected pregnant women have also been reported in studies of TB during pregnancy
(1, 3). Whether this increased risk for EPTB is purely because of immunosuppression from
HIV co-infection [27–28], and whether the immunological changes from pregnancy co-con-
tribute, remain uncertain. All five maternal deaths occurred in HIV-infected women and were
attributed to TB. All the women who died were newly diagnosedwith HIV upon hospital
admission, were severely immune suppressed, and had received a very short period of ART, if
any, prior to delivery. They all had a short antituberculosis treatment duration (between 1 day
and 1 month), making immune reconstitution inflammatory syndrome (IRIS) unlikely. Drug-
resistant TB was confirmed in 6/42 (14%) women in whomM.tuberculosis was bacteriologi-
cally confirmed.We describe the drug-resistant TB from our cohort due to the lack of pub-
lished data in this subgroup of TB patients. Noteworthy is that none of these women routinely
received antituberculosis injectable agents during pregnancy, and that unfavourable maternal
TB treatment outcomes were documented in four of these women.
Two-thirds of infants born to pregnant women with TB were premature and had LBW,
exceeding the already high burden of LBW infant deliveries of 37% at our provincial referral
hospital during the study period [12]. An increased risk of prematurity and LBW infant deliv-
eries have previously been described in pregnant women with TB [10, 29]. Previous literature
has also reported a highmortality in infants born to mothers affected by TB and HIV [4], all
stillbirths and newborndeaths in our cohort were born to HIV-infected mothers. Congenital
TB was only confirmed in 2/72 (3%) newborns, both in infants born to HIV-infected women, a
lower figure than the 16% reported by Pillay et al., between 1997–1999, at a referral hospital in
Durban, South Africa, prior to any ART use in HIV-infected pregnant women [1].
TB treatment completion or cure was only achieved in 41 (55%) women. These poor treat-
ment outcomes are of concern and should be seen in the context of an academic hospital set-
ting with more ill women referred for complications during pregnancy or birth. Almost a fifth
of women with TB were lost to follow-up before being documented to continue treatment at
the local TB clinic services (initial loss to follow-up), emphasizing the need to improve linking
of clinical services between hospital and community-based TB clinics. Maternal HIV infection
was not a predictor for an unfavourable TB treatment outcome; however, LBW deliveries were
associated with unfavourable maternal TB treatment outcomes. It is possible that women with
LBW infants may have had additional challenges to attend personal healthcare, given the chal-
lenges of also caring for these LBW infants.
This study has several limitations and does not represent the general population of pregnant
women with TB in the study setting. Selection bias might have occurred as only women with
complicated pregnancies are referred to TBH for specialised care. Despite this limitation, this
relatively large cohort study of seventy-four women adds to the current limited knowledge base
of TB disease during pregnancy and maternal TB treatment outcomes in a setting with high
HIV prevalence. Another limitation was that the exact time of HIV diagnosis was not systemat-
ically recorded in all HIV-infected women. However, all women were tested for HIV prior to
hospital discharge and all ART provision was recorded. TB and HIV treatment were provided
as part of routine national programmatic services and antituberculosis treatment adherence
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was not monitored in this study. Follow-up was conducted by routine TB services, and only
maternal TB treatment outcome data were collected by the study team. Our definition of unfa-
vourable maternal TB treatment outcomes included women who were LTFU, as recommended
by WHO. Although we cannot confirm that these women did not complete antituberculosis
treatment elsewhere or whether they died, the use of two different TB registry documents
(paper based and electronic) could not trace them.
In settings with high burden of TB and HIV, successful implementation of PMTCT pro-
grammes in HIV-infected women, with earlier initiation of ART, is critical to reduce maternal
and infant morbidity and mortality. In addition, preventing TB deaths among HIV-infected
women requires intensified scale-up of TB prevention, diagnosis and treatment interventions
within maternal health and TB programmes. Basic antenatal TB screening should routinely be
included in high burden TB/HIV settings, and the high risk of TB in the postpartum period
should also be considered in TB screening guidelines [26]. Ascertaining previous TB treatment
episodesmay improve the sensitivity of the current TB symptom-screening tool. The use of
improved molecular diagnostics, including Xpert MTB/RIF, which was not routinely available
at the time of the study, may reduce diagnostic delays and result in more rapid initiation of
antituberculosis treatment, also in pregnant women. A high degree of clinical awareness is
essential to diagnose TB in pregnancy and the postpartum period. Improved recording and
reporting of maternal TB and treatment outcomes during pregnancy will contribute to better
estimates of disease burden, and informmuch needed guidelines to improve TB case finding
and outcomes amongst women and their infants.
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CHAPTER 5 
COMPLETION OF PREVENTIVE ANTITUBERCULOSIS TREATMENT 
AMONG TB-EXPOSED NEWBORNS IN A RESOURCE-LIMITED SETTING 
Isoniazid preventive therapy (IPT) uptake is typically low but variable in resource 
constrained settings worldwide, ranging from 5-50% (44, 46-49). This poor IPT 
uptake in high burden countries has been observed despite the current World Health 
Organization (WHO) guidelines recommending contact investigation and daily 
isoniazid (INH) preventive treatment for 6 months in children < 5 years exposed to 
Mycobacterium tuberculosis (41). Adherence to, and completion of unsupervised IPT 
in children less than 5 years of age has been very poor in Cape Town, South Africa 
(44, 51, 146). Between 2003-2005, a study collecting data from two Cape Town 
suburbs, reported completion of unsupervised IPT in 36/180 (20%) children with a 
known TB index case (50). In 2010, a large retrospective record review performed in 
14 primary health care facilities in Cape Town, identified 525 child contacts from 
1179 infectious adult TB case-records. Of these 525 children, 141 (27%) children 
were initiated on IPT, and less than 14% (19/141) completed 6 months of routine 
programmatic delivery of IPT (147).  IPT uptake and completion are hampered by 
many operational challenges in resource-limited settings (43, 44, 146). It is therefore 
essential to study IPT in TB-exposed newborns, who are at high risk of TB disease 
progression and who develop severe forms of TB disease (32). 
Chapter 3 (study 1) showed poor traceability and low IPT completion rates in a 
retrospective study (audit) conducted amongst TB-exposed neonates who were 
routinely initiated on preventive therapy at a Tygerberg hospital (TBH). A 
decentralized model of TB care was adopted by South Africa, where most patients are 
investigated, diagnosed and treated at their local TB clinic. Newborns initiated on IPT 
at referral hospital level (typically specialist care) have the potential for not “linking” 
to TB care at community-based TB clinics. Down-referral from hospital to the 
community-based TB clinic is thought to be a possible barrier to IPT completion 
(148). We therefore designed and implemented study 2, with the aim of prospectively 
investigating health system, maternal and socio-economic determinants of IPT 
completion among TB-exposed newborns. 
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A prospective cohort study was conducted at TBH, Cape Town, South Africa, from 
January 2011 to June 2012. In this high burden TB and HIV setting, TBH manages up 
to 6000 high-risk deliveries per annum and has a neonatal service that consists of 136 
beds (144). Following routine investigation for TB, newborns initiated on 
antituberculosis treatment (IPT or TB treatment) were followed to 6 months of age by 
the study team. For the purpose of this study, antituberculosis treatment was defined 
as either 6 months of IPT or 6 months of antituberculosis treatment for disease. The 
tested study hypothesis was, that in the presence of certain determinants including 
health system-, maternal- and socio-economic factors, TB-exposed newborns would 
be less likely to complete antituberculosis treatment than TB-exposed newborns in 
whom these determinants were absent. The primary determinant (risk factor) was 
evidence of an appropriate TB treatment referral, i.e. evidence of a standard TB clinic 
referral letter or proof of a hospital pharmacy prescription for antituberculosis 
treatment from the hospital to the local community clinic/other health facility, which 
was used as a proxy for health system function. Covariates included maternal age, 
HIV status, knowledge of neonatal TB, type of caregiver (more than one), completion 
of maternal TB treatment, possession of a child support grant, and monthly household 
income (table 1 of article).  
The primary outcome was completion of antituberculosis treatment at 6 months. Cox 
proportional hazard models were used to calculate the unadjusted and adjusted hazard 
ratios for the association of an appropriate TB treatment referral on completion of 
antituberculosis treatment. Continuation of treatment was verified telephonically at 1 
month, and study visits were completed at 3 and 6 months. Newborns with incomplete 
follow-up were censored at the last documented study visit attended. Given the high 
risk of TB disease progression in TB-exposed newborns in the absence of preventive 
therapy, treatment was reinstituted (additional study intervention) when there was no 
evidence of treatment initiation or if treatment had been interrupted (discontinuation 
of antituberculosis treatment for > 1 month) in the routine healthcare system. For 
analysis purposes, newborns who successfully completed treatment with the aid of 
additional study interventions for adherence, described above, were excluded from the 
‘completion’ TB treatment group. 
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Results 
Of the 56 TB-exposed newborns included in the study (49 with a maternal TB source 
case, and 7 with another infectious household TB source case), 44 (79%) newborns 
were followed to 6 months. Twelve patients left the study: 1 died, 4 withdrew and 7 
were lost to follow-up. Of the 44 newborns followed to 6 months, 29 (66%) 
completed antituberculosis treatment (26 completed a course of IPT and 3 newborns 
completed TB treatment for disease). Another eight newborns only completed IPT 
after an additional study intervention. For analysis purposes, these eight newborns 
were included in the ‘non-completion’ TB treatment group. The documentation of an 
appropriate TB treatment referral was the main determinant predicting completion of 
antituberculosis treatment. In the presence of maternal HIV this association was 
strengthened, which may be indicative of more frequent health care service 
attendance in HIV-infected women for their own and their infants’s care. 
In summary, a simple hospital-based strategy, including an appropriate TB treatment 
referral and linkage to care from hospital to local TB clinic substantially improved 
completion of IPT in TB-exposed newborns. Training of health care professionals on 
appropriate IPT referral of newborns from hospital to TB clinic is important. Health 
systems strengthening for models of maternal-infant TB care is required in high-
burden settings to improve IPT completion amongst infants. Further simple linkage to 
care programmes from hospital to community TB clinics is being investigated for TB 
patients in this setting to improve linkage and retention in TB care. During 2012, 
239/282 (85%) children identified at TBH with TB disease were appropriately 
referred for TB care at community level, and accurately reported in routine provincial 
TB surveillance data (Du Preez et al, work in progress). 
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B A C K G R O U N D :  Newborns exposed to Mycobacterium 
tuberculosis are at high risk of progression to tubercu-
losis (TB) disease. 
D E S I G N  A N D  S E T T I N G :  A prospective cohort study 
conducted in Cape Town, South Africa, from January 
2011 to June 2012. TB-exposed newborns requiring iso-
niazid preventive therapy (IPT) or anti-tuberculosis treat-
ment were followed to 6 months of age. Appropriate 
tuberculosis treatment referral, maternal and socio-
economic determinants were evaluated. The primary out-
come, completion of treatment (6 months IPT, 3 months 
IPT with a negative tuberculin skin test, or 6 months’ 
treatment for disease) was measured at 6 months. Data 
were collected from folders and care giver interviews. 
Cox regression was used to determine hazard ratios 
(HR) for non-completion of treatment. 
R E S U LT S :  Fifty-six (63% human immunodeficiency vi-
rus [HIV] exposed) TB-exposed newborns were included; 
median gestational age and mean birth weight were re-
spectively 36 weeks and 2242 g. Of the 56 newborns, 44 
(79%) were followed to 6 months; 29/44 (66%) com-
pleted anti-tuberculosis treatment without study team 
intervention. Appropriate treatment referral was associ-
ated with a lower hazard of non-completion of treat-
ment (unadjusted HR 0.34, 95%CI 0.12–0.93). This re-
lationship was maintained in multivariable adjustment 
for maternal HIV status and type of care giver (adjusted 
HR 0.26, 95%CI 0.09–0.77). 
C O N C L U S I O N S :  Appropriate anti-tuberculosis treat-
ment referral improves completion of treatment in 
infants.
K E Y  W O R D S :  IPT; exposure; HIV; maternal
IN SETTINGS such as South Africa, with a high bur-
den of tuberculosis (TB) and human immunode! ciency 
virus (HIV), young adults aged 20–39 years, includ-
ing women of reproductive age, are disproportionally 
represented among TB cases.1 In 2011, 65% of all TB 
cases in South Africa were reported to be HIV-infected,2 
contributing to increased mortality among both women 
and their offspring, especially in the presence of ma-
ternal TB.3,4 Surviving TB-exposed newborns are at 
high risk of tuberculous infection and disease pro-
gression; up to 50% of Mycobacterium tuberculosis-
infected infants aged <1 year will develop TB, with 
30% of these developing progressive pulmonary or 
disseminated disease in the absence of appropriate 
anti-tuberculosis preventive therapy.5
Despite post-exposure isoniazid preventive therapy 
(IPT), which reduces the risk of progression to TB dis-
ease by 60–65% over 5 years,6,7 and the World Health 
Organization recommendations to administer IPT in 
the presence of M. tuberculosis exposure/infection in 
children aged <5 years,8 programmatic delivery of 
IPT is typically poor in high-burden settings. In the 
Western Cape, South Africa, many operational chal-
lenges to IPT delivery have been reported, including a 
lack of IPT management tools.9,10 A low completion 
rate of IPT among young child contacts has been re-
ported in this setting, with ! gures ranging from 20% 
to 30% for 6 months of unsupervised daily isoniazid 
monotherapy.11,12 In a study from Tygerberg Children’s 
Hospital, Cape Town, only 5 of 37 TB-exposed new-
borns initiated on IPT were known to have completed 
6 months of IPT.13 Given the high risk of progression 
to TB disease in this paediatric group, the improved 
delivery of IPT is clearly a priority.
The aim of the present study was to investi-
gate health system, maternal and socio-economic 
predictors of TB treatment completion among TB-
e xposed newborns. 
METHODS
Study setting and design
A prospective cohort study was conducted at Tyger-
berg Children’s Hospital (TCH), Cape Town, South 
S U M M A R Y
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Africa, from January 2011 to June 2012. TCH is a 
tertiary referral hospital in the Western Cape Province 
that manages up to 6000 high-risk deliveries per an-
num, with a neonatal service consisting of 124 beds. 
In this high-burden setting, the peak TB noti! cation 
rate among young adults exceeded 1400 per 100 000 
population;14 maternal HIV prevalence was 16.9% 
among public antenatal clinic attendees in 2009.15
TB-exposed newborns requiring treatment were 
followed to 6 months of age. A TB-exposed newborn 
was de! ned as a neonate (<28 days) in close contact 
with an infectious TB source case (maternal TB or 
other TB household case who was sputum smear- or 
culture-positive). If the TB source case posed a signif-
icant risk of infection (on anti-tuberculosis treatment 
for <2 months or had not yet sputum converted), 
the routine clinical care team initiated IPT in all 
newborns, unless they had symptoms or signs sug-
gestive of TB.16 Standard of care included deferral 
of bacille Calmette-Guérin (BCG) vaccine until IPT 
completion. Screening for TB disease was at the cli-
nician’s discretion and included clinical examination, 
respiratory samples for mycobacterial culture and 
chest radiographs. For the purpose of this study, anti-
tuberculosis treatment was de! ned as either IPT or a 
full course of treatment for disease. 
IPT consisted of isoniazid (INH) administered at 
10 mg/kg/day, once daily, 7 days a week, for 6 months 
(standard regimen) or INH for 3 months followed by 
a negative tuberculin skin test (TST), as recommended 
by the local programme.16 
Anti-tuberculosis treatment consisted of a 2-month 
intensive phase, given once daily, 7 days a week, of 
INH (10–15 mg/kg), rifampicin (RMP; 15 mg/kg), py-
razinamide (35 mg/kg) with or without ethionamide 
(15–20 mg/kg), followed by a 4-month continuation 
phase of INH and RMP (same dose). 
The recommended standard of care for newborns 
initiated on anti-tuberculosis treatment included the 
routine completion of a provincial TB clinic referral 
letter and a 1-month prescription of anti-tuberculosis 
treatment following hospital discharge. Newborns 
receiving treatment for TB disease are routinely noti-
! ed to the National TB Programme; however, there is 
no routine noti! cation process for IPT. TB-exposed 
newborns on anti-tuberculosis treatment are rou-
tinely referred for treatment continuation to their lo-
cal TB clinic following discharge, given the decen-
tralised (clinic-based) model of TB care in this set-
ting. TB clinics typically dispense IPT once monthly, 
and anti-tuberculosis treatment once weekly. Directly 
observed treatment is not provided for IPT.
Data collection 
All TB-exposed newborns routinely initiated on ther-
apy at TCH from January 2011 to January 2012 
were followed to 6 months of age. The primary entry 
point for recruitment was all mothers routinely iden-
ti! ed as having been on anti-tuberculosis treatment, 
either antepartum (before delivery), intrapartum (at 
the time of delivery) or postpartum (shortly follow-
ing delivery, but within the same hospitalisation pe-
riod). Written informed consent was obtained from 
the care giver (mother/legal guardian). If the newborn 
died before hospital discharge, or if no legal guardian 
was yet appointed to provide informed consent (e.g., 
when the mother was too ill or had died), they were 
excluded. Surveillance was performed from Monday 
to Friday to identify all potentially eligible partici-
pants. Hospital folders from the weekend were re-
viewed on the following Monday to ensure identi! -
cation of all maternal TB admissions and discharges.
Potential determinants of anti-tuberculosis treat-
ment completion were collected at baseline. Data from 
maternal and infant hospital folders were extracted 
using a standard data collection tool, including infor-
mation on maternal, infant and socio-economic fac-
tors. Using structured interviews, the mother’s knowl-
edge of neonatal TB was ascertained by asking the 
following three questions: Was she aware of any TB 
risk to her newborn? Did she know that preventive 
therapy could be given to her newborn? Did she 
know if the duration of anti-tuberculosis treatment 
for her newborn constituted days, weeks or months? 
Maternal knowledge of neonatal TB was classi! ed 
according to the number of correct answers. If all 
three were answered correctly, knowledge was cate-
gorised as ‘good’; if one or more questions were an-
swered correctly, knowledge was categorised as ‘some’; 
if all questions were answered incorrectly, knowledge 
was categorised as ‘poor’. The study team later pro-
vided the correct answers to the questions. Post-
h ospital discharge, the infants’ hospital folders were 
checked for an appropriate anti-tuberculosis treat-
ment referral, de! ned as evidence of a standard TB 
clinic referral letter or proof of a hospital pharmacy 
prescription for anti-tuberculosis treatment. An ap-
propriate treatment referral was used as a proxy for 
health system function.
All participants were contacted by telephone 
within the ! rst week after hospital discharge to con-
! rm TB treatment status in the newborn. If the care 
giver reported not receiving treatment, they were re-
called by the study team and treatment was initiated. 
If a care giver could not be reached by telephone, a 
home visit was conducted. Continuation of treatment 
was again veri! ed at 1 month, by telephoning the 
care giver and the TB clinic. If either reported no anti-
tuberculosis treatment for the newborn, the study 
team recalled them and re-initiated treatment. Fur-
ther study visits with the study team were scheduled 
at 3 and 6 months, and care givers were asked to 
bring the prescribed medication with them to the 
visit. Due to the high risk of progression to TB dis-
ease in infants, treatment was reinstituted when 
there was no evidence of treatment initiation or if 
treatment interruption was documented. Treatment 
interruption was de! ned as the discontinuation of 
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anti-tuberculosis medication for >1 month. Interven-
tions constituted a recall study visit, where treatment 
was initiated or re-instituted. The primary outcome, 
the completion of anti-tuberculosis treatment (de! ned 
as 6 months of IPT, 3 months of IPT followed by a 
negative TST or 6 months of anti-tuberculosis treat-
ment in the case of suspected or con! rmed disease) 
was measured at 6 months of age. Non-completion 
of treatment was de! ned as the failure of any of these 
criteria. Treatment outcomes for the infectious TB 
source case were also collected.
Data analysis
The primary study hypothesis was that infants with 
an appropriate treatment referral (primary determi-
nant) would be less likely than those with an in-
appropriate referral not to complete anti-tuberculosis 
treatment (primary outcome). Descriptive statistics 
are presented as frequencies for categorical variables, 
mean and standard deviation (SD) for normally dis-
tributed continuous variables or median with inter-
quartile range (IQR) if not normally distributed. Bi-
variable associations between categorical variables 
were evaluated using the χ2 or Fisher’s exact tests 
and continuous variables by Student’s t-test or Wil-
coxon sign-rank-sum test, as appropriate. All hypoth-
esis tests were two-sided, with an α value of 0.05. 
Cox proportional hazards models were used to calcu-
late the unadjusted and adjusted hazard ratios (HRs) 
for the primary association; the degree of precision 
around the HR point estimates were represented by 
95% con! dence intervals (CIs). 
Infants with incomplete follow-up were censored 
at the last study visit attended. The timing of occur-
rence of the event, non-completion of treatment, 
was set as the ! rst study visit at which discontinua-
tion of treatment was identi! ed. Variables considered 
a priori as potential confounders included maternal 
age, knowledge and HIV status, duration of infant 
hospitalisation, and maternal socio-economic status. 
Variables were retained in the multivariable model 
if they shifted the co-ef! cient of the point estimate 
for the primary determinant by ⩾10%. The Schoen-
feld test was used to con! rm that models met the 
proportional hazards assumption. Statistical analysis 
was conducted using R version 2.15.1, with the sur-
vival package (R Foundation for Statistical Comput-
ing, Vienna, Austria).
Ethics approval was obtained from the Health Re-
search Ethics Committee of Stellenbosch University 
(N10/08/279), Cape Town, South Africa, and the Eth-
ics Advisory Group of the International Union Against 
Tuberculosis and Lung Disease (44/10), Paris, France. 
RESULTS 
Inclusion pathways and outcomes of anti-tuberculosis 
treatment for the study cohort (n = 56) are illustrated 
in the Figure. Of 73 women (51 HIV-infected) identi-
! ed as being on anti-tuberculosis treatment (clinical 
data to be reported elsewhere), 49 (67%) newborns 
were included. In addition, another seven newborns 
initiated on IPT due to the presence of a non-maternal 
infectious household TB source case identi! ed during 
the infant’s hospital admission were included, result-
ing in 56 TB-exposed newborns initiated on IPT. 
Nineteen newborns had inadvertently received BCG, 
30 had not and in 7 there was no documentation of 
BCG. All 37 non-vaccinated infants were referred for 
vaccination upon completion of IPT. The median ges-
tational age was 36 weeks (IQR 36–39); the mean 
birth weight was 2242 g (SD 815). Of the total co-
hort, 35 (63%) infants were born to HIV-i nfected 
women; 2 (6%) infants were HIV-infected. Both HIV-
infected infants were initiated on combination anti-
retroviral therapy (cART) by 3 months of age. 
Of the 56 TB-exposed newborns on IPT, 45 (80%) 
were screened for TB; 43 had gastric/tracheal aspirates 
and all 45 had a chest radiograph. All 56 were origi-
nally initiated on IPT. However, 3 (5%) were later 
transferred to a full course of anti-tuberculosis treat-
ment due to suspected or con! rmed TB disease: 1 in-
fant developed suspected miliary TB and was started 
on anti-tuberculosis treatment at 2 months of age 
(the mother had drug-susceptible TB, and the infant 
had been hospitalised since birth); in 1 asymptomatic 
infant, M. tuberculosis was cultured from two gastric 
aspirates taken at birth and treatment was initiated at 
2 weeks of age; and in a third newborn who was on 
ventilation for respiratory insuf! ciency, a tracheal as-
pirate was smear-positive for acid-fast bacilli. All three 
completed 6 months of anti-tuberculosis treatment. 
Of 56 TB-exposed newborns, 44 (79%) had known 
TB treatment outcomes at 6 months and 29/44 (66%) 
completed their anti-tuberculosis treatment; 20 com-
pleted 6 months of IPT (70%), 6 completed 3 months 
of IPT followed by a negative TST (20%) and 3 com-
pleted 6 months of TB treatment (10%). The pres-
ence of INH tablets was checked at follow-up vis-
its. Of the 44 patients, 15 (34%) failed to complete 
treatment, with 8 additional patients successfully 
completing treatment only with a study intervention. 
For analysis purposes, these 8 were included into 
the ‘non-completion’ TB treatment group, as they re-
quired additional treatment support. Reasons for non-
completion included: discharge from hospital with-
out IPT (n = 5), incorrect stoppage of IPT by health 
facilities (n = 6) and care giver’s failure to attend TB 
clinics for IPT (n = 4).
Table 1 describes the characteristics of and treat-
ment outcomes for TB-exposed newborns. In the 
44 infants with a known outcome, 22/29 (76%) with 
an appropriate treatment referral completed anti-
t uberculosis treatment vs. 7/15 (47%) who failed 
to complete (P = 0.05), measured at 6 months. Of 
the 27/44 (61%) HIV-infected mothers with known 
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infant TB treatment outcomes, 20/27 (74%) infants 
completed TB treatment, compared to 9/17 (53%) 
born to non-HIV-infected mothers. The mother was 
the primary care giver in 15/29 (52%) cases where the 
infant’s treatment was completed. Eight mothers had 
‘good’ knowledge of TB. Seven of these underwent ap-
propriate TB referral and all infants completed treat-
ment. Treatment was successfully completed in 31/44 
(71%) maternal and other TB source cases; of these, 
21/31 (68%) infants also completed treatment.
Table 2 presents the HR for non-completion of 
anti-tuberculosis treatment (n = 56). Appropriate 
treatment referral was associated with a 66% lower 
hazard of non-completion of treatment (unadjusted 
HR 0.34, 95%CI 0.12–0.93). Maternal HIV infec-
tion also had a protective effect, while the mother be-
ing the primary and only care giver was associated 
with an increased hazard for non-completion of treat-
ment, although both CIs crossed one. When included 
in a multivariable model adjusted for maternal HIV 
status and type of care giver, the association between 
appropriate referral and non-completion of treat-
ment was marginally strengthened (adjusted HR 0.26, 
95%CI 0.09–0.77). The addition of maternal knowl-
edge and source case TB treatment episode outcome, 
factors also possibly associated with the outcome of 
interest, did not substantially alter the relationship in 
this model. 
DISCUSSION
To our knowledge, this is the ! rst study speci! cally 
investigating the determinants of anti-tuberculosis 
treatment completion in newborns. Appropriate and 
Figure Inclusion pathways and treatment outcomes in TB-exposed infants (n = 56). * 5 patients 
were discharged from hospital without IPT, in 2 the health facility stopped IPT incorrectly, in 1 the 
care giver did not attend the TB clinic. † 4 patients had their IPT stopped incorrectly by the health 
facility; 3 care givers refused to attend the TB clinic. TB = tuberculosis; LTFU = lost to follow-up.
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correct down-referral from hospital to community-
based clinics was strongly associated with improved 
treatment completion. We further document high IPT 
completion rates in young children compared to those 
reported in the literature under routine programmatic 
conditions.9–12 These completion rates were achieved 
with the aid of a dedicated TB care team, consisting 
of a nurse and doctor who provided IPT support and 
ensured regular follow-up. Two thirds of the cohort 
completed treatment, while a large proportion (84%) 
! nally completed with the support of a simple inter-
vention, which included an additional recall visit and 
re-institution of anti-tuberculosis treatment. Although 
additional resources were required, a dedicated TB 
care team substantially improved the delivery of 
treatment in this high-risk group of TB-exposed new-
borns. Given the extreme vulnerability of TB-affected 
Table 1 Characteristics of newborn infants without and those with a known TB treatment outcome (n = 56)
Characteristic
Total cohort
(N = 56) 
n (%)
Unknown 
treatment 
status 
(n = 12)
n (%)
Known 
completion of 
TB treatment*
(n = 29)
n (%)
Known 
non-completion 
of TB treatment* 
(n = 15)
n (%) P value†
Health system
Appropriate TB treatment referral 38 (68) 9 (75) 22 (76) 7 (47) 0.05
Maternal 
Age, years, mean ± SD 29 ± 6 29 ± 6 29 ± 6 29 ± 6 0.87
Knowledge of neonatal TB 0.24
Poor 31 (55) 7 (58) 16 (55) 8 (53)
Some 16 (29) 4 (33) 6 (21) 6 (40)
Good 9 (16) 1 (8) 7 (24) 1 (7)
HIV-infected 35 (63) 8 (67) 20 (69) 7 (47) 0.15
Infant 
Female 32 (57) 9 (75) 15 (52) 8 (53) 0.92
Gestational age, median [IQR] 36 [33–39] 37 [33–40] 36 [33–38] 35 [32–39] 0.59
Birth weight, g, mean ± SD 2242 ± 815 2486 ± 815 2170 ± 744 2186 ± 932 0.95
Duration of hospitalisation, days, median [IQR] 6 [3–28] 6 [3–13] 7 [3–29] 4 [3–16] 0.49
TB source case (maternal and other)
Relationship with TB source case 
Mother 49 (88) 12 (100) 25 (86) 12 (80) 0.67
 Close household contact 7 (12) 0 4 (14) 3 (20)
Time of TB diagnosis
Antepartum 34 (64) 9 (75) 16 (55) 9 (60) 0.76
Intra-/postpartum 22 (36) 3 (25) 13 (45) 6 (40)
TB treatment episode
First time 32 (57) 9 (75) 13 (45) 10 (67) 0.21
 Second time 24 (43) 3 (25) 16 (55) 5 (33)
TB treatment outcome
Completed 6 months 36 (64) 5 (42) 21 (72) 10 (67) 0.74
Defaulted/LTFU/died 20 (36) 7 (58) 8 (28) 5 (33)‡
Socio-economic 
Mother the primary care giver 35 (63) 9 (75) 15 (52) 11 (73) 0.17
Additional care giver 21 (37) 3 (25) 14 (48) 4 (27)
Walking distance from clinic 45 (80) 10 (83) 23 (79) 12 (80) 1.0
Type of housing
Brick house 32 (57) 6 (50) 18 (62) 8 (53) 0.58
 Shack/yard house/flat 24 (43) 6 (50) 11 (38) 7 (47)
Household monthly income, ZAR
  <2500 38 (69) 8 (67) 18 (62) 12 (80) 0.31
  ⩾2500 18 (31) 4 (33) 11 (38) 3 (20)
Receiving child care support 28 (50) 5 (42) 15 (52) 8 (53) 0.91
* Included isoniazid preventive therapy and treatment for TB disease. 
† Calculated for comparison between known completion of TB treatment (n = 29) and non-completion of TB treatment (n = 15).
‡ 2 maternal TB source cases died after their newborns were discharged from hospital; 3 maternal TB source cases were LTFU.
TB = tuberculosis; SD = standard deviation; HIV = human immunodeficiency virus; IQR = interquartile range; LTFU = lost to follow-up; ZAR = South African Rand.
Table 2 Hazard ratios for non-completion of treatment in 
TB-exposed infants (N = 56)
Non-completion of TB treatment 
Unadjusted 
HR (95%CI)
Adjusted 
HR (95%CI)*
TB treatment referral type
Appropriate 0.34 (0.12–0.93) 0.26 (0.09–0.77)
Inappropriate Reference Reference
Maternal HIV status
HIV-infected 0.44 (0.16–1.21) 0.30 (0.10–0.92)
Non-HIV-infected Reference Reference
Care giver type
Mother only 2.03 (0.65–6.41) 3.10 (0.89–10.82)
Other care giver 
and/or mother Reference Reference
* Cox proportional hazards model for the hazard of not completing TB treat-
ment by referral type, adjusted for maternal HIV status and care giver type.
TB = tuberculosis; HR = hazard ratio; CI = confidence interval; HIV = human 
immunodeficiency virus.
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pregnant women and their infants, additional health 
care resources are justi! ed in this context, given 
that two thirds of women with TB were also HIV-
co-i nfected and severely ill, and that the majority of 
infants were premature and had low birth weight 
(<2500 g). It is important to note that in the major-
ity of infants where treatment was discontinued, this 
was primarily due to health system factors.
The strongest predictor for completion of anti-
t uberculosis treatment was appropriate treatment re-
ferral. The presence of a hospital TB referral letter 
addressed to the TB clinic or proof of IPT dispensed 
by the hospital on discharge contributed substan-
tially to the completion of treatment. Linking of hos-
pital and community TB care is therefore of para-
mount importance to ensure completion of treatment 
in infants. Strengthening of health services in the con-
text of busy, resource-poor hospitals and clinics can 
be achieved using a dedicated care team. Strategies 
could be simpli! ed to be delivered by community 
care workers with the involvement of the mothers. 
Appropriate treatment referral and the assistance of 
an additional care giver were associated with better 
completion of infant anti-tuberculosis treatment in 
the presence of maternal HIV infection. One pos-
sible explanation may be that HIV-infected mothers, 
supported by other care givers, attend health care 
services more frequently for their own and their in-
fant’s care, including prevention of mother-to-child-
transmission of HIV (PMTCT) and HIV care, which 
both have strong models of treatment and adherence 
in this setting, and may have led to improved TB ad-
herence in their infants. Given the high prevalence of 
maternal HIV in settings such as ours, models of TB 
care should consider linking into existing maternal 
and infant health programmes, including PMTCT 
programmes.
Limitations to our study included the modest sam-
ple size. However, this is a relatively large sample for 
the very speci! c paediatric group targeted, i.e., TB-
exposed newborns. The primary outcome was un-
known for a substantial proportion of infants; how-
ever, this group did not differ markedly regarding 
baseline characteristics compared to the rest of the 
cohort, and is unlikely to have biased results. Failure 
to retain study participants was mainly due to loss to 
follow-up. Half of the lost participants were reported 
by neighbours to have re-located back to their origi-
nal provinces, a common occurrence where patients 
temporarily transfer to other provinces for social and 
other reasons. 
In conclusion, appropriate treatment referral in 
newborn infants improves completion of IPT and 
anti-tuberculosis treatment. Targeted interventions 
conducted by a dedicated care team further improve 
continuity of care. Health systems should be strength-
ened to improve TB care in this vulnerable paediatric 
subgroup.
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C O N T E X T E  :   Les nouveau-nés exposés à Mycobacte-
rium tuberculosis ont un risqué élevé de progression 
vers la maladie tuberculeuse. 
S C H É M A  :   Une étude de cohorte prospective a été con-
duite au Cap, en Afrique du Sud, de janvier 2011 à juin 
2012. Des nouveau-nés exposés à la tuberculose (TB) 
ayant bénéficié soit d’une chimioprophylaxie par isonia-
zide ou d’un traitement anti-tuberculeux ont été suivis 
jusqu’à l’âge de 6 mois. L’étude a évalué le caractère 
approprié de la référence thérapeutique et les détermi-
nants maternels et socioéconomiques. Le résultat initial, 
l’achèvement du traitement (6 mois d’IPT, 3 mois d’IPT 
en cas de cutiréaction négative ou 6 mois de traite-
ment pour la TB maladie) ont été mesurés à 6 mois. Les 
données ont été recueillies à partir des dossiers et des 
entretiens avec les soignants. La méthode de régression 
de Cox a permis de déterminer le ratio de risque (HR) de 
non achèvement du traitement. 
R É S U LTAT S  :   Cinquante-six nouveau-nés exposés à la 
TB, dont 63% exposés également au virus de l’immuno-
déficience humaine (VIH), ont été inclus ; l’âge gesta-
tionnel médian était de 36 semaines et le poids de nais-
sance moyen de 2242 g. Sur les 56 nouveau-nés, 44 (79%) 
ont été suivis pendant 6 mois ; 29/44 (66%) ont achevé 
leur traitement sans intervention de l’équipe d’étude. Une 
référence appropriée était associée à un moindre risque 
de non-achèvement du traitement anti-tuberculeux (HR 
non ajusté 0,34 ; IC95% 0,12–0,93). Cette relation s’est 
maintenue en ajustement multivarié selon le statut ma-
ternel VIH et le type de soignant (HR ajusté 0,26 ; 
IC95% 0,09–0,77). 
C O N C L U S I O N S  :   Une référence appropriée pour le traite-
ment antituberculeux améliore l’achèvement du traite-
ment chez les nourrissons.
M A R C O  D E  R E F E R E N C I A :   Los recién nacidos expuestos 
a Mycobacterium tuberculosis presentan un alto riesgo 
de progresión hacia la enfermedad tuberculosa. 
M É T O D O :   En un estudio prospectivo de cohortes lle-
vado a cabo en la Ciudad del Cabo en Suráfrica de 
e nero del 2011 a junio del 2012, se practicó un segui-
miento hasta los 6 meses de edad a los recién nacidos 
expuestos a la tuberculosis (TB) que precisaron trata-
miento preventivo con isoniazida (IPT) o tratamiento 
antituberculoso. Se evaluaron la remisión apropiada a 
fin de recibir el tratamiento antituberculoso y los fac-
tores determinantes de compleción del tratamiento de 
carácter socioeconómico y dependientes de la madre. El 
criterio primario de valoración se midió a los 6 meses y 
consistió en la compleción del tratamiento (IPT durante 
6 meses, tratamiento preventivo durante 3 meses con 
una prueba tuberculínica negativa o 6 meses de tra ta-
miento por TB activa). Se recogieron datos a partir de 
los registros y las entrevistas a los cuidadores. Se aplicó 
un análisis de regresión de Cox con el fin de determinar 
el cociente de riesgos instantáneos (HR) de no comple-
tar el tratamiento. 
R E S U LTA D O S :   Se incluyeron en el estudio 56 recién 
nacidos expuestos a la TB (63% expuestos al virus de la 
inmunodeficiencia humana [VIH]); la mediana de la edad 
gestacional fue 36 semanas y el promedio del peso al 
nacer fue 2242 g. De los 56 recién nacidos, se siguieron 
44 durante 6 meses (79%); 29 de los 44 completaron el 
tratamiento antituberculoso sin intervención del equipo 
del estudio (66%). Una remisión apropiada con el fin de 
recibir el tratamiento se asoció con un menor riesgo de 
no completar el tratamiento contra la TB (HR non 
ajustado 0,34; IC95% de 0,12 a 0,93). Esta correlación 
se mantuvo tras la corrección de las variables según la 
situación de la madre frente al VIH y el tipo de cuidador 
(HR ajustado 0,26; IC95% de 0,09 a 0,77). 
C O N C L U S I Ó N :   Una remisión apropiada encaminada a 
la administración del tratamiento antituberculoso me-
jora el índice de compleción del tratamiento de los lac-
tantes menores.
R É S U M É
R E S U M E N
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CHAPTER 6 
PHARMACOKINETICS OF ISONIAZID IN LOW BIRTH WEIGHT 
AND PREMATURE INFANTS 
Chapter 3 to 5 addressed the high burden of TB-exposed newborns at a referral 
hospital in Cape Town, South Africa (143, 149, 150). TB-exposed newborns, who are 
at high risk of TB disease progression (32), urgently need optimal and safe isoniazid 
(INH) dosing. We have shown that there are considerable numbers of premature (< 37 
weeks gestational age) and low birth weight (LBW; < 2500 grams) infants requiring 
post-exposure INH preventive therapy (IPT) in high burden TB and HIV settings 
(143, 149). Despite implementation of health system strengthening strategies to link 
infants to TB care, research presented in chapter 5 showed suboptimal IPT completion 
(150). Determining the appropriate INH dose in TB-exposed newborns was the next 
knowledge gap to be addressed in the prevention and treatment of perinatal and infant 
TB. 
To our knowledge, only one INH pharmacokinetic study has been performed in 
newborns, who received the drug transplacentally; women were given 300 mg INH 
intramuscularly on the day of delivery (52). Only two newborns were studied and 
both had prolonged INH half-lives of 7.8 and 19.8 hours, respectively (52). These 
limited pharmacokinetic data suggest a slow elimination rate of INH and cautions 
against high INH dosing in newborns. The 2009 revised World Health Organization 
(WHO) paediatric dosing guidelines recommended an increase in the INH dose from 
5 mg/kg (4-6 mg/kg) to 10 mg/kg (7-15 mg/kg) (58). The impact of this higher INH 
dosing in newborns has yet to be studied. The aim of study 3 was therefore to 
determine whether the current WHO-recommended INH dose of 10 mg/kg achieves 
adequate target drug concentrations in TB-exposed premature and LBW infants, 
compared to the proposed adult INH target pharmacokinetic concentrations. 
Examining the influence of the N-acetyltransferase (NAT2) genotype on INH 
pharmacokinetics was a secondary aim of this study.  
An intensive sampling pharmacokinetic study was conducted at Tygerberg Hospital, 
between May 2011 and May 2012. LBW infants born to HIV-infected and uninfected 
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women, who were routinely initiated on INH for preventive or curative treatment, 
were consecutively recruited. Clinical characteristics of infants, and alanine 
aminotransferase (ALT) values taken as part of routine care were collected. On the 
day of pharmacokinetic sampling, infants were given an exact dose of 10 mg/kg of 
INH. INH in powder form, obtained from Fluka Chemie AG (Buchs, Switzerland), 
was accurately weighed (to the nearest 0.1 mg) to administer a dose of 10 mg/kg 
according to the naked newborn’s weight (weighed by the study nurse on the day 
prior to study drug administration). Phlebotomy was performed at 2, 3, 4, and 5 hours 
post dosing. The high-performance liquid chromatographic (HPLC) method was used 
for the pharmacokinetic assays, and DNA was extracted from the remaining blood 
cells for NAT2 genotyping. Non-compartmental analysis (NCA) was used to generate 
pharmacokinetic parameters, which were compared by NAT2 genotype, birth weight, 
weight at the time of pharmacokinetic sampling, gestational age, age at sampling, 
gender, HIV exposure, and feeding type (breastfeeding versus formula). 
Twenty LBW infants were recruited (14 [70%] male, 16 [80%] HIV-exposed) for this 
study, of whom 17 (85%) were premature. Of the 16 HIV-exposed infants, 15 infants 
were uninfected and 1 HIV-infected infant was on combination antiretroviral therapy. 
Infants had a median birth weight of 1575 grams (interquartile range: 1190 – 2035 
grams) and a median gestational age of 35 weeks (interquartile range: 34 – 38 weeks). 
The summary pharmacokinetic parameters found a median maximum serum 
concentration (Cmax) of 5.63 μg/ml, a time to Cmax (Tmax) of 2 hours, an area under the 
concentration-time curve 2-5 hours (AUC2-5) of 13.56 μg.h/ml, and a half-life (t½) of 
4.69 hours. Nineteen (95%) infants achieved drug concentrations (range 2.9 – 10.7 
μg/ml) above the current proposed adult pharmacokinetic target concentration of 3 
μg/ml at 2 hours (70). All 20 infants achieved target drug concentrations > 1.5 μg/ml 
at 3 hours post dose (151), comparable to the adult pharmacokinetic target 
concentration. The median Cmax of very low birth weight (VLBW; < 1500 grams) 
infants was significantly higher (6.58 μg/ml versus 4.99 μg/ml; p-value < 0.028) than 
the median Cmax observed in infants weighing between 1500 – 2500 grams, 
suggesting reduced elimination in VLBW infants. Although a higher median Cmax of 
5.66 μg/ml in 17 premature infants was observed compared to a median Cmax of 4.11 
μg/ml in the 3 term infants (p=0.1530), the numbers were too small to show 
significance. The trimodal NAT2 acetylation pattern was already apparent at this very 
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early stage of development, with pharmacokinetic parameters significantly different 
for all three acetylator groups (table 3, figure 2 in article). Slow acetylators had a 
decreased elimination rate compared to intermediate and fast acetylators. No other 
covariates studied showed any differences for INH pharmacokinetic parameters.  
Hepatotoxicity is an uncommon but serious adverse event that may occur in patients 
receiving INH for preventive or curative treatment (81). ALT values obtained during 
routine care by attending clinicians were systematically collected for 19 infants at 
baseline, 14 infants at 3-months and 11 infants at the 6-months follow-up. Based on 
the standard Division of AIDS (DAIDS) grading table for adverse events, two 3-
month values were abnormal; 1 was mildly elevated (<2.5 times elevated; DAIDS 
grade 1) and one moderately elevated (<5 times elevated; DAIDS grade 2) (152). The 
mildly elevated value was not repeated, and the moderately elevated ALT normalized 
at six months. Limited safety data collected among LBW infants in this study were 
reassuring. 
In summary, this is the first INH pharmacokinetic study conducted in LBW and 
premature infants. INH drug concentrations achieved in LBW infants were 
comparable to adult proposed target drug concentrations. Peak concentrations were 
relatively high in LBW infants dosed at 10 mg/kg, the lower end of the recommended 
dosing guideline (58). Higher peak INH concentrations and exposures were observed 
in the smaller infants, and in the genetically determined slow acetylators. These high 
INH concentrations and reduced elimination observed in LBW infants, cautions 
against exceeding a dose of 10 mg/kg of INH in this population. 
Stellenbosch University  https://scholar.sun.ac.za
Pharmacokinetics of Isoniazid in Low-Birth-Weight and Premature
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Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africab; Division for Clinical Pharmacology, Faculty of Medicine and Health
Sciences, Stellenbosch University, Tygerberg, South Africac; MRC Centre of Molecular & Cellular Biology and DST/NRF Centre of Excellence for Biomedical TB Research,
Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africad
Isoniazid (INH) is recommended for use as posttuberculosis exposure preventive therapy in children. However, no phar-
macokinetic data are available for INH treatment in low-birth-weight (LBW) infants, who undergo substantial develop-
mental and physiological changes. Our objectives in this study were to determine the pharmacokinetic parameters of INH
at a dose of 10 mg/kg of body weight/day and to define its pharmacokinetics relative to the arylamine N-acetyltransferase-2
(NAT2) genotype. An intensive prospective pharmacokinetic sampling study was conducted at Tygerberg Children’s Hos-
pital, South Africa, in which we measured INH blood plasma concentrations at 2, 3, 4 and 5 h postdose. Twenty LBW in-
fants (14 male, 16 exposed to HIV) were studied. The median birth weight was 1,575 g (interquartile range, 1,190 to 2,035
g) and the median gestational age was 35 weeks (interquartile range, 34 to 38 weeks). The NAT2 acetylation statuses of the
infants were homozygous slow (SS) (5 infants), heterozygous intermediate (FS) (11 infants), and homozygous fast (FF) (4
infants). Using a noncompartmental analysis approach, the median maximum drug concentration in blood serum (Cmax)
was 5.63 !g/ml, the time after drug administration to reach CmaxTmax) was 2 h, the area under the concentration-time
curve from 2 to 5 h (AUC2–5) was 13.56 !g · h/ml, the half-life (t1/2) was 4.69 h, and the elimination constant rate (kel) was
0.15 h"1. The alanine aminotransferase levels were normal, apart from 2 isolated values at two and three times above the
normal levels. Only the three-times-elevated value was repeated at 6 months and normalized. All LBW infants achieved
target INH blood plasma concentrations comparable to the adult values. Reduced elimination was observed in smaller and
younger infants and in slow acetylators, cautioning against higher doses. The safety data, although limited, were reassur-
ing. More data, however, are required for newborn infants.
TheHIVpandemic has been associatedwith a dramatic increasein tuberculosis (TB) rates among pregnant women (1).Mater-
nal TB, regardless of HIV status, is associated with a high inci-
dence of low birth weight (LBW) (defined as!2,500 g) and pre-
maturity (a gestational age of !38 weeks) in infants (2–4). In
South Africa, with its high burden of both TB and HIV, recent
advances in neonatal care have improved infant survival, resulting
in a considerable group of small and premature TB-exposed new-
borns requiring preventive therapy against TB. Isoniazid (INH) is
the most widely recommended agent for preventing TB disease in
children (5). Following Mycobacterium tuberculosis infection, up
to 50% of infants (!12 months of age) will progress to have TB
disease in the absence of INH preventive therapy (IPT) (6), while
postexposure IPT reduces the risk of TB disease by 60 to 65% (7).
There are limited pharmacokinetic data on the use of INH in
young children and none in newborns or LBW infants requiring
IPT due to maternal TB. INH is primarily metabolized through
acetylation in the liver and intestines, and the acetylation rate is
genetically determined (8). Developmental and physiological
changes in the volume of distribution, maturity of liver enzymes,
and the role of acetylation capacity may influence INH dosage
requirements in this vulnerable population (9, 10). The aimof this
study was to determine the pharmacokinetics of routinely admin-
istered INH at 10 mg/kg of body weight/day in TB-exposed LBW
infants. The World Health Organization (WHO) recommends a
dosage range of 10 to 15 mg/kg daily. We also describe the influ-
ence of theN-acetyltransferase 2 (NAT2) genotype on INH phar-
macokinetics.
MATERIALS AND METHODS
Design and setting. An intensive sampling pharmacokinetic study was
conducted at Tygerberg Children’s Hospital (TCH), Cape Town, South
Africa, between May 2011 and May 2012. TCH is a tertiary referral hos-
pital for 50,000 deliveries per annum. Here, the peak TB notification rate
among young adults was"1,400 per 100,000 population in 2009 (11), and
the provincial maternal HIV prevalence was 16.9% among public antena-
tal clinic attendees in 2009 (12). TCH manages an average of 6,000 high-
risk complicated deliveries per year, 24% of which are LBW infants. The
neonatal service has 136 neonatal beds and includes intensive- and high-
care facilities.
Study procedures and drug administration. LBW infants born to
HIV-infected andHIV-uninfected womenwere consecutively recruited if
routinely receiving daily INH either for 6 months of IPT (10 mg/kg/day)
or as in TB treatment, as per the local guidelines (13). The treatment for
TB disease consisted of a 2-month intensive phase comprising daily INH,
rifampin (RMP), and pyrazinamide (PZA), with or without ethionamide
(ETH), followed by a 4-month continuation phase of INH and RMP
alone. Multidrug-resistant TB (MDR-TB) preventive therapy (consisting
of daily INH, ETH, and ofloxacin) was administered in consultation with
a pediatric infectious diseases specialist. The eligibility criteria included
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weight of !1.2 kg on the day of pharmacokinetic sampling, being clini-
cally stable in room air and tolerating oral preparations, and written
informed consent from the mother/legal guardian. The maternal HIV
infection status was routinely determined by an enzyme-linked immu-
nosorbent assay, preceded by informed consent and appropriate pre- and
posttest counseling. All HIV-exposed newborns (those born to HIV-in-
fected mothers) received nevirapine (NVP) for 6 weeks postpartum or
until cessation of breastfeeding, according to national prevention of
mother-to-child transmission (PMTCT) guidelines (14). Exclusive
breastfeeding was encouraged.
Data on the following characteristics were collected for the infants:
gender, ethnicity, birth weight, gestational age, weight and age at phar-
macokinetic sampling, feeding type (breastfeeding versus formula),
HIV exposure, and concomitant medications. The gestational age was
determined by the date of the mother’s last menstrual period, early
ultrasound findings, and/or a Ballard score performed by a single ex-
perienced neonatologist. Data on alanine aminotransferase (ALT), a
proxy for drug-related hepatotoxicity, were collected at baseline (at
pharmacokinetic sampling) and at 3- and 6-month follow-up visits.
The Division of Microbiology and Infectious diseases (DMID) tables
were used to grade potential hepatotoxicity (15). The infants required
regular feeding (every 2 to 3 h), as per routine care. INH in powder
form, obtained from Fluka Chemie AG (Buchs, Switzerland), was used
on the pharmacokinetic sampling days. The INH powder was accu-
rately weighed to administer a dose of 10 mg/kg according to the
weight of a newborn when naked (weighed by the study nurse on the
day prior to study drug administration). The INH powder was dis-
solved in 1 to 2 ml of sterile water, administered through a nasogastric
tube, and flushed with 1 ml of water.
Pharmacokinetic sampling and laboratory analysis. On the day of
pharmacokinetic assessment, the INH dose, time of administration, and
data obtained by phlebotomy were documented precisely. Four arterial
blood specimens of 0.5 ml each were taken at 2, 3, 4, and 5 h postdose and
collected in EDTA-coated tubes. The specimens were kept on ice and
delivered to the laboratory within 30 min of collection. After centrifuga-
tion, the separation plasma fragment was assayed using the high-perfor-
mance liquid chromatographic (HPLC) method described previously
(16). The remaining blood cells were used to extract DNA for NAT2
genotyping. Genomic DNA (gDNA) was prepared with a simple salting-
out procedure for extracting DNA from human nucleated cells (17). The
gDNA was analyzed for the NAT2*5, NAT2*6, NAT2*7, NAT2*12,
NAT2*13, and NAT2*14 alleles via a PCR-based strategy (18). Separate
PCR aliquots were restricted with the MspI, FokI, KpnI, TaqI, DdeI, and
BamHI restriction enzymes to delineate the polymorphisms at nucleotide
positions 191, 282, 481, 590, 803, and 857, respectively. According to
Vatsis nomenclature, the wild-type fast allele (F) was assigned asNAT2*4,
NAT2*12, or NAT2*13 (19). These alleles confer normal enzyme activity
on the NAT2 protein, while the mutant slow alleles (S), classified as
NAT2*5, NAT2*6, NAT2*7, and NAT2*14 in humans, confer decreased
enzyme activity on theNAT2 protein. Accordingly, the study participants
were classified as homozygous fast (FF), heterozygous intermediate (FS),
or homozygous slow (SS) acetylators, depending on the allele combina-
tion observed.
Pharmacokinetic parameters and statistical analysis. The following
pharmacokinetic parameters were generated using fixed sampling times
for each patient through noncompartmental analysis (NCA): Cmax (the
maximum drug concentration observed), Tmax (the time after drug ad-
ministration to reach Cmax), the AUC2–5 (area under the time-concentra-
tion curve from 2 to 5 h), t1/2 (the plasma half-life), and the kel (elimina-
tion constant). The AUC was calculated according to the linear
trapezoidal rule. The pharmacokinetic parameters were summarized us-
ing medians and interquartile ranges (IQR), except for Tmax, which was
summarized using means and standard deviations (SD). The pharmaco-
kinetic parameters for the infants were compared by NAT2 genotype,
birth weight, weight at the time of pharmacokinetic sampling, gestational
age, age at sampling, gender, HIV exposure status, and feeding type. All
covariates were analyzed dichotomously, except for NAT2, which was
analyzed categorically into three levels: FF (fast), FS (intermediate), and
SS (slow) acetylator types. Since the sample sizes were small, the dichoto-
mous covariates were analyzed using the Wilcoxon rank-sum test. NAT2
was analyzed using the Kruskal-Wallis test, and if statistically significant,
the trend test was used to assess for trends across ordered NAT2 groups.
Dichotomous confounders, weight at pharmacokinetic sampling, and
feeding type were assessed using Fisher’s exact test. Any P value of!0.05
TABLE 1 Clinical characteristics of low-birth-weight infants at
sampling (n# 20)a
Clinical characteristics Values
Sex (male) (no. [%]) 14 (70)
Ethnicity (black) (no. [%]) 12 (60)b
HIV exposed (no. [%]) 16 (80)
Exclusive breastfeeding (no. [%]) 9 (45)
Formula feeding (no. [%]) 11 (55)
Birth wt (median [IQR]) (g) 1,575 (1,190–2,035)
"1,500 and!2,500 (no. [%]) 10 (50)
!1,500 (no. [%]) 10 (50)
Gestational age (median [IQR]) (wk) 35 (34–38)
Term (!38 wk) (no. [%]) 3 (15)
Premature (!38 wk) (no. [%]) 17 (85)
Wt on day of PK sampling (median [IQR]) (g) 1,874 (1,361–2,120)
Age at time of PK sampling (median [IQR]) (days) 14 (9–31)
Concomitant medications (no. [%])c
Nevirapined 15 (75)
Theophylline 8 (40)
Combination of anti-TB drugs (RMP, PZA,
ETH, ofloxacin)
4 (20)e
cART (abacavir, lopinavir/ritonavir,
lamivudine) and cotrimoxazole
1 (5)f
Hydrochlorothiazide and spironolactone 1 (5)g
a PK, pharmacokinetic; RMP, rifampin; PZA, pyrazinamide; ETH, ethionamide; cART,
combination antiretroviral therapy.
b Seven infants of mixed race, one white infant.
c Some infants were on a different combination of the listed concomitant medications.
d Two infants on nevirapine (NVP) and isoniazid (INH) had a raised alanine
aminotransferase (ALT) level at 3 months.
e Two infants on RMP and PZA; 1 infant on RMP, PZA, and ETH; 1 infant on ofloxacin
and ETH.
f One infant with HIV infection was treated with cART and cotrimoxazole on day 59 of
life.
g Used to control mild cardiac failure in infant with a ventricular septal defect.
TABLE 2 Summary of pharmacokinetic parameters in low-birth-weight
infants (n# 20)
Pharmacokinetic parametersa Median (IQR)b
Cmax ($g/ml) 5.63 (4.86–7.53)
Tmax (h) 2 (2–2)
AUC2–5 ($g · h/ml) 13.56 (11.75–19.10)
kel (h
%1)c 0.15 (0.10–0.23)
t1/2 (h)
c 4.69 (3.08–7.60)
a Cmax, maximum drug concentration; Tmax, time to Cmax; AUC2–5, area under the
concentration-time curve; kel, first-order elimination rate constant; t1/2, half-life.
b IQR, interquartile range.
c kel and t1/2 not calculated for 1 patient due to continuous high plasma drug
concentrations.
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was considered statistically significant. All data were analyzed using Stata
12.1 special edition software (StataCorp, College Station, TX, USA).
Study approval was obtained from the Health Research Ethics Com-
mittee at Stellenbosch University (approval no. N10/07/232).
RESULTS
Twenty infants, 16 (80%) of whom were HIV exposed, were en-
rolled; 17 received IPT and 3 received treatment for TB. Ten in-
fants (50%) had a birth weight of !1,500 g, and 17 (85%) were
premature (Table 1). On the day of pharmacokinetic sampling,
the median weight was 1,874 g (interquartile range, 1,361 to 2,120
g). Eight (40%) infants received theophylline for apnea of prema-
turity, and 15 (75%) of the 16 HIV-exposed infants received NVP
for PMTCT (one HIV-infected infant received abacavir, lopina-
vir/ritonavir, and lamivudine).
The pharmacokinetic measures are shown in Table 2. The
Cmax, kel, and consequently the t1/2 could not be accurately deter-
mined for one infant in whom INH plasma concentrations re-
mained high (2-h value, 4.6$g/ml; 5-h value, 4.9$g/ml). The t1/2
ranged from 1.45 to 14.25 h. Figure 1 illustrates the INH plasma
concentrations at 2, 3, 4, and 5 h postdose (n # 20). Nineteen
infants achieved plasma concentrations above the reference of 3
$g/ml at 2 h (20), with a range of 2.9 to 10.7 $g/ml, while all 20
infants achieved target drug plasma concentrations of"1.5$g/ml
at 3 h postdose (21).
The pharmacokinetic parameters were compared by demo-
FIG 1 Individual isoniazid drug concentrations in low-birth-weight infants
(n# 20). Symbols show the progressions for individual infant subjects.
TABLE 3 Effect of clinical and other characteristics on isoniazid pharmacokinetic parameters in low-birth-weight infants (n# 20)
Subject characteristics
Cmax parameter
a AUC2–5 parameter
b t1/2 parameter
c
No. of
infants
Median (IQR)
value ($g/ml) P
No. of
infants
Median (IQR)
value ($g · h/ml) P
No. of
infants
Median (IQR)
value (h) P
NAT2 genotype
SS (slow) 5 6.54 (5.60–8.05) 5 16.93 (14.59–21.87) 5 6.56 (4.86–9.57)
FS (intermediate) 11 6.41 (5.03–7.66) 11 13.21 (12.03–21.26) 11 4.52 (3.48–6.27)
FF (fast) 4 3.90 (2.95–4.86) 0.0235 4 6.78 (4.96–11.31) 0.0199 3 1.78 (1.45–2.04) 0.0134
Birth wt
Very low (!1,500 g) 10 6.58 (5.60–8.05) 10 15.35 (13.21–21.62) 10 4.56 (3.74–6.27)
Low (!1,500 to!2,500 g) 10 4.99 (4.11–6.41) 0.0284 10 12.61 (8.14–14.59) 0.0696 9 4.52 (1.95–6.56) 0.4142
Wt at PK time (g)
!1,750 9 7.66 (5.60–8.05) 9 21.26 (13.21–21.62) 9 5.93 (4.12–9.15)
!1,750 11 5.03 (4.11–6.54) 0.0304 11 13.19 (8.14–14.59) 0.0441 10 3.60 (1.95–5.09) 0.0864
Gestational age
!38 wk 17 5.66 (5.03–7.66) 17 14.48 (13.19–21.26) 16 4.69 (3.61–6.42)
!38 wk 3 4.11 (3.02–6.41) 0.1530 3 11.46 (5.41–12.03) 0.0502 3 2.04 (1.95–8.64) 0.4338
Corrected gestational age at PK time
!36 wk 11 5.66 (4.94–8.05) 11 14.48 (13.09–21.62) 10 4.39 (3.74–6.27)
!36 wk 9 5.33 (4.11–6.54) 0.1837 9 13.19 (11.46–14.59) 0.1837 9 4.86 (2.04–6.56) 0.6242
Gender
Female 6 5.14 (3.02–8.05) 6 14.54 (5.41–21.62) 5 6.27 (2.04–6.56)
Male 14 6.04 (5.03–7.40) 0.4579 14 13.27 (12.03–16.93) 0.8690 14 4.39 (3.48–5.93) 0.7812
HIV status
Exposed 16 5.45 (4.45–6.97) 16 13.49 (10.19–16.91) 15 4.52 (2.04–6.27)
Negative 4 7.34 (6.14–9.39) 0.0472 4 17.60 (13.27–25.08) 0.1306 4 6.53 (3.08–11.91) 0.4237
Feeding type
Breastfed 9 7.66 (5.66–8.05) 9 21.26 (13.33–21.62) 9 5.93 (4.12–9.15)
Formula fed 11 4.94 (3.35–6.41) 0.0027 11 12.03 (8.14–14.59) 0.0135 10 4.13 (1.95–5.09) 0.1208
a Cmax, maximum drug concentration; IQR, interquartile range.
b AUC2–5, area under the concentration-time curve.
c t1/2, half-life. The t1/2 not calculated for 1 patient due to continuous high drug plasma concentrations.
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graphic and clinical covariates (Table 3). The distribution of acet-
ylation status was as follows: 5 were slow, 11 were intermediate,
and 4 were fast acetylators. Statistically significant differences in
the Cmax, AUC2–5, t1/2, and kel were shown (P # 0.024, 0.020,
0.013, and 0.013, respectively) between slow, intermediate, and
fast acetylators. Slow acetylators had a higher median Cmax (6.5
$g/ml), larger AUC2–5 (16.93 $g · h/ml), and longer t1/2 (6.56 h)
than those of intermediate and fast acetylators, in decreasing or-
der. Figure 2 illustrates INH concentrations in relation to the
NAT2 genotype.
Infants weighing!1,750 g on the day of pharmacokinetic sam-
pling had a higher Cmax and AUC2–5 than those of heavier infants
(7.66 $g/ml versus 5.03 $g/ml [P # 0.030] and 21.26 $g · h/ml
versus 13.19 $g · h/ml [P# 0.044], respectively). The data in Fig.
3 suggest increased INH absorption and reduced clearance in
smaller infants. Similar findings were observed in infants with
younger gestational age; however, these differences were not sta-
tistically significant. Feeding also affected the Cmax and AUC2–5
values: exclusively breastfed infants had a higherCmax andAUC2–5
than did formula-fed infants (7.66 $g/ml versus 4.94 $g/ml [P#
0.003] and 21.26 $g · h/ml versus 12.03 $g · h/ml [P # 0.014],
respectively). Since weight at the time of pharmacokinetic sam-
pling was associated with feeding status (P# 0.001), feeding and
weight were likely confounded, with smaller babies more likely to
receive breastmilk. Gender did not influence the pharmacokinetic
parameters.
FIG 2 Isoniazid concentrations in relation to NAT2 genotyping by acetylator type. Each line represents a different infant subject (n# 20).
FIG 3 Isoniazid concentrations relative to current weight in low-birth-weight infants. Each line represents a different infant subject (n# 20).
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ALT levels were determined in 19 (95%) infants at baseline, in
14 (70%) at 3months, and in 11 (55%) at 6months. Two 3-month
values were abnormal; 1 was mildly elevated (!2.5 times elevated
[DMID grade 1]) and onemoderately elevated (!5 times elevated
[DMID grade 2]). Themildly elevated value was not repeated, and
the moderately elevated ALT value normalized at 6 months. Both
raised ALT values occurred in HIV-exposed infants receiving IPT
and NVP.
DISCUSSION
This is the first study describing the pharmacokinetics of INH and
correlating with NAT2 genotypes in LBW and premature infants.
The INH plasma concentrations in LBW infants, administered at
a dose of 10 mg/kg, compared well to the published target adult
values (20–22). An increased although variable half-life was ob-
served in LBW infants, cautioning against higher-INH-dosing
strategies. Markedly reduced clearance was present in smaller in-
fants and in slow acetylators. The most important pathway for
INH metabolism in humans is dependent on the trimodal NAT2
acetylation (18) already apparent in this young age group.
Optimal and safe INHdosing for TB prevention and treatment
are especially relevant for LBW infants. We administered INH at
the lower end of the WHO recommended dosage of 10 to 15
mg/kg (23). The desirable pharmacokinetic targets for children
include either a 2-h blood plasma concentration of 3 to 5$g/ml
(20) or a 3-h value of "1.5 $g/ml (21), both correlating with
good clinical response in adults. We found good absorption of
INH in all infants, and the adult pharmacokinetic target values
were achieved. All but one infant achieved a 2-h drug plasma
concentration of !3 $g/ml; the 2-h value for that infant was 2.9
$g/ml. All infants achieved a 3-h value of!1.5 $g/ml. The effect
of routine feeding every 2 to 3 h for LBW infants did not influence
the Cmax. However, food intake is known to decrease the bioavail-
ability of INH (24), and we were unable to evaluate pharmacoki-
netics in the absence of feeding. Concomitant medicines fre-
quently used in LBW infants included theophylline and NVP,
neither of which should impact the pharmacokinetic parameters
of INH (25, 26).
In our study, we observed an increased but variable half-life
(1.45 to 14.25 h) using a dose of 10 mg/kg of INH, in line with an
earlier study of two neonates in whom the half-lives were 7.8 and
19.8 h, respectively (27). This is not surprising, sincemost drugs in
newborns have a prolonged elimination half-life in general. This
finding, however, cautions against using a high dose of INH in
small infants. Furthermore, a study describing the INH pharma-
cokinetics according to phenotype, performed in 34 children (two
infants! 1 month of age), showed a definite decrease of half-life
with increasing age, suggesting slower elimination of INH in
young children (28). Although desirable INH pharmacokinetic
targets are essential for efficacy in infants, caution should be ap-
pliedwhendosing at the higher range to prevent potential toxicity.
In this study, markedly reduced INH clearance was noted in
the smaller and younger LBW infants. INH has a significant first-
pass metabolism, with the rate of drug metabolism depending
largely on the maturation of hepatic enzymes. Impaired elimina-
tion in the smaller and younger LBW infants is therefore probably
due to immature hepatic enzymes. The development of drug-me-
tabolizing enzymes varies widely between neonates and may be
prolonged in premature infants (29). Pharmacokinetic studies
show that the grade of maturation of enzymes is the most impor-
tant factor in determining the rate of metabolism of a drug, with
most liver enzymesmaturing after the first year of life (30, 31). The
effect of reduced INH elimination was even more pronounced in
breastfeeding infants. However, this was confounded by the fact
that smaller infants were more likely to receive breast milk. Anti-
tuberculosis drugs, including INH, are secreted in the breast milk
of women on TB treatment, with levels ranging between 0.05 and
28% (32). The levels of antituberculosis drugs in breast milk are
inadequate to prevent or treat infants but may increase the expo-
sure to these medications. Therefore, Tran et al. recommended
dosing at the lower end of the therapeutic range (i.e., 10 mg/kg/
day of INH) in order to decrease the risk of potential toxicity (32).
Age and acetylator status influence INH pharmacokinetics in
children (28, 33). INH is acetylated to acetylisoniazid by a hepatic
and intestinal enzyme, N-acetyltransferase 2, which is coded for
genetically. In our study, trimodal clearance of INH as a function
of the NAT2 genotype was already apparent, even in this young
age group. Our results showed that all compared parameters were
significantly different for all three acetylator groups, with slow
acetylators having decreased elimination compared to intermedi-
ate and fast acetylators. Recent data froman IPT trial conducted in
children 3 to 24 months of age illustrated not only the difference
for each genotype group but also immatureNAT2 activity, partic-
ularly in fast acetylators, with the acquisition of activity to adult
values occurring over the first 2 years of life (34). This is in keeping
with the maturation of genetically determinedNAT2 activity over
time. The impact of enzymematurity on the INH dosing for LBW
infants requires further study.
The transient elevation of blood serum transaminases occurs
commonly with INH, but clinically manifested hepatotoxicity is
rare. No formal relationship has been demonstrated between INH
plasma concentrations and hepatotoxicity. Previous observations
indicate that hepatotoxicity may be dose related (35, 36). In our
study, only two ALT results were slightly raised at month 3, with
the thrice-elevated value returning to normal at month 6. The
limited safety data collected were reassuring, and no jaundice was
observed in any infant. A limitation of the study was the few phar-
macokinetic sampling points, mainly because of the small blood
volume available in LBW infants. An earlier time point may have
assisted with determining the Cmax more accurately, as previous
pharmacokinetic studies in children indicate that the Tmax occurs
any time between 1 and 2 h (28, 37).
In conclusion, a sound understanding of the pharmacokinetic
properties of currently used antituberculosis drugs is essential for
optimal use in newborns and infants. LBW infants receiving 10
mg/kg of INH had desirable blood drug concentrations, which
were comparable to the adult target values. However, a prolonged
half-life and reduced elimination of INH were noted in smaller
and younger infants, especially in those genetically determined to
be slow acetylators. Therefore, we caution against exceeding a dos-
age of 10 mg/kg in this population. Although no serious adverse
effects were observed, more data on safety are needed. Also, more
research is needed on the appropriate dosing requirements for TB
drugs in newborns and infants.
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CHAPTER 7 
PHARMACOKINETICS OF RIFAMPICIN, ISONIAZID, PYRAZINAMIDE, 
AND ETHAMBUTOL IN INFANTS 
To ensure optimal curative treatment in infants (<12 months of age), a sound 
understanding is required of the pharmacokinetic properties of rifampicin (RMP), 
isoniazid (INH), pyrazinamide (PZA), and ethambutol (EMB), as drug disposition is 
influenced by developmental and physiological changes early in life (56). Age-
dependent elimination of first-line antituberculosis drugs has been previously 
demonstrated, with substantially lower exposures documented in younger children for 
RMP (97-99), INH (97, 98, 153), PZA (97, 127), and EMB compared to adults (154). 
However, few pharmacokinetic studies have been conducted in children less than two 
years of age with TB (60, 97), and none specifically in infants. In addition, the World 
Health Organization (WHO) revised their first-line antituberculosis drug dosing 
guidelines for children in 2009, by recommending considerably higher doses of RMP 
(10-20 versus 8-12 mg/kg/day), INH (7-15 versus 4-6 mg/kg/day), PZA (30-40 versus 
20-30 mg/kg/day), and EMB (15-25 versus 15-20 mg/kg/day) (39, 58). Study 4 was 
designed to test whether these substantially higher recommended mg/kg doses of first-
line antituberculosis drugs, achieve adequate serum drug concentrations in infants, 
compared to current adult pharmacokinetic target concentrations.  
An observational cohort study with intensive pharmacokinetic sampling  (single day) 
was conducted among HIV-infected and HIV-uninfected infants routinely initiated on 
first-line antituberculosis treatment in Cape Town, South Africa, from March 2014 
through March 2015. Participants were recruited from Tygerberg Hospital, 
Khayelitsha District Hospital and Brooklyn Chest Hospital. Routine South African 
National TB Programme (SANTP) antituberculosis drugs were given for the duration 
of TB treatment, and consisted of a fixed dose combination (FDC) tablet of RMP and 
INH (60:60) mg (Sandoz, South Africa), and a 500 mg PZA tablet (Sandoz, South 
Africa), with or without a 400 mg EMB tablet (Sandoz, South Africa). On the 
pharmacokinetic sampling day only, routine antituberculosis drugs were replaced by 
regulatory approved single-drug formulations. This strategy allowed for more 
accurate weight-banded drug dosing in our young study population, and more closely 
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reflected the revised WHO recommended dosing guidelines. The new FDC tablets 
(1.5:1 ratio of RMP and INH), supporting the revised WHO dosing recommendations, 
were not yet available at the time the study was implemented, and the routinely used 
SANTP fixed-dose combination (FDC) tablets (1:1 ratio of RMP and INH) were not 
suitable for accurate dosing. A limitation of the study was that we did not procure all 
regulatory approved single-drug formulations prior to study implementation, although 
this provided us with RMP pharmacokinetic data for two RMP formulations. The 
manufacturer temporarily halted production of the RMP suspension (RMP 
formulation 1) halfway through the study; it was then substituted by a second RMP 
suspension (RMP formulation 2), manufactured in South Africa and registered by the 
Medicines Control Council of South Africa.  
Pharmacokinetic blood samples were obtained pre-dose (0 hours) and at 1, 2, 4, 6 and 
8 hours following the administration of the single-drug formulations. Blood samples 
for alanine aminotransferase (ALT) levels were collected on the day of 
pharmacokinetic sampling, and again at TB treatment completion (6 months after TB 
treatment initiation). Antituberculosis drug concentrations were determined at the 
Pharmacology Laboratory at the University of Cape Town using validated liquid 
chromatography mass spectrometry methods (136). Pharmacokinetic parameters were 
calculated using non-compartmental analysis (NCA). The Cmax, AUC0-8 and t½ for 
RMP, INH, PZA and EMB were compared by the clinical covariates of age at time of 
pharmacokinetic study evaluation (0-6 months versus 7-12 months), nutritional status 
(WAZ < -2 versus WAZ ≥ -2), prematurity (premature, < 37 weeks versus term), HIV 
status, ethnicity (black versus mixed race), gender and, for RMP pharmacokinetic 
parameters only, by RMP formulation and RMP dose (10-15 mg/kg versus 15-20 
mg/kg). Multivariable regression models were generated to determine if any clinical 
covariates were associated with INH, RMP or PZA Cmax or AUC0-8.  
Results 
Thirty-nine infants on antituberculosis treatment were studied; 15 (38%) were 
premature (<37 weeks gestation) at birth, and 5 (13%) were HIV-infected and on 
antiretroviral therapy. The mean corrected age and weight was 6.6 months (standard 
deviation 3.3 months) and 6.45 kilograms (standard deviation 1.67 kilograms), 
respectively. 
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Table 1. Dosing ranges and pharmacokinetic parameters in infants on routine first-
line antituberculosis drugs (n=39) (94) 
First-line 
antituberculosis 
drugs 
WHO 
recommended 
dose 
(mg/kg) 
Mean 
(range) 
actual 
study dose 
(mg/kg) 
Mean 
(range) Cmax 
of study 
(μg/ml) 
Adult 
PK target 
Concentra-
tions 
(μg/ml) 
Cmax  
 of study 
compared to 
adult PK target 
concentrations 
Rifampicin 15 (10-20) 15 (10-21) 2.9  (0.6-7.9) 8-24 lower 
    Formulation 1 
         (n=14) 
13 (10-18) 4.1 (0.7-7.9) lower 
    Formulation 2 
 (n=25) 
17 (10-21) 2.2 (0.6-6.9) lower 
Isoniazid 
  (n=39) 
10 (7-15) 13 (10-15) 7.9 (4 – 
11.3) 
3-6 similar 
Pyrazinamide 
  (n=39) 
35 (30-40) 33 (28-38) 41.9 (26.3 – 
68.4) 
20-50 similar 
Ethambutol 
   (n=16) 
20 (15-25) 20 (15-24) 1.3 (0.2 – 2) 2-6 lower 
Cmax=maximum serum concentration; PK=pharmacokinetics; WHO=World Health Organization 
Very low RMP exposures were observed for both RMP formulations studied; none of 
the 39 infants achieved the minimum proposed target adult RMP peak concentration 
(Cmax) of ≥ 8 μg/ml (94). Despite RMP formulation-1 being dosed at the lower range, 
the RMP Cmax and AUC0-8 for RMP formulation-1 were significantly higher compared 
to RMP formulation-2 (Cmax: 4.1 versus 2.2 μg/ml, p=0.007; AUC0-8: 16.8 versus 9.5 
μg.h/ml; p=0.021). In multivariable regression, adjusting for the effects of age and 
weight, RMP formulation was associated with RMP Cmax and exposure. When 
stratified by RMP formulation, RMP dose did not have an effect. The bioavailability 
of these two RMP formulations was subsequently tested and is addressed elsewhere 
(89). For INH, all 39 infants achieved the proposed target adult Cmax of ≥ 3 μg/ml 
(94). For PZA, all achieved the adult minimum target Cmax of ≥ 20 μg/ml (94); 31/39 
(80%) achieved a Cmax ≥ 35 μg/ml for PZA, which was previously correlated with 
better TB treatment outcomes in adults (155). In this Botswana study, patients with a 
Cmax of < 35 μg/ml were more than 3 times as likely to have poor TB treatment 
outcomes, compared to patients with a Cmax of ≥ 35 μg/ml, after adjustment for HIV-
infection and CD4 cell count (adjusted risk ratio, 3.38; 95% confidence interval, 1.84-
6.22) (155). Multivariable analyses for PZA showed that HIV-infected infants had a 
lower Cmax and AUC0-8 controlling for age and weight. This is similar to a Malawian 
study conducted in 27 children (mean age 5.7 years), where 18/27 (67 %) HIV-
Stellenbosch University  https://scholar.sun.ac.za
84 
infected children on PZA had a lower Cmax than the PZA Cmax observed in HIV-
uninfected children (127). For EMB dosed at 20 mg/kg, only 1/16 (6%) infant 
achieved the minimum recommended adult Cmax target value of ≥ 2 μg/ml (94). At 
doses exceeding 20 mg/kg ocular toxicity may occur (122). This cautions against 
higher EMB dosing, especially in infants where visual acuity and colour vision testing 
is challenging. No other important associations were found for the key 
pharmacokinetic parameters of first-line antituberculosis drugs including now effect 
of age, weight, weight-for-age Z-score, prematurity, HIV-status, ethnicity, gender or 
TB treatment outcome.  
No study infants developed symptomatic hepatotoxicity. Alanine aminotransferase 
(ALT) values were performed at baseline and at treatment completion, 5/73 (7%) 
alanine aminotransferase (ALT) values were elevated in 5 infants. ALT values were 
graded by using the Division of AIDS (DAIDS) adverse event tables. Two Grade 1 
adverse events (elevated 2-fold), and one Grade 3 event (elevated 7-fold) occurred on 
the day of pharmacokinetic visit; one Grade 1 event and one Grade 2 event (elevated 
3-fold) occurred following 6 months of treatment. All resolved spontaneously at 
follow-up measurement. Final TB treatment outcomes were favourable (cure or 
treatment completion) in 37/39 (94%) infants while on routine programmatic FDC 
tablets (1:1 relation of RMP and INH), as per SANTP guidelines (156). TB treatment 
was reinitiated in four of them and six-months of TB treatment was subsequently 
completed. In two other infants, the treatment outcomes were unknown (both 
relocated to a different province after 3 months of treatment). 
This is the first study reporting pharmacokinetic parameters for the four first-line 
antituberculosis drugs in infants, using the 2009 revised WHO dosing guidelines. 
INH, PZA and EMB concentrations were comparable to previous paediatric studies 
when administered at the revised higher WHO recommended doses, with INH and 
PZA reaching recommended adult target concentrations. However, RMP exposures 
were low regardless of the formulation used when administered at a dosing range of 
between 10-20 mg/kg. The effect of these low RMP exposures on TB treatment 
outcomes in infants with immature immunity is unclear. As routine programmatic 
antituberculosis FDC tablets were given for the duration of TB treatment in our 
cohort, we could not evaluate the relation between the low antituberculosis drug-
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exposures for the single drug formulations and favourable TB treatment outcomes. 
Low RMP exposures described in paediatric pharmacokinetic studies (97-99, 157), 
supports RMP dose optimization in children. High RMP doses have become 
especially relevant in the context of treatment shortening regimens and when treating 
children with severe forms of TB. Future planned research by our group will 
investigate higher RMP doses in children, including safety, in line with adult studies 
(55). N-acetyltransferase 2 (NAT2) genotyping and enzyme maturation in the young 
child impacts on INH serum concentrations (158). NAT2 genotyping was determined 
for all infants on INH in this study. We are currently in the process of analyzing the 
NAT2 genotyping data in relation to the INH pharmacokinetic parameters, with the 
aim to determine the effect of acetylator status on INH exposures. Population 
pharmacokinetic modeling will be applied to a cohort of 96 children <2 years of age 
with both NAT2 genotyping and INH pharmacokinetic measurements available; data 
from study 3 and 4 will be included. Data generated from this proposed study will 
clarify the role of enzyme maturation on target INH drug concentrations in young 
children. 
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Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and
Ethambutol in Infants Dosed According to Revised WHO-
Recommended Treatment Guidelines
A. Bekker,a H. S. Schaaf,a H. R. Draper,a L. van der Laan,a S. Murray,b L. Wiesner,c P. R. Donald,a H. M. McIlleron,c A. C. Hesselinga
Desmond Tutu TB Center, Department of Pediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africaa;
Department of Clinical Research, Global Alliance for TB Drug Development, New York, New York, USAb; Division of Clinical Pharmacology, Department of Medicine,
University of Cape Town, Cape Town, South Africac
There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when
drug disposition may differ. Intensive pharmacokinetic sampling was performed in infants routinely receiving antituberculosis
treatment, including rifampin, isoniazid, pyrazinamide, and ethambutol, usingWorld Health Organization-recommended
doses. Regulatory-approved single-drug formulations, including two rifampin suspensions, were used on the sampling day. As-
says were conducted using liquid chromatography-mass spectrometry; pharmacokinetic parameters were generated using non-
compartmental analysis. Thirty-nine infants were studied; 14 (36%) had culture-confirmed tuberculosis. Fifteen (38%) were pre-
mature (<37 weeks gestation); 5 (13%) were HIV infected. The mean corrected age and weight were 6.6 months and 6.45 kg,
respectively. The meanmaximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9,
7.9, 41.9, and 1.3g/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6g/
ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0–8) were 12.1, 24.7, 239.4, and 5.1
g · h/ml, respectively. After adjusting for age and weight, rifampin exposures for the two formulations used differed in Cmax
(geometric mean ratio [GMR], 2.55; 95% confidence interval [CI], 1.47 to 4.41; P 0.001) and AUC0–8 (GMR, 2.52; 95% CI, 1.34
to 4.73; P 0.005). HIV status was associated with lower pyrazinamide Cmax (GMR, 0.85; 95% CI, 0.75 to 0.96; P 0.013) and
AUC0–8 (GMR, 0.79; 95% CI, 0.69 to 0.90; P< 0.001) values. No other important differences were observed due to age, weight,
prematurity, ethnicity, or gender. In summary, isoniazid and pyrazinamide concentrations in infants compared well with pro-
posed adult target concentrations; ethambutol concentrations were lower but similar to previously reported pediatric studies.
The low rifampin exposures require further investigation. (This study has been registered at ClinicalTrials.gov under registra-
tion no. NCT01637558.)
Infants (age12 months) in settings with high-burden tubercu-losis (TB) andHIV are at high risk ofMycobacterium tuberculosis
exposure, infection, disease, and mortality, emphasizing the need
for rigorous evidence from pharmacokinetic studies to guide op-
timal antituberculosis treatment in this vulnerable population.
Up to 50% of infants exposed to and infected withM. tuberculosis
will develop TB disease in the absence of preventive therapy, with
up to 30% of these progressing to severe pulmonary or dissemi-
nated disease (1). A 4-fold increase inmortality has been reported
among infants with maternal HIV-associated TB in India (2),
while 24% mortality was observed in South African infants 3
months of age with culture-confirmed TB (3).
In 2010, theWorld Health Organization (WHO) revised pedi-
atric TB dosing guidelines by recommending considerably higher
doses of first-line antituberculosis drugs in children (rifampin
[RMP], 10 to 20 versus 8 to 12 mg/kg of body weight/day; isonia-
zid [INH], 10 to 15 versus 4 to 6mg/kg/day; pyrazinamide [PZA],
30 to 40 versus 20 to 30 mg/kg/day; and ethambutol [EMB], 15 to
25 versus 15 to 20 mg/kg/day) (4, 5). These guidelines were based
on evidence frompharmacokinetic studies involvingmainly older
children, which showed that higher mg/kg body weight dosing
was necessary to achieve equivalent adult target concentrations
(6–10). The pharmacokinetic and safety profiles of antituberculo-
sis drugs in infants at these higher doses remain largely unknown.
Infants undergo developmental and physiological changes that
may influence drug disposition and susceptibility to toxicity (11,
12). Enzyme maturation, efflux transporter activity, increased
drug clearance for body weight, and formulations and their prep-
arations are all important factors determining drug exposure in
young children (12). Few pharmacokinetic studies have been
completed in children2 years of age with TB (13, 14), and none
were specifically in infants. A study in Indian children found sig-
nificantly lower maximum plasma concentrations (Cmax) and ar-
eas under the concentration-time curves (AUC) for RMP, INH,
and PZA in children3 years of age compared to older children
(ages 3.1 to 12.0 years) when the drugs were given thrice weekly,
highlighting the need for age-dependent dosing considerations
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(14). The aim of our study was to determine key pharmacokinetic
parameters for RMP, INH, PZA, and EMB at the revised WHO-
recommended doses in infants routinely treated for TB.
MATERIALS AND METHODS
Study design and setting. An observational cohort study with intensive
pharmacokinetic sampling (single day) was conducted among HIV-in-
fected and -uninfected infants routinely initiating first-line antitubercu-
losis treatment in Cape Town, South Africa, from March 2014 through
March 2015. Participants were recruited from Tygerberg Children’s Hos-
pital, Khayelitsha District Hospital, and Brooklyn Chest Hospital.
Study population and antituberculosis drugs. HIV-infected and
-uninfected infants were eligible after at least 2 weeks of intensive phase
first-line antituberculosis treatment, allowing for RMP autoinduction
(15). Infants were consecutively recruited after parental informed consent
was obtained. HIV testing was routinely performed. TB treatment con-
sisted of a standard 2-month intensive phase of RMP, INH, and PZA,with
or without EMB, given once daily, 7 days a week, followed by a 4-month
continuation phase of INH and RMP at the same doses (16). Weight-
banded doses were consistent with theWHO interim guidelines for treat-
ment of TB in young children using the available dispersible fixed-dose
combinations for children. EMB was added at clinician discretion (typi-
cally in the case ofmore severe TBdisease), as per national guidelines (16).
Routine South African national TB program antituberculosis drugs, con-
sisting of a fixed-dose combination (FDC) tablet of RMP and INH (60:60
mg) (Sandoz, South Africa) and a 500-mg PZA tablet (Sandoz, South
Africa)with orwithout a 400-mgEMB tablet (Sandoz, SouthAfrica), were
given for the duration of TB treatment. Nevirapine (NVP) as part of
prevention of mother-to-child transmission and combination antiretro-
viral therapy (cART) consisting of abacavir, lamivudine, and lopinavir/
ritonavir were given to HIV-exposed and -infected infants, respectively
(17).
Pharmacokinetic sampling was deferred in critically ill infants, those
with aweight of1.8 kg, and thosewith a hemoglobin level of8 g/dl.On
the pharmacokinetic sampling day only, routine antituberculosis drugs
were replaced by single-drug formulations. This allowed for more accu-
rate dosing in the very young study population,more closely reflecting the
revised WHO-recommended dosing guidelines, since the routinely used
FDC tablets (1:1 relation of RMP and INH) were not suitable for accurate
dosing and the new FDC tablets (1.5:1 relation of RMP and INH) sup-
porting the revisedWHOdosing recommendations were not yet available
at the time of the study. INH, PZA, and EMB were available in tablets of
50, 150, and 100mg, respectively, andRMPwas a granulate for suspension
(100mg/5ml; Eremfat, referred to here as RMP formulation 1). TheRMP,
INH, and EMB formulations were manufactured by Riemser Arzneimit-
tel, Germany, were registered with a stringent regulatory authority, and
appeared on the global fund list of approved medicines. Pyrazinamide
(Svizera Laboratories, Pty Ltd., the Netherlands) was manufactured in a
WHO-certified facility complying with good manufacturing practices. In
June 2014, Riemser temporarily halted the manufacturing of Eremfat,
necessitating its substitution with a second RMP suspension, R-cin (100
mg/5 ml; manufactured by Aspen Pharmacare, South Africa, and regis-
tered by the Medicines Control Council of South Africa; referred to here
as RMP formulation 2).
Sample size calculations. The aim of the study was to enroll approx-
imately 40 infants, based on prior knowledge of RMP variability, reported
RMP exposures in adults and children, and the feasibility of enrolling this
substantial number of infants with TB over a 12- to 18-month accrual
period.
Pharmacokinetic investigation. Infants were fasted for 2 h prior to
TB drug dosing to facilitate improved absorption (18, 19). A nasogastric
tube (NGT) was inserted to ensure accurate dosing, and the pH of gastric
aspirates was measured using an instacheck 0-13 pHydrion pH test kit
(Micro Essential Laboratory, USA). An indwelling peripheral venous
catheter was inserted, and a predose (0-h) blood sample was obtained for
drug concentration determination and for albumin and alanine amino-
transferase (ALT) levels. The RMP suspension, followed by INH and PZA
with or without EMB tablets crushed andmixed with water, was given via
NGT, which was then flushed with 5ml of water. Fivemore samples of 0.6
ml each at 1, 2, 4, 6, and 8 h postdose were collected in EDTA-coated tubes
and centrifuged to separate the plasma before freezing at80°Cwithin 30
min of sampling. Drug concentrations were determined at the pharma-
cology laboratory at the University of Cape Town using validated liquid
chromatography-mass spectrometry methods. The methods were vali-
dated over the concentration ranges of 0.0977 to 26.0g/ml for isoniazid,
0.117 to 30.0 g/ml for rifampin, 0.200 to 80.0 g/ml for pyrazinamide,
and 0.0844 to 5.46g/ml for ethambutol (20). All samples thatwere below
the level of quantification (BLQ) were set to half of the lower limit of
quantification (LLOQ). ALT measures were repeated at the end of 6
months of TB treatment.
Pharmacokinetic parameters and statistical analysis. Pharmacoki-
netic parameters were calculated using noncompartmental analysis
(NCA). Stata 12.1 SE software (StataCorp 2011, College Station, TX,
USA) was used for analyses. Cmax and time to Cmax (Tmax) were recorded
directly from the concentration-time data. The AUC0–8 was calculated
using the linear trapezoidal rule. The elimination half-life (t1/2) was de-
noted as ln2/Kel, where Kel (elimination rate constant) was the negative
slope of the log-linear regression of three final data points of the concen-
tration-time curve. The Cmax, AUC0–8, and t1/2 for RMP, INH, PZA, and
EMB were compared by the clinical covariates of age at time of pharma-
cokinetic study evaluation (0 to 6 versus 7 to 12 months), nutritional
status (Weight-for-age Z-score [WAZ]2 versus2), prematurity
(premature,37 weeks, versus term), HIV status, ethnicity (black versus
mixed race), and gender as well as, for RMP pharmacokinetic parameters
only, byRMP formulation andRMPdose (10 to 15 versus 15 to 20mg/kg).
All comparisons were generated using t tests. For preterm infants, ages
corrected for gestational age were calculated. Age was analyzed with and
without corrected ages; no differences were found, so unadjusted age at
the time of pharmacokinetic sampling was used. WAZs were calculated
using theUnitedKingdomWHOpreterm growth chart, inwhich preterm
infant (37 weeks) WAZs were adjusted for gestational age (21). Clear-
ance was calculated for all first-line antituberculosis drugs using dose and
AUC0–8 for age comparisons. Adverse events were classified using the
division of AIDS (DAIDS) tables. TB treatment outcomes were defined
using standard international criteria (22): cured or treatment completion
was considered favorable, while treatment failure, death, and loss to fol-
low-up, including treatment interruption of2months, were classified as
unfavorable outcomes. TB treatment outcome was compared by theCmax
and AUC0–8 for the first-line antituberculosis drugs.
Multivariable regression models were generated to determine if any
clinical covariates were associated with the INH, RMP, or PZA Cmax or
AUC0–8. In total, six models were generated using the INH, RMP, and
PZA log-transformed Cmax and AUC0–8 values as dependent variables,
each analyzed separately. The geometric mean ratios (GMR) were re-
ported alongwith 95% confidence intervals (CI) andP values. The clinical
covariates considered for inclusion into the models were age at time of
pharmacokinetic study (continuous), weight on pharmacokinetic day
(continuous), HIV status, prematurity (premature versus term), ethnic-
ity, nutritional status (WAZ2 versus WAZ2), and gender. Co-
variates with a P value of 0.10 and factors known to affect drug dispo-
sition (age and weight) were included in each multivariable model. To
determine if RMPdosewas associatedwithCmax orAUC0–8, a subanalysis
was done using multivariable linear regression stratified by RMP formu-
lation, where dose was analyzed, categorically controlling for continuous
age and weight. The resulting regression coefficients (s) for dose, along
with the corresponding 95% CI and P values, are reported.
Regulatory approval. The study (NCT01637558) was approved by
Medicines Control Council of South Africa, by the research ethics com-
mittees of Stellenbosch University (N13/03/031), and by the University of
Cape Town (180/2011).
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RESULTS
Patient characteristics at pharmacokinetic assessment. Table 1
displays the characteristics of the 39 infants, of whom 15 (39%)
were documented as premature. At pharmacokinetic sampling,
the mean age, corrected for gestational age, and weight were 6.6
months and 6.5 kg, respectively.M. tuberculosis infectionwas con-
firmed in 14 (36%) infants. Twenty-two (56%) infants were born
to HIV-infected mothers; 5 infants seroconverted shortly after
birth. All 5 HIV-infected infants were established on cART at the
time of pharmacokinetic assessment. All infants received RMP,
PZA, and INH; 16 (41%) also received EMB. Ethionamide was
given in 7 (18%) infants (n  2 with TB meningitis, n  1 with
miliary TB, and n  4 due to clinician preference). The dosing
ranges and summary statistics for the pharmacokinetic parame-
ters for RMP (i.e., formulation 1 and formulation 2), INH, PZA,
and EMB are displayed in Table 2. No difference was noted for
clearance of the first-line antituberculosis drugs by age (data not
shown).
Rifampin. None of the 39 infants achieved the target adult
peak RMP concentration of8g/ml. Table 3 provides the RMP
pharmacokinetic parameter comparisons for Cmax, AUC0–8, and
t1/2 by clinical covariates; the comparison for RMPCmax, AUC0–8,
and t1/2 by RMP formulation andRMPdose are also displayed.On
the pharmacokinetic sampling day, 14 of 39 (36%) infants re-
ceivedRMP formulation 1 (median dose, 12.1mg/kg) and 25 of 39
(64%) infants received RMP formulation 2 (median dose, 18.6
mg/kg; difference between themedian doses of RMP formulations
was P 0.025). Despite the lower dose range of RMP formulation
1, the RMPCmax and AUC0–8 for RMP formulation 1 were higher
than those of RMP formulation 2 (Cmax: 4.1 versus 2.2g/ml, P
0.007; AUC0–8: 16.8 versus 9.5 g · h/ml; P  0.021). While this
comparisonwas not adjusted for dose, it is worthwhile to note that
the lower-dosed formulation resulted in higherCmax andAUC0–8.
When the analysis of formulation was adjusted for dose, the dif-
ferences in Cmax and AUC0–8 remained, and the formulation ef-
fect was increased in the same direction (results not shown). In
multivariable analysis stratified on formulation, RMP dose (10 to
15 versus 15 to 20 mg/kg) was not associated with either Cmax or
AUC0–8 after adjusting for age and weight (Cmax for subset of
RMP formulation 1: dose  1.33, 95% CI, 0.43 to 3.09, P 
0.132; Cmax for subset of RMP formulation 2: dose  2.02, 95%
CI,1.30 to 5.34, P 0.206; AUC0–8 for subset of RMP formu-
lation 1:dose 5.93, 95%CI,2.17 to 14.03, P 0.143; AUC0–8
for subset of RMP formulation 2: dose 9.81, 95% CI,3.68 to
23.31, P  0.136). Figure 1 illustrates RMP concentrations over
time by formulation, including suggested adult target values (23,
24). Inmultivariable regression adjusting for the effects of age and
weight, RMP formulation was associated with RMP peak concen-
trations and exposure. For Cmax, the GMR for the RMP formula-
tion 1 to the RMP formulation 2 was 2.55 (95%CI, 1.47 to 4.41; P
 0.001); for AUC0–8, theGMR for the same comparisonwas 2.52
(95% CI, 1.34 to 4.73; P 0.005).
Isoniazid. All 39 infants achieved the target adult peak INH
concentration of3g/ml. Table S1 in the supplementalmaterial
provides the INH pharmacokinetic parameter comparisons for
Cmax, AUC0–8, and t1/2. Infants with a lowerWAZ (2.0) had a
shorter t1/2 (1.77 versus 2.2 h; P 0.046). Figure 2 shows the INH
concentration over time for infant participants, including re-
TABLE 1 Characteristics of infants with tuberculosis at the time of
pharmacokinetic sampling (n 39a)
Characteristic Value
No. (%) male 26 (67)
No. (%) black ethnicity 29 (74)
Mean (SD) corrected age, mo 6.6 (3.3)
Mean (SD) weight, kg 6.45 (1.67)
Mean (SD) WAZb 1.62 (1.53)
Mean (SD) WLZc 0.41 (1.26)
No. (%) with premature birth (37 wk gestational age) 15 (38)
Median (IQRd) birth weight, kg 2.70 (2.33–3.08)
Mean (SD) hemoglobin, g/dl 10.9 (1.6)
Mean (SD) albumin, g/liter 42 (3)
No. (%) with gastric pH3 (n 11) 11 (100)
Maternal HIV status
No. (%) with HIV-infected mother 22 (56)
Median maternal log viral load (n 15) 2.8
No. (%) with maternal cART/PMTCTe (n 21) 15 (71)
Infant HIV status
No. (%) HIV infected (n 39) 5 (13)f
Median (IQR) infant CD4 percentage 35.4 (26.9–38.5)
Median (IQR) infant log viral load 6.33 (6.14–6.7)
Median (IQR) cART in weeks before PK study 8 (5–8)
Infant TB characteristics
No. (%) with culture and/or Xpert MTBg/rifampin
confirmed
14 (36)h
Median (IQR) duration of TB treatment in weeks at PK 7 (5–9)
No. (%) with BCGi vaccination history/scar 32 (82)
No. (%) with positive tuberculin skin test (n 16) 7 (44)
No. (%) with documented TB source case (n 28) 28 (72)
No. (%) with mother as source case 15 (54)
No. (%) with other household TB source case 8 (29)
No. (%) with nonhousehold TB source case 5 (17)
No. (%) with smear/culture and/or Xpert positive
source case
18 (64)
No. (%) with type of TBj
PTB 36 (92)
EPTB (n 1 TBM) 1 (3)
PTB and EPTB (n 1 miliary TB; n 1 TBM) 2 (5)
Mean (range) routine antituberculosis drug dose, mg/kg
Rifampin (n 38) 13.8 (9.0–19.7)
Isoniazid (n 38) 13.8 (9.0–19.7)
Pyrazinamide (n 39) 31.5 (18.7–44.6)
Ethambutol (n 16) 19.9 (13.3–29.0)
No. (%) with concomitant medicationsk
ABC, 3TC, LPV/rl 5 (12)
Prednisone 1 (3)
Diuretics and spironolactone 1 (3)
a Total number of infants evaluated was 39, unless otherwise noted in table.
b WAZ, weight for age Z-score.
c WLZ, weight for length Z-score.
d IQR, interquartile range.
e cART, combination antiretroviral therapy; PMTCT, prevention of mother-to-child
transmission.
f Three of these mothers received no PMTCT or cART before delivery.
g Xpert: Gene Xpert for MTB/rifampin.
h Culture and Xpert positive for 10 infants (n 3, only culture; n 1, only Gene
Xpert).
i BCG, bacillus Calmette-Guérin.
j Types of TB: PTB, pulmonary TB; EPTB, extrapulmonary TB.
k Nevirapine therapy was completed for HIV-exposed infants; steroid therapy, for
severe airway compression; diuretics, for ventral septal defect.
l ABC, abacavir; 3TC, lamivudine; LPV/r, lopinavir and ritonavir.
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ported adult target values (23, 24). No significant associations
were found in log-transformed multivariable regression.
Pyrazinamide.All 39 infants achieved adult peak PZA concen-
trations of20g/ml, and 31 of 39 (80%) achieved aCmax of35
g/ml. Table S2 in the supplemental material provides the PZA
pharmacokinetic parameters comparisons for Cmax, AUC0–8, and
t1/2. Younger infants had a longer t1/2 (8.92 versus 7.01 h; P 
0.047), while malnourished infants, versus those with normal nu-
TABLE 2 Summary statistics for infant pharmacokinetic parameters of rifampin, isoniazid, pyrazinamide, and ethambutol (n 39a)
First-line
antituberculosis drug
Recommended
dose (range)
(mg/kg)
Mean (range)
actual dose (mg/kg)
Mean (range)
Cmax (g)
Mean
(IQRb) Tmax
(h)
Mean (range)
AUC0–8 (g · h/ml)
Mean (range) t1/2
(h)c
Mean (range)
CL/Fd (liter/h/kg)
Rifampin 15 (10–20) 15.37 (10.13–20.51) 2.90 (0.59–7.96) 2.0 (2.0–2.0) 12.12 (1.78–33.01) 2.05 (1.06–4.06) 2.57 (0.37–16.68)
Formulation 1
(n 14)
12.91 (10.13–18.18) 4.13 (0.65–7.96) 2.0 (1.0–2.0) 16.77 (1.59–33.01) 2.07 (1.11–4.06) 1.55 (0.37–7.07)
Formulation 2
(n 25)
16.75 (10.13–20.51) 2.22 (0.59–6.94) 2.0 (2.0–2.0) 9.52 (1.78–32.29) 2.04 (1.06–3.93) 3.14 (0.58–16.68)
Isoniazid 10 (10–15) 12.80 (10.31–15.38) 7.92 (3.97–11.30) 1.0 (1.0–1.0) 24.68 (11.56–50.18) 2.00 (1.00–3.92) 0.57 (0.26–1.00)
Pyrazinamide 35 (30–40) 33.32 (28.48–38.46) 41.9 (26.3–68.4) 1.0 (1.0–2.0) 239.4 (147.1–450.0) 8.01 (4.40–20.63) 0.15 (0.08–0.20)
Ethambutol (n 16) 20 (15–25) 20.18 (15.38–24.10) 1.26 (0.24–2.01) 2.0 (1.5–3.0) 5.09 (1. 24–8.87) 3.59 (1.61–6.94) 4.69 (2.13–12.45)
a Total number of infants evaluated was 39 unless otherwise noted.
b IQR, interquartile range.
c t1/2, half-life of the drug. Due to late peaks, t1/2 was not calculated in the following infant samples: n 4 rifampin (of n 36); n 1 isoniazid (of n 38); n 1 pyrazinamide (of
n 38); and n 1 ethambutol (of n 15).
d CL, clearance; F, fraction absorbed.
TABLE 3 Rifampin pharmacokinetic parameters by age, nutritional status, prematurity, HIV status, ethnicity, gender, formulation, and dose
(n 39)
Variable
Parameter data for:
Cmax (g/ml) AUC0–8 (g · h/ml) t1/2 (h)
a
No. evaluated Mean (SD) value P No. evaluated
Mean (SD)
value P No. evaluated Mean (SD) value P
Age at PK sampling, mo
0–6 20 2.89 (2.16) 20 12.78 (9.72) 17 2.17 (0.70)
7–12 19 2.92 (2.24) 0.975 19 11.43 (9.63) 0.664 19 1.95 (0.88) 0.425
Nutritional status on day of PK
2.0 21 2.65 (1.94) 21 10.60 (8.20) 20 2.02 (0.78)
2.0 18 3.21 (2.44) 0.429 18 13.90 (10.93) 0.289 16 2.08 (0.84) 0.830
Prematurity
Term (38 wk) 24 2.73 (1.90) 24 11.46 (8.65) 23 1.99 (0.84)
Premature (37 wk) 15 3.18 (2.60) 0.538 15 13.18 (11.12) 0.593 13 2.17 (0.73) 0.520
HIV status
HIV infected 5 3.67 (3.31) 5 16.46 (15.00) 5 2.27 (1.14)
HIV uninfected 34 2.79 (2.00) 0.404 34 11.48 (8.66) 0.283 31 2.02 (0.75) 0.522
Ethnicity
African 29 3.00 (2.37) 29 12.04 (10.20) 28 1.88 (0.64)
Mixed race 10 2.63 (1.52) 0.644 10 12.37 (7.94) 0.926 8 2.67 (1.04) 0.011
Gender
Female 13 3.27 (2.39) 13 13.00 (10.01) 13 1.75 (0.57)
Male 26 2.72 (2.08) 0.468 26 11.68 (9.52) 0.692 23 2.22 (0.87) 0.088
Rifampin formulation
Formulation 1 14 4.13 (2.35) 14 16.77 (10.50) 14 2.07 (0.84)
Formulation 2 25 2.22 (1.77) 0.007 25 9.52 (8.11) 0.021 22 2.04 (0.79) 0.918
Rifampin dose, mg/kg
10–15 17 2.74 (2.34) 17 10.86 (10.01) 17 1.91 (0.71)
15–20 22 3.03 (2.09) 0.691 22 13.10 (9.34) 0.447 19 2.17 (0.87) 0.340
a t1/2, half-life of the drug.
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trition, had a higher AUC0–8 (268.09 versus 214.72g · h/ml; P
0.018). Figure 3 shows the PZA concentration over time, includ-
ing reported adult target values (23, 24). Multivariable analyses
from a log-transformed regression model for PZA showed that
HIV-infected infants had a lower Cmax (GMR, 0.85; 95% CI, 0.75
to 0.96; P 0.013) and a lower AUC0–8 (GMR, 0.79; 95%CI, 0.69
to 0.90; P  0.001), controlling for age and weight. No other
significant associations were observed.
Ethambutol. Only one of 16 infants (6%) had a Cmax2 g/
ml, which is the recommended adult target value (Fig. 4). Table S3
in the supplemental material displays the EMB pharmacokinetic
parameter comparisons for Cmax, AUC0–8, and t1/2. HIV-infected
infants had a lower Cmax (0.4 versus 1.4 g/ml; P 0.004) and a
lower AUC0–8 (2.0 versus 5.5 g · h/ml; P  0.008) than HIV-
uninfected infants.
Safety. Themedian ALT at the time of sampling was 21 U/liter
(interquartile range [IQR], 15 to 35 U/liter; n 37) and at treat-
ment completion was 22 U/liter (IQR, 18 to 30 U/liter; n 36). In
total, 5 of 73 (7%) ALT values in 5 separate infants were elevated.
Two grade 1 adverse events (elevated 2-fold) andone grade 3 event
(elevated 7-fold) occurred on the pharmacokinetic visit; one grade
1 event and one grade 2 event (elevated 3-fold) occurred following
6 months of treatment. All resolved spontaneously at a follow-up
measurement. These safety data are relevant only to the routine
antituberculosis drugs, as study drugs were administered only on
the PK sampling day.
TB treatment outcome. Thirty-three of the infants (85%) had
favorable TB treatment outcomes; cure occurred in 4, and treat-
FIG 1 Mean plasma rifampin (RMP) concentrations (g/ml) after the intake
of a mean dose of 12.9 mg/kg for RMP formulation 1 (n 14) and of a mean
dose of 16.7 mg/kg for RMP formulation 2 (n 25). Cmax adult target values,
8 to 24 g/ml when RMP is administered at 600 mg daily in American adults
(23); Cmax, 5.9 g/ml when RMP is administered at 10.9 mg/kg in South
African adults (24).
FIG 2 Mean plasma isoniazid (INH) concentrations (g/ml) after the intake
of a mean dose of 12.8 mg/kg of INH (n 39). Adult targetCmax values, 3 to 6
g/ml when INH is administered at 300 mg daily in American adults (23);
Cmax, 6.5 g/ml when INH is administered at 6.5 mg/kg in South African
adults (24).
FIG 3 Mean plasma pyrazinamide (PZA) concentrations (g/ml) after the
intake of amean dose of 33.3mg/kg of PZA (n 39). Adult targetCmax values,
20 to 50g/ml when PZA is administered at 25mg/kg/day in American adults
(23); Cmax, 52.7 g/ml when INH is administered at 35.7 mg/kg in South
African adults (24).
FIG 4 Mean plasma ethambutol (EMB) concentrations (g/ml) after the
intake of amean dose of 20.2mg/kg of EMB (n 16). Adult targetCmax values,
2 to 6 g/ml administered at 25 mg/kg/day in American adults (23); Cmax, 5
g/ml when EMB is administered at 24.5 mg/kg in South African adults (24).
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ment completion was documented in 29. Of six infants, all with
poor social circumstances, initially classified as having unfavor-
able treatment outcomes, 4 infants (n 1HIV-infected and n 3
HIV-exposed) initially classified as lost to follow-up were success-
fully reinitiated on TB treatment (n 1 each at month 3, 4, 5, and
6) and completed 6 months of TB treatment. In the other 2 in-
fants, the treatment outcome was unknown (both relocated to a
different province after 3months of treatment).Cmax andAUC0–8
for RMP, INH, PZA, and EMB were not associated with TB treat-
ment outcome.
DISCUSSION
This is the first study reporting pharmacokinetic parameters for
the four first-line antituberculosis drugs, using the 2010 revised
WHO dosing guidelines, specifically in infants. Encouragingly,
infants demonstrated INH and PZA concentrations similar to
those reported in adult studies; EMB concentrations were low but
comparable to other pediatric pharmacokinetic studies using the
same dose. However, very low RMP exposures were observed for
both RMP formulations studied. RMP formulation 2, which was
dosed at a higher dosing range, had lower RMP Cmax and AUC0–8
than RMP formulation 1. The RMP dose was not associated with
RMPCmax and AUC0–8 when stratified by formulation; therefore,
the formulation probably contributed more than the dose toward
the observed difference in RMP pharmacokinetic parameters.
PZA and EMB exposures were lower in the few HIV-infected in-
fants studied. No other important associations were found for the
key pharmacokinetic parameters of first-line antituberculosis
drugs by age, weight, weight-for-age Z-score, prematurity, HIV
status, ethnicity, gender, or TB treatment outcome. No infants
developed symptomatic hepatotoxicity, and at least 85%of infants
had a favorable TB treatment outcome.
Amarkedly low RMPmean Cmax of 2.9g/ml was observed in
infants, even when dosed at 12 to 20 mg/kg/day. Desirable RMP
2-hour postdose concentrations of between 8 and 24 g/ml have
been suggested in adult healthy volunteers and in TB patients
receiving a dose of 9 to 12 mg/kg (23); however, few adult and
pediatric patients reach the often-recommended minimum RMP
2-hour concentration of 8 g/ml (24, 25). In our study, RMP
exposures were low using both RMP suspensions, and no infant
achieved a 2-hour value of 8 g/ml. Infants on RMP formula-
tion 1 achieved significantly higher exposures than those on RMP
formulation 2, despite the lower-mg/kg administered dose (Fig.
1). RMPdose itself was not associatedwithRMPCmax, or AUC0–8;
however, these findings and conclusions must be interpreted with
caution. Further analysis showed that the formulation mainly
contributed toward observed differences in pharmacokinetic pa-
rameters, emphasizing the importance of bioavailability of drug
formulations and the use of high-quality formulations. High-per-
formance liquid chromatography (HPLC) testing revealed similar
RMP concentrations for both formulations, and, in a laboratory-
based study, aliquots of the RMP formulation 1 used in the study
that were left to stand for 30 min at room temperature in 3 naso-
gastric tubes had RMP concentrations similar to a control aliquot
of the suspension (26). McIlleron et al. (26) also reported no im-
pact of NGT drug delivery on the effect of RMP formulation on
the AUC in the large DATiC (dosing antiretroviral- and tubercu-
losis drugs in children) study, where children were given an RMP
suspension either byNGTor per os. The peakRMPconcentrations
of 4.0 and 2.2 g/ml for the two different RMP formulations,
respectively, were similar to those reported in other pediatric
studies, documenting low peak concentrations of 2.8, 2.9, 3.5, 3.8,
and 3.9 g/ml following an oral administration of 10 to 20 mg/kg
(27–31). Higher median RMP peak concentrations of 10 and 12
g/ml were achieved when dosed at 10 and 15mg/kg (P 0.008),
respectively, in Indian children (32). RMP mean peak concentra-
tions of 6.4 and 11.7 g/ml, when dosed at 10 and 15 mg/kg (P
0.005), respectively, were observed in 11 South African children
younger than 2 years of age using a different RMP formulation.
The authors noted that children with high drug concentrations at
the lower RMP dose did not necessarily have comparatively high
drug concentrations following the higher dose (13). RMP formu-
lations are known for considerable intra- and interindividual vari-
ability, which may partly be explained by differences in RMP bio-
availability. In a study with 20 children, only 50%  22% of a
freshly prepared oral suspension was absorbed compared to an
intravenous dose (33). Although the cause for this variable RMP
bioavailability remains unclear, the following factors have been
proposed: raw material characteristics, changes in the crystalline
habit of the RMP, excipients, manufacturing and/or process vari-
ables, degradation in the gastrointestinal tract, and inherent vari-
ability in absorption and metabolism (34). RMP is the only hy-
drophobic drug of the first-line antituberculosis drugs, is
characterized by low solubility, is easily adsorbed by common
pharmaceutical excipients, and also shows a pH-dependent solu-
bility affecting its absorption (35). All of these factors highlight the
need for stringent quality assurance of antituberculosis drugs in
clinical care and research. A limitation of this study was that all of
the study drugs were not purchased prior to the start of the study.
The effect of gastric pHonRMPbioavailability remains unclear. A
low gastric pH, as found in 11 study infants tested, was associated
with low RMP exposures; Khalil et al. described reduced oral ab-
sorption of RMP when combined with antacids (36).There are
limited data available on the ontogeny of the expression of p-gly-
coprotein, known to influence RMP absorption, with develop-
mental differences in efflux transporter activity markedly altering
the bioavailability of drugs (37). The specific relevance of p-gly-
coprotein in the dosing of young children with RMP requires fur-
ther investigation in young children.
All infants had 2-hour plasma INH concentrations of 3
g/ml following a mean dose of 12.8 mg/kg, which is above the
suggested adult lower limit target range of 3 to 6 g/ml (23).
Infant INH concentrations also compared well with other pediat-
ric pharmacokinetic studies with similar 2-hour concentrations
reported of 4.5, 5.6, and 3.9 to 8.6, following 10 to 15mg/kg (7, 27,
38). The effect of acetylator status on INH exposures is not re-
ported here (future work).
PZA is probably the best absorbed among the first-line antitu-
berculosis drugs, and infants achieved a high mean Cmax of 41.9
g/ml at 1 h, following a dose of 33.3 mg/kg. A proposed PZA
adult target range of 20 to 60g/ml has been suggested (23), but a
study fromBotswana showed that aCmax of less than 35g/mlwas
associated with a poor outcome in adult pulmonary TB patients
(39). Our results were similar to other pediatric studies reporting
peak concentrations of 34.6 to 47.8 g/ml when dosed at 30 to 40
mg/kg (8, 13, 28, 32).
Themean EMBCmax of 1.3g/ml at 2 h following amean dose
of 20.2 mg/kg was low, with a proposed adult therapeutic 2-hour
peak concentration of 2 g/ml (23). Other pediatric studies re-
ported similarly low concentrations of between 0.78 and 2.1
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g/ml when dosed at 10 to 20 mg/kg (27, 28, 32, 40, 41). Increas-
ing EMB dosage in children has been reported to result in higher
peak concentrations (42, 43); however, dose-dependent ocular
toxicity is a limiting factor in dosing increases (44) especially in
young children, in whom clinical evaluation is more challenging.
In a recent study, 3 of 11 children 5 years of age developed
reversible visual impairment secondary to 23, 25, and 27 mg/kg/
day of EMB (45). Routine eye examinations are not common in
resource-constrained settings; therefore, caution should be ad-
vised with increased EMB dosage. Ethionamide is sometimes
preferentially given to infants due to clinical concerns of optic
neuritis. EMB is the least efficacious of the first-line antituber-
culosis drugs and is used mainly to protect companion drugs
against resistance. The clinical relevance of these findings in
infants, who typically have paucibacillary TB and in whom the
theoretical risk of acquision of drug resistance is low, needs
further evaluation.
Age-dependent elimination of first-line antituberculosis drugs
has been shown, with lower exposures documented in younger
children for RMP (10, 14, 40), INH (14, 40, 46), PZA (8, 14), and
EMB (42). These findings havemainly been attributed to themore
rapid clearance of drugs and to a relatively larger liver-to-body size
ratio. In our study, however, where all children were 1 year of
age, age did not influence clearance. To our knowledge, this is the
first study specifically performed in infants on antituberculosis
drugs that also incorporated postconceptual age, andwe found no
remaining influence of prematurity. There is no clear evidence
regarding the potential association between low TB drug expo-
sures and concomitant cART (8, 13, 27, 47). In our study, we
observed lower PZA and EMB exposures in HIV-infected infants;
however, we studied only 5 HIV-coinfected infants. The higher
PZA AUC0–8 observed in malnourished infants, compared to
those with normal nutrition, was confounded by the fact thatmal-
nourished infants were dosed at the higher end of the dosing
range.
Hepatotoxicity is themain adverse event associated with RMP,
INH, and PZA. All infants were asymptomatic for symptoms and
signs of hepatotoxicity, but ALT values were raised in 5 (7%)
infants while on routine antituberculosis drugs. However, ALT
values returned to normal within 3 months without intervention.
Few pediatric studies have reported on hepatotoxicity at the re-
vised WHO dosing recommendations. Hiruy et al. documented
an ALT range of 9 to 71 U/liter in 31 children younger than 10
years at the revised higher doses (27). Two (3.1%) of 64 children
developed hepatitis on the previously recommended lower doses,
and 3 (4.8%) of 63 children did so on the revised higher doses in a
study conducted in Indian children younger than 15 years of age
(32).
The majority of infants had favorable TB treatment outcomes,
despite the observed low RMP exposures for both formulations
and the extensive disease in most. Higher RMP dosing strategies
are currently being investigated in early bactericidal activity stud-
ies in adults; the short-term safety results have been reassuring. In
adult RMP dose-escalation studies of up to 35 mg/kg/day for 2
weeks, higher doses showed a disproportionate plasma exposure
increasewith dose and a greater fall in bacterial load (48).Multiple
factors influence the relationship between drug concentrations
and TB treatment outcome, including M. tuberculosis genotype,
gene polymorphisms, extent of TB disease, bacillary burden, and
immune status, including HIV infection status (46). A limitation
of our study is that the study drug was administered only on the
pharmacokinetic day, while routine drugs were used for the
6-month treatment; this limits the interpretation of drug concen-
trations on TB treatment outcome.
NCA was used due to its timeliness and also for ease of
interpretation to a broad clinical audience. Multivariable anal-
ysis was used to determine if pharmacokinetic parameters were
associated with clinical covariates applicable to a clinical audi-
ence. In the absence of pediatric pharmacodynamic data, the
optimal required target concentrations remain unclear and are
typically extrapolated from adult studies. Furthermore, direct
comparison of pharmacokinetic studies is complicated by vari-
ations in dose administered, type of formulation, single drugs
versus fixed-dose combinations, daily versus intermittent ther-
apy, and different sampling schedules, all of which influence
plasma drug concentrations. In our study, INH, PZA, and EMB
concentrations were comparable to other pediatric studies
when dosed at the revised higher WHO recommendations,
with INH and PZA reaching recommended adult target con-
centrations. However, RMP exposures were low regardless of
the formulation used when administered at a dosing range of
10 to 20 mg/kg, highlighting the importance of using high-
quality formulations and of bioavailability studies for RMP
formulations in children and potentially arguing in favor of
using dispersible tablets instead of liquid formulations in
young children. In addition, the low RMP exposures argue for
RMP dose-optimization studies in children. Reported TB
treatment outcomes are generally good in children with drug-
susceptible TB, independent of drug concentrations achieved,
but this may be different for infants with immature immunity,
for HIV-infected children, and in those with extensive and dis-
seminated TB disease. Therefore, the low RMP exposures may
become increasingly relevant in children who receive treat-
ment-shortening regimens and in children with severe forms of
TB; both populations are currently under evaluation.
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CHAPTER 8 
CONCLUSIONS AND FUTURE DIRECTIONS 
The interwoven epidemics of tuberculosis (TB) and human immunodeficiency virus 
(HIV) have led to a global resurgence of TB, especially in sub-Saharan Africa (1). In 
settings with high prevalence of HIV, women of childbearing age (20-39 years) are 
disproportionately affected by TB (2, 4). Infants (<12 months of age) born to women 
with TB are therefore also at high risk of Mycobacterium tuberculosis exposure (33, 
34) early in life. Up to 50% of infants infected with M. tuberculosis will develop TB
disease in the absence of preventive chemotherapy and bacillus Calmette-Guérin 
(BCG) vaccination (32, 34). Poor completion of isoniazid preventive therapy (IPT) in 
children (44, 46, 47) contributes towards increased risk of TB and TB-related 
morbidity. Addressing barriers to IPT delivery in newborns may lead to improved IPT 
initiation and completion in resource-constrained settings.  
Rigorous pharmacokinetic data regarding the use of first-line antituberculosis drugs in 
neonates (<28 days of age) and infants, where developmental changes may 
substantially influence drug disposition (56), is essential to inform the effective and 
safe dosing of antituberculosis drugs in young children. Prior to the pharmacokinetic 
study described in chapter 6, no pharmacokinetic data were available to guide the use 
of isoniazid (INH), a key first-line antituberculosis drug, in neonates, and there was 
very limited pharmacokinetic data regarding the use of first-line antituberculosis 
drugs in infants. The aim of this dissertation was therefore to comprehensively 
investigate strategies to prevent and treat perinatal and infant TB in the context of 
maternal HIV infection.  
The first study (chapter 3) demonstrated that a high number of neonates were 
investigated for TB at a large provincial referral hospital, Tygerberg Hospital (TBH) 
in Cape Town, South Africa. Despite the high background prevalence of TB and HIV 
in this setting, no routine data had previously been collected on maternal-infant TB in 
this setting. Despite the retrospective nature of this study, valuable information was 
obtained by documenting high TB exposure among neonates. Seventy neonates (60% 
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HIV-exposed) were investigated for TB during a single year. Maternal TB was the 
primary indication for TB screening among infants. Nearly three-quarters of neonates 
screened for TB were initiated on IPT due to concerns regarding maternal 
infectiousness, suggesting delayed TB diagnosis in pregnant women. Data on the 
completion of IPT was limited, although overall the IPT completion was poor. 
Telephonic follow-up at one-year post hospital discharge traced only a third of 
neonates confirmed to have initiated IPT. Of the 12 traceable infants, only 5 had 
completed 6 months of IPT. This study highlighted the critical gaps in knowledge and 
implementation for maternal and infant TB control interventions in high prevalence 
TB and HIV-endemic settings, informing the design and implementation of a 
prospective cohort study (study 2; chapters 4 and 5). This next prospective study 
aimed to generate more rigorous clinical and epidemiological data on maternal TB 
disease and maternal and infant outcomes, collected prospectively. Identifying 
barriers to IPT completion in TB-exposed neonates was also prioritized as an 
important research gap to be addressed.  
The second study (chapter 4) therefore prospectively enrolled pregnant and 
postpartum women on TB treatment at TBH during 2011. Of 74 women routinely 
treated for TB, 35 (47%) women were diagnosed with TB only upon hospital 
admission for labour or within 6 weeks of delivery. This delayed TB diagnosis in 
pregnant women illustrated the lack of appropriate antenatal TB screening and the 
frequency of delayed presentation and diagnosis of TB in the postpartum period. 
Furthermore, 22 (30%) of 74 women reported a previous TB treatment episode, 
highlighting the importance of previous TB episodes as a risk factor for maternal TB. 
Consideration of previous TB may therefore be useful as an additional part of current 
World Health Organization (WHO) TB-screening algorithms in pregnant women, 
given the poor performance of the algorithm in HIV-infected pregnant women 
documented in two recent studies with reported sensitivities of 28% and 54%, 
respectively (9, 10). In addition, improved molecular diagnostic tools, including Xpert 
MTB/RIF (Cepheid), which was not available at the time of the study, may potentially 
decrease diagnostic delays and result in more rapid initiation of TB treatment for 
pregnant women. Xpert MTB/RIF would also allow for the identification of potential 
drug-resistant TB, which was present in 6/42 (14%) women with bacteriologically- 
confirmed TB in our study. Maternal HIV infection was associated with high maternal 
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and newborn mortality in this study. All five TB-related maternal deaths occurred in 
HIV-infected women, and the four stillbirths and six newborn deaths were all from 
HIV-infected women. A large proportion 53/74 (72%) of these women were HIV co-
infected, many with severe immune suppression. Only 34/53 (64%) HIV-infected 
women received any form of prevention of mother-to-child transmission (PMTCT) 
therapy or combination antiretroviral therapy (cART) in the context of widespread 
access to ART in the public sector. Not surprisingly, women presented with severe 
extrapulmonary TB (EPTB) manifestations, i.e. TB meningitis, TB spine, TB 
pericarditis, abdominal TB and TB-associated bacteraemia, experiencing high 
morbidity. Earlier initiation of ART in HIV-infected pregnant women could reduce 
the high morbidity and mortality presently observed in HIV co-infected women and 
their infants.  
Maternal TB treatment outcomes in this cohort of pregnant women, who mostly had 
high-risk pregnancies, were poor. TB cure and treatment completion (favourable TB 
treatment outcomes) was achieved in only 41/74 (55%) of pregnant women treated for 
TB. Intensified scale-up of TB prevention, diagnosis and treatment interventions in 
PMTCT and TB programmes will lead to earlier TB diagnosis during pregnancy and 
better completion and outcomes of maternal TB treatment. Both TB and HIV impact 
adversely on perinatal outcomes and have been associated with premature and low 
birth weight (<2500g; LBW) deliveries (29, 159).  This study also showed a high risk 
of delivering a LBW infant in the presence of maternal TB (59%), against an already 
high background of 37% LBW deliveries at our referral hospital during the study 
period (144). Earlier treatment of both TB and HIV will likely lead to healthier 
pregnant women who are more likely to carry to term, reducing the risk of preterm 
labour and LBW infants. In a pregnant woman with TB, giving birth to a LBW infant 
was associated with increased risk of unfavourable maternal TB treatment outcomes 
(OR 3.83, 95% CI 1.40-10.53, p=0.009). It is possible that women with LBW infants 
would have had additional challenges to attend TB clinics for their own treatment, 
given the challenges of caring for these LBW infants. Two (3%) of 72 live born 
infants had bacteriologically-confirmed TB (2 sets of twins), and completed 6 months 
of antituberculosis treatment. Three (7%) of 45 HIV-exposed infants had HIV-
infection diagnosed on routine postnatal testing and were initiated on cART. This 
vertical transmission rate for HIV was higher than national transmission rate of 2.8% 
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in 2011 (160), however this cohort consisted of a selected group of high-risk 
pregnancies. Important clinical epidemiological data were generated by prospectively 
characterizing TB during pregnancy and systematically documenting perinatal, infant 
and maternal TB treatment outcomes. Data generated from this study contributed 
towards current understanding of maternal and infant TB in the context of maternal 
HIV, and may assist with improved strategies to prevent perinatal and infant TB. 
Of note was the large proportion of TB-exposed newborns who required IPT because 
of a maternal infectious TB source case. Unsupervised IPT completion rates in 
children below 30% were reported from two studies in Cape Town (50, 51). Very few 
of the newborns initiated on IPT at TBH in the first study of this dissertation were 
traceable and known to have completed IPT. This led me to conduct a prospective 
study to identify barriers to completion of IPT in TB-exposed newborns. A cohort of 
56 newborns who had been routinely initiated on IPT at TBH in 2011 was enrolled. 
Of the 56 TB-exposed newborns included, 49 had a maternal TB source case and 7 
had another infectious household TB-source case. The aim of this study was to 
identify health system, socio-economic and maternal predictors of IPT completion 
among TB-exposed newborns. A dedicated hospital-based TB care team followed 
44/56 newborns to 6 months; 12 patients left the study (1 died, 4 withdrew and 7 were 
loss to follow-up). Twenty-nine (66%) of the 44 TB-exposed newborns who were 
followed to 6 months completed IPT without study team intervention. Linkage to 
care, which included an appropriate TB treatment referral resulted in improved IPT 
completion, after adjusting for maternal HIV status and type of caregiver. In 
conclusion, a simple intervention, including hospital-community linkage of care and 
appropriate TB referral from hospital to local TB clinic, resulted in improved IPT 
completion in TB-exposed newborns. Further operational research is required in 
South Africa and other high-burden settings, to identify health system strengthening 
strategies to improve the down-referral of newborns initiated on IPT from hospital to 
community-based TB clinics. 
Antituberculosis drug doses in newborns and infants 
Infants undergo substantial physiological changes influencing drug disposition during 
the first year of life (56, 57). For this reason, achieving safe and effective dosing of 
first-line antituberculosis drugs in neonates and infants is an important consideration 
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for the chemoprevention and treatment of perinatal and infant TB. Although children 
with drug-susceptible TB often have paucibacillary TB disease and good treatment 
outcomes, infants are more prone to develop progressive pulmonary and disseminated 
TB disease, highlighting the importance of optimal antituberculosis drug 
concentrations in infants to ensure good outcomes. Substantial uncertainty remains 
around the optimal target concentrations and exposures for several of the first-line 
antituberculosis drugs.  Additional studies are needed to establish the appropriate dose 
in children, in order to inform paediatric dosing to achieve current adult target levels. 
Recent studies have shown that higher mg/kg body weight doses of antituberculosis 
drugs are necessary in children to achieve comparable adult antituberculosis drug 
target concentrations. This evidence led to the WHO revising its paediatric 
antituberculosis dosing guidelines for first-line antituberculosis drugs in 2009, 
recommending higher doses in children (58). Pharmacokinetic evidence for these 
higher doses is lacking in premature and LBW infants, with only sparse 
pharmacokinetic data available for infants overall. These higher doses should be 
thoroughly investigated in neonates and infants, where reduced clearance of drugs 
may lead to high exposures and possible toxicity, and too low a dose may not be 
successful in achieving cure. 
In the third study, an intensive pharmacokinetic sampling study was conducted in 20 
LBW infants receiving INH at a dose of 10 mg/kg/day, prescribed in the course of 
routine care for the prevention or treatment of TB disease. To our knowledge, this 
was the first INH pharmacokinetic study conducted in LBW infants. The median 2-
hour post dose INH concentration in LBW infants was 5.63 μg/ml, ranging from 2.9 – 
10.7 μg/ml, which is similar or higher than the recommended adult minimum 2-hour 
post dose concentration of 3 μg/ml (94). Very low birth weight (VLBW; < 1500 
grams) infants had significantly higher INH exposures, compared to infants weighing 
between 1500 – 2500 grams, suggesting reduced INH elimination in the smaller 
infants. All 20 LBW infants phenotypically behaved as slow acetylators, reflected by 
the high-observed INH concentrations. Interestingly, the trimodal N-acetyltransferase 
2 (NAT2) acetylation pattern was already apparent at this very early stage of 
development. Genotypically slow acetylators had a decreased elimination rate 
compared to genotypically intermediate- and fast acetylators. NAT2 enzyme 
maturation differences have never been documented this early in life. Zhu and 
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colleagues illustrated a different NAT2 enzyme maturation profile present at 3 months 
of age for each of the three acetylation groups in another study, with no change in the 
apparent clearance of the slow acetylator group over the course of 24 months (133). 
Further research on the developmental expression of the NAT2 gene in the neonatal 
period and infancy is needed to understand the impact of enzyme maturation on 
clearance, and ultimately inform dosing of INH in infancy. The limited safety data 
collected during our study was reassuring; however, caution should be expressed 
against exceeding an INH dose of 10 mg/kg/day in this very young paediatric 
population, given the INH exposures achieved using the lower range of the current 
WHO dosage recommendations. 
The aim of the fourth study was to determine whether the revised higher 2009 WHO-
recommended doses in children for RMP, INH, PZA and EMB, achieved adequate 
drug concentrations in infants compared to current adult pharmacokinetic target 
concentrations for these drugs. An observational cohort study with intensive 
pharmacokinetic sampling was conducted among HIV-infected and HIV-uninfected 
infants who were routinely started on first-line antituberculosis treatment, from March 
2014 through March 2015 in Cape Town, South Africa. On the pharmacokinetic 
sampling day only, routine antituberculosis drugs were replaced by regulatory 
approved single-drug formulations to more closely reflect the revised WHO 
recommended doses. Thirty-nine infants on RMP, INH and PZA were studied; 14 on 
RMP formulation-1 and 25 on RMP formulation-2. Sixteen infants were also on EMB 
and pharmacokinetic samples were obtained for all first-line antituberculosis drugs. 
Very low RMP exposures were observed for both RMP formulations studied, when 
dosed at 10-20 mg/kg. Not one of the 39 infants achieved the minimum proposed 
target adult peak concentration (Cmax) of ≥ 8 μg/ml (94). Few adult and paediatric 
patients reach this often-recommended minimum RMP 2-hour target of 8 μg/ml, 
when dosed at 8-12 mg/kg (95, 96). This fixed RMP dose of 600 mg in adults (8-12 
mg/kg in children) was originally recommended on the basis of cost rather than on 
efficacy or safety (55, 161). Higher RMP dosing strategies are currently being 
investigated in adults in the context of dose-escalation and efficacy trials. RMP given 
at 35 mg/kg/day for two weeks in adults, showed a disproportionate plasma exposure 
increase with dose, a greater fall in bacterial load, and provided reassuring short-term 
safety results (55). There is a need to conduct RMP dose-escalation studies in 
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children. Low RMP exposures may become increasingly relevant in the context of 
treatment shortening regimens in children and in children with severe forms of TB, 
e.g. TB meningitis. For INH, all 39 infants achieved the proposed target adult Cmax of 
≥ 3 μg/ml (94), and NAT2 genotyping analysis is pending for this cohort. For PZA, all 
infants achieved the adult minimum target Cmax of ≥ 20 μg/ml (94). PZA differs from 
other first-line antituberculosis drugs regarding the need of a higher mg/kg dose in 
children than in adults to achieve the same Cmax. In a literature review, Donald et al., 
demonstrated little difference between the Cmax achieved in children and adults 
following various mg/kg body weight doses (162). For EMB, dosed at 20 mg/kg, only 
one of sixteen infants achieved a Cmax ≥ 2 μg/ml, which is the recommended adult 
Cmax target value (94). Due to EMB dose-related ocular toxicity (122) and difficulty 
of testing vision in infants, caution should be advised against higher dosing of EMB 
in infants at this stage. No other important associations were found for the key 
pharmacokinetic parameters of first-line antituberculosis drugs including effect of 
age, weight, weight-for-age Z-score, prematurity, HIV-status, ethnicity, gender or TB 
treatment outcome. There were no clinically significant safety concerns and no 
indication of liver toxicity.  
Summary of pharmacokinetic studies 
Data from the pharmacokinetic studies forming part of this dissertation showed 
relatively high INH Cmax in LBW infants dosed at 10 mg/kg/day, compared to adult 
proposed INH target Cmax. Both the smaller infants, and the genotypically slow 
acetylators, had higher INH exposures and longer half-lives, suggesting reduced 
elimination of INH. This study showed that the INH dose in premature and LBW 
infants should probably not exceed 10 mg/kg/day. The final study was conducted in 
infants treated for TB disease at the revised higher mg/kg body weight dose 
recommended by WHO for first-line antituberculosis drugs (58). Similar INH and 
PZA target Cmax were achieved in infants, compared to adults. However, low target 
Cmax in infants were observed for RMP and EMB, compared to adults. RMP is 
difficult to dose, with considerable intra- and interindividual variability, partly 
explained by differences in RMP bioavailability (89, 92). In addition, uncertainty 
exists around the historical target RMP Cmax of 8 μg/ml in adults, chosen mainly due 
to cost implications rather than for efficacy and safety reasons (55). Recent RMP 
dose-escalation studies in adults show promise with regards to better efficacy, and 
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low toxicity when administering RMP at higher doses over short dosing periods. 
Although EMB peak concentrations in children were low, the dose dependent adverse 
effect of optic neuritis currently prevents the recommendation of substantially higher 
doses at this stage. More pharmacokinetic data of first-line antituberculosis drugs are 
needed in a larger numbers of neonates and infants of different genetic backgrounds, 
with and without HIV co-infection and with different drug doses, to determine 
optimal dosing in this age group. Furthermore, there is a need for better defining 
target pharmacokinetic concentrations of first-line antituberculosis drugs in neonates 
and infants to guide dose finding. Higher doses of RMP in infants should be 
considered. A pharmacokinetic/pharmacodynamic model-based approach, using 
pharmacokinetic data from children and adults, including outcome data from adult TB 
meningitis trials, showed that RMP doses of at least 30 mg/kg/day are needed to attain 
proposed target RMP exposures (163). 
Future directions 
Several factors should be considered in the prevention and treatment of perinatal and 
infant TB. Important considerations for reducing the burden of TB in infants are the 
prevention, early diagnosis and optimal treatment of TB disease in pregnant women. 
Untreated TB in pregnancy poses a significant risk to the mother and her newborn and 
is associated with high morbidity and mortality (20, 28, 143, 149). The WHO 
recommends all four first-line antituberculosis drugs (RMP, INH, PZA and EMB) for 
use in pregnancy (164), which are widely regarded as safe and do not appear to have 
harmful effects on the foetus. Although the US Centers for Disease Control and 
Prevention (CDC) does not recommend the routine use of PZA during pregnancy, 
CDC supports the inclusion of PZA for HIV-infected pregnant women, as it may 
outweigh the undetermined potential risk to the foetus (165). Isolated cases of drug-
induced hepatitis on antituberculosis drugs have been reported in pregnancy (166), 
but this low risk of fatal liver damage is also present in non-pregnant women (35, 
167).  Uncertainty exists as to whether the risk of drug-induced hepatitis is increased 
during pregnancy.  
Ongoing and future research 
The International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) 
network have recently completed enrolment for the P1078 trial, including several 
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South African sites, to evaluate the safety of antepartum versus postpartum INH in 
HIV-infected pregnant women (n=950). Safety data generated from this trial will 
inform much needed guidance on the use of INH in HIV-infected pregnant women. 
Limited pharmacokinetic data of first- and second-line antituberculosis drugs are 
available in pregnant women with TB to guide the optimal dosing of both first- and 
second-line antituberculosis drugs during pregnancy (168). The IMPAACT P1026 
study is currently investigating pharmacokinetic properties of first and second-line 
antituberculosis drugs in pregnant women with and without HIV co-infection. 
Evidence from this study will hopefully guide safe and effective dosing in pregnant 
and postpartum women with TB. Early initiation of ART in HIV-infected pregnant 
women also reduces TB disease progression, and the risk of TB and HIV in newborn 
infants. Integration of maternal HIV and TB services is essential to improve early 
case detection.  
The incidence of TB during pregnancy remains unknown and there are poor data to 
inform global estimates of TB burden during pregnancy. The development and 
implementation of a TB pregnancy registry at national and international level to 
record and report cases of TB in pregnant women, may assist in better estimating the 
true TB incidence and treatment outcomes during pregnancy. As a first step towards 
establishing better data on TB in pregnant women, a TB pregnancy registry protocol 
has been developed to establish the first global registry of pregnancy-associated TB 
(Chair: Bekker; beyond the scope of this PhD). The proposed project would pool data 
on pregnant women enrolled in completed, ongoing, and planned trials of HIV and 
TB treatment, generating much needed data on TB during pregnancy and outcomes of 
women and infants affected by TB. 
Robust and representative pharmacokinetic data of antituberculosis drugs in LBW 
infants are needed to inform the appropriate use of the first-line antituberculosis 
drugs. No data are available for second-line antituberculosis drugs in this population. 
The ongoing multi-center IMPAACT P1106 study (protocol vice-chair: Bekker) aims 
to describe the pharmacokinetic and safety characteristics of ART and first-line 
antituberculosis medicines in LBW infants. Mathematical modeling (population 
pharmacokinetic models) will be done to optimally characterize the pharmacokinetics 
of these drugs in LBW infants, and inform dosing guidelines. Future research should 
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further study the association between INH concentrations and NAT2 genotyping in 
young children. The role of enzyme maturation in this population should be explored, 
as this may potentially influence dosing recommendations. Low RMP concentrations 
observed in the infant pharmacokinetic study (study 4) were of concern. A phase I/II 
open label multi-cohort dose escalation study to evaluate the pharmacokinetics and 
safety of increased doses of RMP in HIV-negative children with TB disease will start 
recruitment in the last quarter of 2016. Findings from this study will potentially 
inform future dosing for TB treatment shortening trials in children and provide 
guidance on optimal treatment of severe forms of TB disease in infants, including TB 
meningitis. 
In summary, pregnant women and TB-exposed infants face a considerable burden of 
TB disease, especially in the context of maternal HIV infection. Pregnant women and 
infants should be included in observational and interventional trials of TB prevention 
and treatment. Concurrently, health systems should be strengthened and antenatal TB 
screening, diagnosis and treatment improved. Health care workers practicing in high 
burden TB and HIV settings should have a high index of suspicion to investigate 
newborns for TB. Pharmacokinetic data generated from pregnant women and infants 
on existing and new antituberculosis drugs will optimize preventive and curative TB 
treatment, especially in the context of maternal HIV infection, where outcomes are 
currently poor for both women and their infants. Health systems should be 
strengthened to improve the care of pregnant women with TB and their infants and 
new findings from clinical research should inform both policy development and 
implementation to improve TB care in these vulnerable populations.  
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ABSTRACTresp_1784 747..763
Although tuberculosis (TB) has its highest burden
among young adults, especially since the advent of HIV
infection, twoother groupswith low immunity, the very
young (<1 year) with immature immunity and the
elderly (>65 years) with waning immunity, are vulner-
able groups not to be forgotten. This review describes
theepidemiology,clinicalaspects,publichealthaspects
and outcome of TB in patients at the extremes of age.
The epidemiology differs therein that TB in infants
occurs in developing countries with high incidences of
TB andHIV,while TB in the elderly occurs in developed
countries with ageing populations.The clinical presen-
tationmaybenon-specific,history of contactwithTB is
oftennot knownandTB is oftennot considered at these
age extremes, and when the diagnosis is considered,
disease progression may already be advanced. Anti-TB
treatment regimensare thesameas inotheragegroups,
but drug dosages may need adjustment according to
weight, renal function, liver function and other poten-
tially complicating factors.Adverse events aremoredif-
ficult to observe and both the young and the elderly are
reliant on others for adherence to treatment.Mortality
at both age extremes is higher than in the general TB
population. For all the above reasons, public health
measures to:prevent transmissionof infection; identify
those infected and providing preventive therapy; high
index of suspicion in order to make an early diagnosis;
andtimely initiationof treatmentare important inboth
the very young and the elderly.
Key words: tuberculosis, congenital, infant, perinatal,
elderly.
INTRODUCTION
Tuberculosis (TB) is one of the world’s most serious
diseases. According to the World Health Organization
(WHO), one-third of the world’s population are
infected with TB. Each year, there are over nine
million cases of TB and almost 1.8 million TB-related
deaths worldwide. Furthermore, TB is one of the
leading causes of death in HIV-infected people.1 More
than 90% of global TB cases and deaths occur in the
developing world. In the USA, 10–15 million people
are estimated to be TB-infected, with 14 093 active
cases of TB in 2005.1
Apart from severe immune compromise, such as
seen with HIV infection, immune immaturity related
to young age (mainly children infected before
<2 years of age) is associated with a greatly increased
risk to develop active disease following infection with
Mycobacterium tuberculosis. Infants (i.e. children
<12 months of age) experience the highest risk; 50%
develop TB after infection in the absence of preven-
tive measures and up to 30% develop progressive pul-
monary or disseminated (miliary) TB.2 HIV infection
increases this risk even further; a recent study in
the Western Cape province, an area with a high
TB incidence of 1037/100 000 population in 2006,
demonstrated a relative risk of 24 (95% CI: 17–34)
for culture-confirmed TB in HIV-infected infants
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compared with HIV-uninfected infants.3 Reasons
postulated for this increase were immunosuppres-
sion, more exposure to adult TB source cases
because of increased susceptibility to TB in adults
caring for these infants and the likelihood that
Bacille Calmette-Guérin (BCG) vaccination is less
effective in HIV-infected children.3 It is possible that
not only HIV-infected but also HIV-exposed unin-
fected infants are at higher risk of TB, because of
increased exposure to TB from immunodeficient
household members and potential immunosuppres-
sion in these infants.4,5
On the other end of the spectrum, life expectancy
continues to increase in the developed world; there-
fore, TB in the elderly is likely to be a continuing, if not
an increasing problem. In many developing coun-
tries, especially in Africa, life expectancy is decreasing
mainly because of HIV infection in young adults,
leading to a likely decline in number of elderly people,
but with the general population having increased
exposure to TB, it is likely that worldwide TB in the
elderly may become an increasing problem.
Although HIV infection is relatively uncommon in
the elderly and therefore not a major risk factor in this
age group, immunity in the elderly is often waning,
and because of high infection rates with M. tubercu-
losis at young age even in currently developed coun-
tries, the elderly remain at high risk for TB disease
mainly due to reactivation.
In both extremes of age, the symptoms at presenta-
tion are often uncharacteristic at best, and often
vague. Alertness and awareness of TB as a possible
diagnosis in these age groups is paramount. Adverse
events to anti-TB treatment are more common in the
elderly and more difficult to identify in the very
young; therefore, more careful monitoring is needed.
Identifying patients at risk in both age groups is chal-
lenging, because mothers or other household
members are often not yet diagnosed with TB or
unaware of the risk to the infant if an adult has TB,
while contact tracing of patients living in residential
or nursing homes can be very problematic and
resource intense. The mortality at both extremes of
age is therefore, not surprisingly, high.
It is vital that all those involved in the care of very
young and elderly patients consider TB as a differen-
tial diagnosis and be aware of the pitfalls and difficul-
ties in diagnosis and treatment, especially as it is
potentially a curable disease, unlike many conditions
that either an infant or elderly patients present with.
METHODS
Search strategies
Tuberculosis in the very young—for this review we
refer to TB in infants. However, TB in infants is a
diverse group. Pubmed was searched under the terms
‘congenital tuberculosis (or TB)’, ‘perinatal tuberculo-
sis’, ‘infant tuberculosis’ and ‘connatal tuberculosis’
and available articles or abstracts with sufficient
information about epidemiology and clinical aspects
were used for this overview. Additional articles were
found by using references from articles identified by
these searches. We have used our own experience
with surveillance of TB in children in the Western
Cape of South Africa (population 4.8 million), an area
with a TB incidence of >1000/100 000 population in
2008 and a HIV prevalence in 2008 of approximately
15% in pregnant women attending public health
antenatal clinics, to demonstrate some points.
From the available literature we have reviewed 75
cases of congenital TB for this study, a group of
patients that is often referred to in this article and
some findings are summarized in Tables 1 and 2.6–43
Tuberculosis in the elderly: Pubmed was searched
under the terms ‘elderly tuberculosis (or TB)’ and ‘Old
age TB’. A Google search using the same words was
also performed. Additional articles from the refer-
ences of these obtained articles were also used par-
ticularly for epidemiology data.
The authors of this review have published exten-
sively on TB; therefore, the authors’ own work and
experiences have also been incorporated into this
article.
Definitions
Infant TB is all TB diagnosed in the first year of life.
However, it is not a single entity, as TB in infants can
be congenitally acquired or they can be infected
Table 1 Symptoms and signs in congenital TB: com-
bined data from 75 individual cases of congenital TB,
median age 2–3 weeks with range 1–112 days of age
(collected from 38 case series and reports)6–43
Symptoms and signs Occurrence
Respiratory distress including
tachypnoea
Common (i.e. >40%)
Hepatomegaly, splenomegaly
Fever (usually low grade)
Prematurity/low birth weight
Cough, may be acute or chronic Frequent (i.e. 25–40%)
Poor feeding
Failure to thrive
Abdominal distension (including
ascites)
Irritability Infrequent (i.e. 10–25%)
Peripheral lymphadenopathy
Sepsis syndrome
Skin papular/pustular or
ulcerative lesions
Rare (i.e. <10%)
TB meningitis
Jaundice (obstructive)
Otorrhoea/mastoiditis
Wheeze or stridor
Apnoea or cyanosis attacks
Facial nerve palsy
Shock
TB, tuberculosis.
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shortly after birth (usually within the first few weeks
after birth and often referred to as postnatal TB) or
later in infancy. Congenital TB occurs when M. tuber-
culosis is transmitted from the mother to the fetus in
utero or during birth. Postnatal TB (transmission of
infection within first weeks after birth) is acquired
after birth from the mother or another source case.
Some authors prefer to combine the entities of con-
genital and postnatal TB as perinatal TB, as it is often
difficult to distinguish at what point the infant was
infected.45,46
Tuberculosis in the elderly: for this review the term
‘elderly’ is used to define those persons in the popu-
lation over 65 years old. Because of the lack of clear
definition, many referenced papers have different age
cut-offs, such as age 60, 75 or 80 years. Where
not mentioned the age referred to should be assumed
to be 65 years old.
TUBERCULOSIS IN THE VERY YOUNG
Epidemiology
Despite the high risk of developing TB after infection,
not many studies address TB in infants. In a survey of
culture-confirmed TB cases in children less than
13 years of age from March 2003 through February
2005 at the two major tertiary paediatric referral hos-
pitals in the Western Cape province of South Africa,
156 of the 596 (26.2%) culture-confirmed childhood
TB cases were less than 12 months of age at diagno-
sis,47 similar to a study in 1985 in the same province
with 26% of culture-confirmed children <12 months
of age.48 Another study from the Western Cape (same
referral hospitals) confirms that infants are exposed
to TB early in infancy with 10% of infants 3–4 months
of age already exposed to a known adult TB source
case usually someone in the same household or
regular close contact.49 Adults are presenting with TB
at younger age not only in high TB burden countries
but also in developed countries with low TB burdens,
which may impact on infant TB.45,50,51 In high TB
burden countries, such as South Africa, TB among
pregnant women is strongly associated with HIV
infection, as more younger women at child-bearing
age develop TB when HIV-infected.52
Congenital TB, however, is often reported to be a
rare disease, but this is challenged by some authors.6
Many continue to quote a figure of 300 reported cases
in the English literature,7,8,45 but these authors do not
take into account many reports published after the
300 cases mentioned in Cantwell’s report in 19949 or
the fact that many cases are either not reported or the
diagnosis is missed.53 Culture-confirmed childhood
(<13 years of age) TB surveillance data from March
2003 through February 2009 at Tygerberg Children’s
Hospital, one of the two main referral hospitals in the
Western Cape province, found 72 of 905 cases (8%)
were <3 months of age at diagnosis and of these at
least 12 (1.3%) had congenital TB (H.S. Schaaf,
unpubl. data, 2010). Pillay et al.10 reported that 16
babies born to 107 mothers (15%) with TB in preg-
nancy developed TB in the first 3 weeks of life, 12 in
the first week, which most likely represent congenital
TB.
Perinatal tuberculosis
It is often difficult to clinically distinguish between
true congenital TB, transmitted in utero by haematog-
enous spread via the umbilical vein or ingestion/
aspiration of infected amniotic fluid during birth, and
postnatal transmission that occurs by inhalation of
bacilli spread by the airborne route from a mother or
other close source case with infectious pulmonary TB.
The term perinatal TB is now often preferred. The
revised criteria from Cantwell9 help to distinguish true
congenital TB from postnatal transmission. According
to these criteria, any infant with a TB lesion and one or
more of the following most likely has congenital TB: (i)
present within the first week of life; (ii) a primary
hepatic complex or caseating hepatic granuloma; (iii)
Table 2 Comparison of chest radiograph features in infants with culture-confirmed congenital TB versus those
<3 months of age with mainly postnatal TB
Radiographical feature
Congenital TB6–43 TB in infants44 (<3 months of age)
n = 53 (%) n = 27 (%)
Lymphadenopathy (hilar/paratracheal) 4 (8) 14 (52)
Lobar/segmental opacification (unilateral or bilateral) 18 (34) 14 (52)
Airtrapping NA 15 (56)
Large airway compression NA 13 (48)
Bronchopneumonia (bilateral) 17 (32) 5 (19)
Miliary TB 16 (30) 7 (26)
Ghon focus NA 2 (7)
Cavities or cystic lesions 4 (8) NA
Lobar collapse NA 4 (15)
Pleural effusion 1 (2) 2 (7)
Normal chest radiograph 4 (8) 1 (4)
NA, not applicable; TB, tuberculosis.
Tuberculosis at extremes of age 749
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TB infection of the placenta or endometrial TB in the
mother; or (iv) exclusion of the possibility of postnatal
transmission by excluding TB in other contacts. New-
borns are these days rarely removed from an infectious
mother and often the mother’s TB is diagnosed only
after the infant is diagnosed with TB. Pregnant
mothers with recent TB infection or primary TB, pre-
senting with pleural effusion, disseminated TB
(miliary TB or tuberculous meningitis) or other extra-
pulmonary TB, which has a bacillaemic phase, are
more likely to transmit in utero than mothers with
typical cavitating adult-type disease, who in turn are
more likely to transmit postnatally.9,11 In the review of
75 congenital TB cases (see Methods) we found that
information on maternalTB was available in 65; 43 had
chest radiograph results. Of these 43, 14 (33%) had a
normal chest radiograph with confirmed extrapulmo-
nary TB, 12 (28%) had pleural effusions of whom six
also had other pulmonary infiltrates (only one culture-
positive), eight (19%) had miliary TB and 10 (23%) had
only pulmonary TB, most of which was culture-
negative TB.6–43 Other types of extrapulmonary TB
identified in these mothers were endometrial TB con-
firmed in 22 of 25 tested, central nervous system TB in
six, osteoarticular and abdominal TB in three each.
Close contact with an infectious pulmonary TB
source case poses a transmission risk of 30–80% in
infants, with risk between 60% and 80% for sputum
acid-fast bacilli (AFB) smear-positive and 30–40% for
smear-negative source cases.54 Mothers, nursing staff,
visitors or even other neonates may have undiag-
nosed pulmonary TB. Heyns et al. described four
infants that were infected and developed disease after
being exposed to a mother with undiagnosed pulmo-
nary TB in a kangaroo mother care unit (i.e. where
mothers nurse their premature babies in a hospital
setting).55 Although infection in a neonatal unit is not
common, mainly because of relatively short duration
of exposure in healthy newborns, transmission may
occur.56 A single case of neonatal transmission via
contaminated respiratory equipment has been
described, confirmed by DNA fingerprinting of the
organism.57
The clinical presentation of congenital TB in the
review of 75 cases is summarized in Table 1.6–43
Although postnatal TB may clinically be indistin-
guishable from congenital TB, the presence of a
hepatic granuloma is fairly pathognomic of congeni-
tal TB.9 The clinical and radiological picture may vary
in perinatal TB.44 Postnatal TB often presents with
cough, tachypnoea, wheeze and stridor, while con-
genital TB cases present with acute respiratory dis-
tress and/or hepatomegaly and abdominal signs;
other presenting symptoms and signs, such as poor
weight gain, are similar.44,51 The radiological features
described in 53 of the 75 congenital TB cases are com-
pared with features of culture-confirmed TB in infants
less than 3 months in Table 2.
Infant tuberculosis
Although perinatal TB forms part of the larger infant
TB group, this section highlights a few points in the
larger infant group compared with TB in children
>1 year of age. Few articles on TB in infancy, address-
ing the peculiarities of TB in infancy, have been
published in the last 20 years.44,51 Pulmonary TB (or
intrathoracic TB as many paediatricians prefer to
refer to it because hilar and/or mediastinal lymphad-
enopathy is included, while in adults it is mostly clas-
sified as extrapulmonary TB) is present in >90% and
extrapulmonary TB occurs in 15–30% of infant cases.51
Common and less common types of
tuberculosis in infancy
Hilar and paratracheal lymphadenopathy (with or
without primary lung parenchymal lesions) is a
common presentation, often causing complications,
such as large airway compression with distal lung
pathology. The thymic shadow may obscure hilar
adenopathy on the anteroposterior view; a lateral
chest radiograph may identify hilar adenopathy.58 The
anteroposterior chest radiograph should be carefully
examined for compression of the large airways, which
may be present without obviously visible lymphaden-
opathy. Bronchoscopy and CT may be of value if avail-
able.59 If response to anti-TB treatment and steroids is
inadequate, thoracotomy with lymph node enucle-
ation (removing the liquefied inner part of the nodes)
may be indicated to restore airway patency.60
Cavitating TB, a condition more likely to be associ-
ated with adult-type TB, also occurs in infants.47,61 The
pathogenesis of lung cavities may be different in
infants compared with adults, and can be placed in
two categories. First, poor containment of primary
infection with enlargement of the primary (Ghon)
focus with caseous liquefaction.62,63 This then rup-
tures into an airway causing endobronchial spread of
TB resulting in bronchopneumonic opacification and
eventually widespread cystic cavities. Second, lym-
phobronchial TB caused by lymph node obstruction
of large airways with distal caseating pneumonia
resulting in bulging fissures (expansile pneumonia)
and thick-walled cavities.64 Cavities are present in
63% of children with TB expansile pneumonia.59 Pro-
gressive, uncontained pulmonary TB in infants may
lead to lung destruction and death.
Miliary TB is common in all infants, but tuberculous
meningitis occurs more frequently in older infants
(>3 months).44,51 This is because TB meningitis is
usually preceded by infection in the lungs a few weeks
to months earlier.65 Disseminated TB disease (miliary
TB and tuberculous meningitis) is responsible for
most of the TB-related mortality seen in infants.
Peripheral lymphadenopathy, mainly cervical, is the
most common form of extrapulmonary TB in older
children (>1 year), but is uncommon in infants.66
However, axillary lymphadenopathy has become a fre-
quent adverse event in especially HIV-infected infants
who received BCG vaccination at birth.67
Other types of extrapulmonary TB, such as osteoar-
ticular TB and abdominal TB, are rare in older infants
(abdominal TB common in congenital TB).47 Tubercu-
lous otitis media, caused by haematogenous or direct
spread to the ear, is uncommon but seen more
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frequently in infants. It should be considered in any
chronic suppurative otitis media.68 HIV infection has
lead to an increase in tuberculous otitis media.69
Complications of Bacille Calmette-Guérin
vaccination
In countries or regions with high TB burden, BCG is
given to infants at birth to prevent TB and it is cur-
rently the most widely used vaccine worldwide. The
vaccine is mainly effective in preventing miliary TB
and tuberculous meningitis.70 BCG adverse events,
ranging from a local vaccination site abscess, ipsilat-
eral axillary lymphadenopathy to disseminated BCG
disease (i.e. M. bovis BCG spreading to other organs,
e.g. the lungs), almost always present during infancy.
These adverse events are more common in HIV-
infected than in HIV-uninfected infants. The clinical
picture of BCG adverse events may be indistinguish-
able from TB.67 To further complicate matters M.bovis
BCG is part of the group of organisms identified as M.
tuberculosis complex, and specific PCR tests are
needed to differentiate M. bovis BCG from M. tuber-
culosis var hominis (i.e. true TB).
Current WHO guidelines for the management of
HIV-infected children recommend that all infants
diagnosed with HIV should start antiretroviral therapy
(ART) irrespective of their clinical or immunological
stage.71 This reduces death from HIV and most likely
will prevent disseminated BCG disease, but could
cause restoration of the immune response, which in
some children may lead to an immune reconstitution
inflammatory syndrome (IRIS; a paradoxical reaction
of either unmasking of disease or worsening of symp-
toms or signs) to BCG at the injection site or draining
lymph nodes. Although these BCG-IRIS abscesses
may need aspiration of pus or drainage for relieve of
symptoms, ART should be continued and no anti-TB
treatment is indicated.72,73
Clinical aspects
Diagnosis
The recognition of TB in infants, whether it be con-
genital, postnatal or later transmission, may be diffi-
cult due to non-specific or even absent symptoms
until disease progression occurs. A high index of sus-
picion is necessary to make the diagnosis. In infants,
symptoms are often acute (days) rather than chronic
(weeks), especially in those infants less than 3 months
of age. Available diagnostic tests, such as the tubercu-
lin skin test (TST) and the new interferon-gamma
release assays (IGRA), are more often negative in
infants with TB compared with older children and are
therefore often not helpful in the diagnosis.74,75 Infants
with congenital TB may be symptomatic within the
first week of life, but mostly present between 2 and
4 weeks of age. Infants tend to develop disease after
infection much more rapidly than older children—
within weeks rather than months.
Perinatal TB should be considered at least in the
following situations: (i) pneumonia not responding to
broad spectrum antibiotics, especially in TB endemic
settings or if the mother/primary caregiver has TB; (ii)
non-specific symptoms but mother (or other source
case) diagnosed with TB; (iii) high lymphocyte count
in cerebrospinal fluid with no identified pathogen;
(iv) fever and hepatosplenomegaly; or (v) abdominal
distension with ascites and hepatomegaly.76
As in other children, TB in infants is mostly diag-
nosed by a constellation of history of contact with an
infectious source case, chronic (weeks) symptoms
and signs, a positive TST and suggestive chest radio-
graphical findings. Microbiological confirmation is
often sought to confirm the diagnosis. Although chil-
dren often have low mycobacterial yields of approxi-
mately 10–20% smear positivity and 40% culture
positivity,47,77 infants may have culture-confirmed TB
in up to 70% of cases.51 Of the 75 congenital TB cases
reviewed in this report, 53 (71%) yielded specimens
(e.g. gastric aspirates, endotracheal and bronchial
aspirates, ear swabs and biopsy specimens of lymph
nodes, liver and skin) smear-positive for acid-fast
bacilli, which confirmed the diagnosis of TB in sus-
pected cases. This high bacillary load with positive
smears may be because of late recognition of disease
or because of uncontrolled multiplication of bacilli in
the absence of a well-developed immune system. It is,
however, possible that this high yield of positive
smears is due to publication bias, as mainly cases with
confirmed TB are likely to be reported.
Broth-based automated mycobacterial culture
methods, such as Mycobacterial Growth Indicator
Tube (Becton Dickenson, Cockeysville, MD, USA),
have significantly reduced time to culture detection
from the traditional solid culture media. However, new
rapid culture and drug susceptibility testing (DST)
methods are necessary and methods, such as micro-
scopic observation drug susceptibility assay, may
prove to be useful in poorly resourced areas,78 giving
results for both culture and DST in 7–10 days. Confir-
mation of M. tuberculosis complex and DST for
rifampicin and isoniazid in smear-positive cases can
be done by line probe assay, such as the MTBDRplus
assay (Hain Lifescience, Nehren, Germany), and
yield results within as little as 2 days under field
conditions.79
Abdominal ultrasound examination is valuable in
cases with suspected congenital TB, the majority of
true cases have hepatomegaly. Sonography can iden-
tify hypoechoeic foci in the liver and spleen, confirm
ascites in neonates with abdominal distension
and identify lymphadenopathy. Ultrasound-guided
biopsy from hepatic lesions can confirm the diagnosis
if AFB or granulomatous lesions are found.12 Other
imaging investigations for abdominal involvement do
not yield much more information compared with
ultrasound in congenital TB cases.
Treatment
Prompt treatment is essential to prevent severe mor-
bidity and mortality in infants. Current WHO and
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International Union against Tuberculosis and Lung
Disease recommended dosages of first-line anti-TB
drugs for children have been challenged lately because
of several studies showing lower concentrations of
serum drug levels in children compared with adults at
the same mg/kg body weight dose for isoniazid,
rifampicin, pyrazinamide and ethambutol.80–84 New
WHO recommended dosages for children including
infants are summarized in Table 3. No studies have
been carried out to determine anti-TB drug levels in
premature or full-term neonates. Although neonates
will most likely require higher doses, pharmacokinetic
studies in this age group still need to be done.
Treatment regimens used to treat infants with con-
genital TB vary widely. A combination of isoniazid,
rifampicin and pyrazinamide with or without a fourth
drug (mainly an aminoglycoside or ethambutol) was
used in the intensive phase of 2 months in most
reported cases,6–43 with a continuation phase of iso-
niazid and rifampicin varying from 4 to 10 months.
Adverse events are seldom reported, but hepatotoxic-
ity (isoniazid, rifampicin and pyrazinamide), hearing
loss (aminoglycosides) and visual disturbance
(ethambutol) should be considered. Hearing loss and
visual testing are difficult in infants, and alternative
fourth drug, such as ethionamide, should be consid-
ered, although with correct dosaging of ethambutol
<1% of children develop visual problems and it is
mostly reversible once drug is stopped.84 In infants
with miliary TB or TB meningitis some experts recom-
mend ethionamide as the fourth drug because of
better cerebrospinal fluid penetration compared with
ethambutol and the aminoglycosides.85
Infants with TB may be co-infected with HIV. These
TB/HIV co-infected infants require additional treat-
ment to improve response to anti-TB treatment. As
mentioned above, WHO recommends that all HIV-
infected infants receive ART irrespective of clinical or
immunological stage.71 If not already on ART, anti-TB
treatment should first be introduced followed by ART
within 2–4 weeks to reduce morbidity and mortality.
The delay in starting ART is to distinguish possible
adverse events from anti-TB drugs from those of anti-
retroviral drugs that could be similar, and also to
reduce the risk of TB-IRIS (i.e. is worsening of symp-
toms or signs due to restoration of immune response
to the TB bacilli). All TB/HIV co-infected infants
should receive co-trimoxazole prophylaxis against
Pneumocystis jiroveci pneumonia. Pyridoxine levels
in TB/HIV co-infected children were shown to be con-
sistently low in one study and some antiretroviral
drugs could also cause peripheral neuropathy; there-
fore, these infants are also recommended to receive
pyridoxine supplementation.86
Nearly 5% of all incident TB cases in 2007 world-
wide were multidrug-resistant (MDR, i.e. resistant to
isoniazid and rifampicin).87 Infants in contact with
adults with drug-resistant TB will most likely be
infected with the same resistant strain.88,89 If TB is
diagnosed in these infants they should be treated
according to the DST result of the adult source case
and not wait for the infant’s own culture and DST
results.85 If a positive culture of the infant is obtained,
DST should still be done and treatment changed
according to the infant’s isolate DST if indicated.
Outcome
Mortality in congenital TB remains high at 22–50%.9,90
Of the 75 cases with congenital TB reviewed in this
study, 48 of 70 (69%) were alive at discharge or follow
up and 22 of the 70 with known outcome (31%) died.
In a study of 596 culture-confirmed TB cases in chil-
dren, eight of 33 (24%) infants <3 months of age died,
while only 6% deaths occurred in older children.47
Vallejo et al. reported two out of 47 (4%) deaths in
children 3–12 months of age in a developing coun-
try.51 The outcome of isolated pulmonary TB is usually
good if treatment is started early. In a study of 17
infants 2–5 months of age ventilated for respiratory
failure because of TB all survived, although some with
chronic lung disease.60
Public health aspects
Infants are mainly infected by household contact with
an infectious adult TB case, frequently the mother or
primary caregiver. Early identification and treatment
of TB in pregnancy will improve outcome of both
mother and infant and it will reduce the risk of peri-
natal TB.45,46,50 However, diagnosis may be difficult due
to non-specific symptoms, often ascribed to the preg-
nancy itself.90 A high index of suspicion is required in
TB endemic areas, where screening of all pregnant
women, especially those who are HIV-infected, seems
warranted.53 A thorough history of recent TB contact,
and screening for TB-associated symptoms would
suffice in most cases. Shielded chest radiography and
sputum microbiology for M. tuberculosis should be
done if TB is suspected. Pregnant mothers may have
extrapulmonary TB and be sputum smear and
culture-negative. First-line anti-TB drugs with the
exception of streptomycin are safe in pregnancy.
Some second-line drugs, such as ethionamide, ami-
noglycosides and capreomycin used for the treatment
of MDR-TB, have been associated with teratogenic
effects or adverse events in newborns. Outcome of
MDR-TB treatment in pregnancy for both mother and
infant has been improved by starting treatment
during pregnancy in the few cases described; there-
fore, risk and benefit for both mother and infant of
Table 3 New WHO dosage recommendations for first-
line anti-tuberculosis drugs in children including infants
First-line drug
Dosage in mg/kg
body weight (range)
Isoniazid 10 (10–15)
Rifampicin 15 (10–20)
Pyrazinamide 35 (30–40)
Ethambutol 20 (15–20)
Streptomycin 15 (12–18)
WHO, World Health Organization.
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starting treatment during pregnancy or delaying full
MDR-TB treatment until after birth in these cases
should be weighed in each individual case.50,91–93
Infants born to mothers with TB diagnosed during
pregnancy or soon after delivery should be screened
for TB. If no respiratory symptoms, feeding problems
or abdominal pathology is found and the infant is
clinically well, chemoprophylaxis should be provided
and BCG should be withheld until after completion of
chemoprophylaxis. The recommended chemopro-
phylaxis regimen in drug-susceptible contacts is iso-
niazid for 6–9 months, but isoniazid plus rifampicin
for 3 months is an acceptable alternative.46,85 If BCG
was withheld in a HIV-exposed infant at birth, BCG
should not be administered later if the infant is con-
firmed HIV-infected.94
Breastfeeding is not contraindicated in drug-
susceptible TB, and infants and mothers do not have
to be separated provided mothers receive treatment
and infants receive chemoprophylaxis. The decision
about breastfeeding and separation of infants and
mothers are more complex in MDR and extensive
drug-resistant TB (i.e. resistance to isoniazid, rifampi-
cin, the fluoroquinolones and a second-line inject-
able anti-TB agent). Some experts recommend
separation of mother and infant in all MDR-TB cases.
Standard first-line chemoprophylaxis has failed in
these cases.95 Separation is not always feasible, and
chemoprophylaxis with two drugs to which the moth-
er’s M. tuberculosis isolate is susceptible (including a
fluoroquinolone) has been used, together with con-
tinuing or starting the mother on MDR-TB treatment.
Respiratory protection (mask for the mother) is
advised and the infant should sleep in a separate
room. Close follow up for 2 years is recommended.96
All infants should be separated from mothers with
extensive drug-resistant TB. Infants exposed to infec-
tious TB cases after birth should receive chemopro-
phylaxis as above after excluding TB disease.
Bacille Calmette-Guérin reduces the risk of dissemi-
nated TB (miliary TB and TB meningitis) in infants and
young children by approximately 75%.97 It is the most
widely used vaccine and is safe in immunocompetent
infants. However, recent studies have shown a high
incidence of disseminated BCG disease in HIV-
infected infants and the benefit versus risk of BCG in
these infants has been questioned.70 WHO has recently
recommended not giving BCG to HIV-infected infants;
this would mean delaying BCG vaccination in all HIV-
exposed infants until HIV status is confirmed.98 This is
not feasible in settings with both a high TB incidence
and a high prevalence of HIV infection, as with a well-
established prevention of mother-to-child-HIV-
transmission programme, fewer than 5% of infants will
be infected and in most high prevalence HIV areas,
PCR screening for HIV infection in HIV-exposed
infants only occur at 6 weeks—this could lead to many
vulnerable HIV-exposed but uninfected infants who
are at high risk of exposure to infectious TB cases not
receiving BCG in timely manner or at all.94 Early initia-
tion of ART in infants has shown to reduce IRIS asso-
ciated with TB in HIV-infected infants and will most
likely also reduce both the risk of TB disease and dis-
seminated BCG disease.99,100
TUBERCULOSIS IN THE ELDERLY
The ageing population
In the USA, the percentage of the population
75 years old in 1990 was 5.3% and increased to 5.9%
in 2000.101 In the UK, 65-year age group increased
from 13% in 1991 to 16% in 2001, and is expected to
rise to 23% by 2031. In Europe, a rise in the mean age
of the population is expected from 34.9 years in 2004
to 44.4 years in 2024.102 In India, an increase in life
expectancy and the resultant increase in the older
population (50 years old) has led to an increase in
the number of TB cases in this age group.103 On the
other hand, life expectancy in sub-Saharan African
countries has significantly declined due to HIV/AIDS
and its related opportunistic infections, in particular
TB.
Epidemiology
Within the elderly population in the UK, Europe and
North America, it is the indigenous white populations
in whom TB is principally an issue, with rates highest
in this group.104,105 This is because many of these
people were alive when TB was much more prevalent
and a great number of them would have been infected
with the tubercle bacilli.106 This was also before the
time of BCG vaccination and effective anti-TB treat-
ment. An increase in the rates of TB in the elderly
has been noted in some economically developed
countries.
In countries with a high prevalence of TB there is a
contrasting picture, the disease still remains mostly a
disease of the young in Africa,105 but in the Indian
subcontinent is increasingly common in the elderly.
Worldwide, despite the increasing availability of
effective treatment, TB remains one of the leading
causes of human illness and premature death.107
According to the latest WHO report, the estimated
global incidence of TB peaked in 2004 and is now
slowly declining by about 1% per year.108 The number
of cases, however, continues to rise as a result of
population growth. The most recent WHO estimates
indicated that there were 9.4 million cases and 1.8
million deaths caused by TB in 2008.108
In 2008 in the UK, 8655 cases of TB were reported, a
rate of 14.1 per 100 000 population. This represents an
increase of 2.2% in the rate of disease (Table 4).109 The
majority of all TB cases continue to occur in the
non-UK born (72%) and those aged 15–44 years
(61%). Those 65 years old accounted for 14%. In
Wales, Northern Ireland and North East of England, a
greater proportion of cases were found in those
65 years compared with other areas of the UK.
In the USA, the annual Centers for Disease Control
and Prevention report showed a total of 12 904 TB
cases (rate of 4.2 per 100 000) in 2008. The TB rate in
2008 was the lowest recorded since national reporting
began in 1953. The TB rate has been declining in the
USA each year since 1992 (Fig. 1). TB rates are declin-
ing in all age groups (Fig. 2). However, the number of
cases among non-USA born individuals, particularly
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in those45 years old, is steadily rising.1 Around 20%
of newly diagnosed cases of TB occur in those aged
65 years old (Fig. 3).
There is concern that previously infected elderly
individuals will develop TB due to reactivation while
others may be more likely to develop active TB if
exposed to an index case, as immunity declines with
increasing age.
Predisposing factors
It is well known that immunocompetency declines
with increasing age. In TB, cell-mediated immunity
plays a key role in controlling infection. As age
advances the related decline in immunity increases
the chance of reactivation of latent disease.
Much of the research into the ageing immune
system has been done in mice rather than humans.
Elderly mice have a strong innate immune system.
Conflicting data exist. Some data suggest that the
elderly may develop a lack of regulation in pro-
inflammatory cytokines and enzymes that control the
expression of reactive oxygen species and inflamma-
tory mediators, and that cytokine expression, respon-
sible for interferon-gamma (IFN-g) transcription from
CD4+ T cells, can be restored by dietary supplemen-
tation in mice. Mucosal immune responses were also
noted to be reduced in ageing mice.110 Dietary vitamin
E supplementation restored both the humoral and
mucosal immune responses to normal adult mice
levels. This implies that much of the immune dys-
function is correctable.110
It is unlikely that the reduced T cell-mediated
response is entirely responsible for the increased sus-
ceptibility of the elderly to TB. IL-2 and IFN-g, both
especially important in host defence against TB, are
reduced in the elderly but are potentially reversible.111
However, other studies on the humoral response in
elderly TB patients showed no decline in response112
and well preserved cytokine production in response
to stimulation with M. tuberculosis.113
Vesosky and Turner114 showed that in response to
TB infection, although old mice had impaired genera-
tion of antigen-specific CD4+ T-cell immunity, they
Table 4 Tuberculosis case reports and rates by age group and gender, UK, 2008 (109 with permission from HPA data)
Age group
(in years)
Number of
male cases
Rate (per
100 000) male
Number of
female cases
Rate (per 100 000)
female
Total number
of cases
Total rate
(per 100 000)
0–14 229 4.2 261 5.0 495 4.6
15–44 2870 22.5 2377 19.0 5265 20.8
45–64 961 12.7 722 9.2 1690 11.0
65+ 639 14.8 559 10.0 1204 12.1
Total 4700 15.6 3919 12.5 8655 14.1
Year
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Figure 1 Reported tuberculosis cases in USA, 1982–
2008;1 updated as of 20 May 2009.
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Figure 2 Tuberculosis case rates by age group in USA,
1993–2008;1 updated as of 20 May 2009. ( ) <15 years,
( ) 15–24 years, ( ) 25–44 years, ( ) 45–64 years,
( ) 65 years.
Figure 3 Reported tuberculosis cases by age group
in USA, 2008.1 ( ) <15 years, ( ) 15–24 years, ( )
25–44 years, ( ) 45–64 years, ( ) 65 years.
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had a transient enhanced resistance in the first few
weeks; this resistance was associated with the pres-
ence of CD8+ T cells, and therefore IFN-g, before
younger mice.114 Further research may allow research-
ers to enhance this effector function and improve the
immune response in elderly patients to TB.
Comorbidities that are more common in the
elderly, such as diabetes mellitus, chronic kidney
disease, intercurrent illness, malnutrition, excess
alcohol use, underlying malignancy and the use of
immunosuppressant drugs (most commonly ste-
roids) can clearly impair the cell-mediated immune
system, increasing the risk of both reactivation and
new infection progressing to disease, and decreasing
the chance of cure in those diagnosed with active TB.
The mode of TB infection is always difficult to
determine. However, over 90% of TB in the elderly is
felt to be reactivation of dormant infection (endog-
enous) rather than new (exogenous) infection.115
Various types of pulmonary TB are seen. New infec-
tion is less commonly seen in the elderly in developed
countries.115 If this does occur it is usually in care
homes with an outbreak affecting several residents
from one index case.116
Clinical aspects
Diagnosis
Diagnostic difficulties in the elderly are common in
many diseases, not solely TB. Problems, such as poor
memory, deafness, blindness/partial sight, impaired
speech, poor short-term memory, all contribute,
often making an accurate history difficult. Patient,
family and doctor may often attribute symptoms to
‘old age’. Comorbidities often further complicate
matters, especially malignancy that may often
coexist.116–118
Many papers have been published with regards to
clinical and radiologic presentation of TB in varying
ages. Unfortunately none of these studies is truly
comprehensive or definitive. In many the sample size
is small and cut-off age arbitrary. The term ‘atypical’ in
terms of clinical presentation is best avoided as this
may lead to the incorrect conclusion that the patient
in fact has an environmental mycobacterial infection
or a less typical site of TB infection.
A classical TB presentation is difficult to define.
Non-specific symptoms with a lack of focal signs are
more common in patients with reduced immune
competency. Patients may present with a lack of res-
piratory symptoms and may be unable to expectorate
sputum due to weakness. In a comparison between
clinical features in the young and old (adults), the
classical symptoms of productive cough, night
sweats, fever, weight loss and haemoptysis were much
less common in the older age group.119 Confusion was
common in the elderly. One study showed that bio-
chemical and haematological abnormalities were
more common in older patients, such as anaemia,
deranged liver function tests, low sodium, potassium
and albumin.120 This may suggest silent extrapulmo-
nary disease or be secondary to comorbidities.
Katz et al.121 found no significant difference in pre-
senting symptoms between younger adults and the
elderly. Cavitatory lesions and haemoptysis were sig-
nificantly less likely in the elderly but complaints of
dyspnoea and lower lobe infiltrates were more
common. Chan et al.122 found that older patients had
lower body weight, less haemoptysis but more non-
specific complaints, but the differences were not sig-
nificant. Past history of TB and comorbidities were
more common but upper lobe infiltrates were less
common in the older group. Older patients had more
extensive disease but less cavity formation. Age-
related mortality was significantly higher in the
elderly.
A study from Brazil comparing 117 patients
60 years old and 464 patients aged 15–49 years
showed dyspnoea (P = 0.018) and weight loss
(P = 0.047) were more predominant in the older age
group. In the younger group, haemoptysis (P = 0.002),
chest pain (P = 0.027) and fever (P = 0.006) were more
common.123 A study from Korea of 326 patients agreed
that haemoptysis and fever were more frequent in the
65-year age group, whereas weakness, dyspnoea,
anorexia and mental change were more frequent in
the elderly.124
Non-pulmonary TB, such as TB meningitis, bone
and joint TB, genito-urinary and gastrointestinal TB
are seen in all age groups 125.
The elderly patient may present with ‘atypical’
radiological features, such as middle or lower lobe
(rather than upper lobe) infiltrates,117,121,124 mass-like
lesions or nodules appearing more like cancers,
extensive bronchopneumonia without cavitation or
non-resolving infiltrates. Lesions are frequently mis-
diagnosed as pneumonia or lung cancer in the eld-
erly.124 Some authorities suggest that any elderly
person admitted to hospital for pneumonia should
have at least one sputum culture for TB.1 In another
study the most common radiological abnormalities
were infiltrates and cavitations.126 Bilateral involve-
ment was more common in the elderly patients
(P = 0.009).126Some studies have reported that pleural
effusion is more common in the elderly, but a recent
study showed the highest incidence of pleural disease
to be in men aged 30–59 years old rather than older
patients.127
Miliary TB is the most common form of TB seen in
the elderly. With miliary TB there are large concentra-
tions of multiplying tubercle bacilli with no or
minimal immune response. It often presents in a
chronic, indolent form, possibly with prolonged low-
grade fever without focal signs or symptoms, and as a
protracted wasting illness rather than the classical
presentation of high-grade intermittent fever in
an acute or subacute pattern. On examination
hepatosplenomegaly and anaemia may be present. A
normal chest radiograph is compatible with miliary
TB.128 The majority of both undiagnosed and diag-
nosed fatal cases are seen in patients 60 years
old.129,130
There does therefore not appear to be a consistent
difference in the clinical presentation of TB in the
elderly according to the current literature, except that
the elderly do appear to more commonly have miliary
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disease and lower-zone infiltrates on chest radiogra-
phy,131 and haemoptysis is less common than in
younger adult TB patients.
Tuberculin skin test sensitivity is known to wane
with age and is therefore undoubtedly less helpful in
older rather than younger age groups. TST studies
show a steady decline in skin test positivity from 15%
in the over 70s to 3% in the over 90s.132 Extensive infec-
tion, advancing age and malnutrition leading to
immunosuppression can all be associated with non-
reactiveTST despite the presence of active disease.The
booster effect, an increasing TST reaction to repeated
TST inoculation over a limited period (usually
months), which may be wrongly interpreted as new
infection, occurs at all ages but is more common in the
elderly. Van den Brande and Demedts133 suggest that
the failing immune response to tuberculin can be
restored progressively by repeated TST administra-
tion. Care should therefore be taken in interpreting
any positive ‘test–retest TST’ as conversion, when in
fact they are due to the booster response.
Kobashi et al. evaluated the usefulness of the Quan-
tiFERON TB-2G (QFT-2G) test and the TST in patients
with active TB disease stratified by age in 10-year
increments in a Japanese population.134 The positive
rate on TST was 55% in patients aged 70–79 years and
33% in patients 80 years. However, the positive rate
on QFT-2G testing was 79% and 75% respectively. The
indeterminate result rate of QFT-2G increased with
age. It was suggested that this may be due to comor-
bidities. They suggest that although the positive rate
of QFT-2G was seen to decrease with age, it may be a
useful supportive diagnostic method for active TB
disease compared with the TST in elderly patients.
QFT-2G could potentially be used in elderly patients
in whom TB is suspected but where all other investi-
gations are inconclusive or not practical because of
the patients’ general condition.
Diagnosis of miliary TB can be difficult and anti-TB
treatment may have to be started without definitive
evidence of TB in the critically ill elderly patient.
Transbronchial biopsy may be useful in association
with bronchial washings performed at bronchoscopy.
Bone marrow with or without liver biopsies should be
considered if miliary TB is suspected with a normal
chest radiograph. The yield for bone marrow biopsy
and liver biopsy is likely to be better if anaemia is
present or liver function tests are abnormal respec-
tively. The risks of invasive investigations are greater
in the elderly due to increasing comorbidities. The
risks of invasive procedures therefore need to be
balanced against the risk of potentially missing the
correct and curable condition of TB.
Treatment
The adherence to and tolerance of anti-TB treatment
are the main issues, with the former being the main
reason for treatment failure in all age groups. Adher-
ence is a larger problem in the elderly due to factors,
such as poor vision (unable to read labels and there-
fore use correct doses/frequency), poor mobility and
low income (unable to collect prescription), poor
memory (unable to remember to take drugs or at
correct dose/time), increased risk of drug interactions
and adverse events, and increased rates of
depression/low mood (may lack determination to
complete full 6-month treatment regimen).
These reasons may lead to a patient receiving
inadequate treatment. Closer monitoring to ensure
adherence is needed and the role of the TB nurse
is therefore vital. In many countries treatment is
therefore directly observed by health-care providers.
In the UK, treatment completion declines with age,
but the proportion of cases reported as dying before
completing treatment increases (Table 5). TB was
known to have caused or contributed to 30% of the
deaths among cases aged 65 years or older.109
An Indian study showed a completion rate under
directly observed therapy, short-course (DOTS) of
82% in 50- to 65-year age group and 70% in65-year
age group and treatment default rates of 7.5% and
12.5% respectively.103
Adverse events
It is well known that, in general, adverse drug events
occur more commonly with increasing age, due to
age-related physiological changes and the coexist-
ence of other diseases leading to polypharmacy. More
careful/rigorous monitoring of adverse events is
needed especially if there is known renal or liver dys-
function. Studies have shown that increasing age is a
predictor of hepatotoxicity due to both isoniazid and
rifampicin, manifesting as hepatitis and fatal fulmi-
nant hepatic necrosis.135,136 Rifampicin in combina-
tion with isoniazid has an additive, although not
synergistic effect of liver dysfunction. It has been sug-
gested that the elderly are almost three times as likely
to experience adverse events compared with younger
Table 5 Treatment completion and death before or during treatment by age group, UK, 2007 (109 with permission from
HPA data)
Age group
(in years)
Number (%) completed
treatment
Number
died (%)
Total cases outcomes
determined
0–14 418 (90.7) 2 (0.4) 461
15–44 4115 (83.7) 88 (1.8) 4914
45–64 1202 (80.0) 116 (7.7) 1502
65+ 722 (65.3) 267 (24.1) 1106
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patients.136,137 Clinical monitoring for hepatotoxicity
is most important. Some clinicians recommend
monthly monitoring of serum transaminases, but this
is not generally accepted. An additional problem is
that the elderly may not recognize adverse events
because they may put them down to age, general poor
health or other medication.
The role of toxic metabolites in adverse events is
not clear. Isoniazid metabolites (hydrazine and
monoacetylhydrazine) are both hepatotoxic. One
study showed the maximum concentration of hydra-
zine after the first dose was significantly higher in
older patients (all patients were on four-drug regi-
men).138 Combination therapy may predispose to
adverse events. Metabolic induction by rifampicin
may lead to increased levels of hepatotoxic isoniazid
metabolites.139 A Korean study involving 207 younger
patients (<65 years old) and 119 elderly patients
(65 years old) confirmed that the elderly had a
higher frequency of adverse events compared with
younger adults (18.5% vs 40.7%, P < 0.05).124
Non-pharmacological factors may also increase the
risk of hepatotoxicity, such as liver involvement by
extensive mycobacterial disease, underlying chronic
liver disease and poor nutritional state (drug metabo-
lism and toxicity is affected by dietary intake). The
latter may partly explain the higher rates of hepato-
toxicity in patients in India (3–22%) compared with
the USA (2–3%).140
Clinicians should take the above factors into con-
sideration to help avoid hepatotoxicity. Nutrition
support should be offered where necessary and close
clinical monitoring of all patients is essential. More
pharmacokinetic and pharmacodynamic studies are
needed to determine optimal dosages for elderly
patients, taking into account these different factors,
without compromising cure.
Ethambutol can potentially cause reduction in
visual acuity, central scotomas and colour vision
defects due to optic neuritis. The risks and benefits of
ethambutol in anti-TB treatment regimens in the
elderly with retinopathy or cataracts (in whom initial
assessment of visual acuity may be difficult) should
be carefully considered.
Streptomycin may cause oto- and nephrotoxicity
more frequently in those with renal dysfunction, and
these adverse events are generally irreversible. The
use of streptomycin in the elderly should take risks
and benefits of treatment into account.
Drug interactions
Drug interaction is more frequently a problem
because elderly patients often receive polypharmacy.
A variety of drugs may interact, notably, anticonvul-
sants, for example, phenytoin (isoniazid can elevate
levels, whereas rifampicin can lower levels due
to inhibition and induction of metabolism
respectively—overall phenytoin levels are usually
lower on first-line anti-TB therapy),141 digoxin and ste-
roids (rifampicin can reduce levels). Isoniazid,
rifampicin and pyrazinamide are predominately
metabolized by the liver.142 Hepatic volume and blood
flow decrease with age143 and the rate of hepatic
metabolism of certain drugs may decline.144,145 There
are only a few studies on the pharmacokinetics of
anti-TB drugs, many of them assessing each drug in
isolation rather than in combination.
In the elderly, malnutrition and chronic disease
mean lower serum albumin levels.146 Acidic drugs
bind to albumin; therefore, free-drug concentrations
may rise in those with lower serum albumin levels.
The relationship between free-drug levels and toxicity
is not known, but this may play a role in increasing
adverse events in the elderly.147
Drug resistance
The incidence of drug resistance (39% vs 16%,
P < 0.05) was significantly higher in the older patients
in China.148 Lung resection surgery can be used as an
adjuvant to anti-TB therapy in patients with MDR-TB.
A Japanese study suggests that pulmonary resection
achieves a high cure rate with low morbidity and mor-
tality. The oldest person in this study was 65 years, but
the authors suggest that pulmonary resection should
be considered in all age groups including the eld-
erly.149
In the UK, isoniazid resistance, MDR-TB and resis-
tance to any first-line drug decreased as age increased
(Table 6). The majority of drug-resistant TB cases
were in the age group 15 to 44 years old.109
Mortality
High mortality in the elderly is a common finding
across the world. Patients with comorbidities tend to
Table 6 Number and proportion of tuberculosis cases with drug resistance by age group, UK, 2008 (109 with permission
from HPA data)
Age group
(in years)
Isoniazid-
resistant (%)
Multi-drug-
resistant (%)
Resistant to any
first-line drug (%) Total†
0–14 7.6 3.4 8.4 119
15–44 6.8 1.3 7.8 3204
45–65 5.4 0.9 6.2 883
65+ 2.0 0.0 2.2 602
† Culture-confirmed cases with drug susceptibility test results for at least isoniazid and rifampicin.
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have higher mortality rates whatever the disease
process; and elderly people, in general, have higher
rates of comorbidity and therefore mortality. The key
to reducing mortality is earlier diagnosis. Worldwide
mortality rates of up to 30–50% can be expected
in those aged over 70 years, and especially those in
their 80s.
A survey conducted in England and Wales in 1978–
1979 showed that 12% of adult patients notified with
TB died before completing treatment. Multivariate
analysis showed there to be a significant association
between age, extent of disease, positive smear result
and mortality.150 A later mortality survey (1974–1987)
showed a 32% mortality in those aged 75 years and
above, 4% in those aged 35–54 years, 1% in those aged
15–34 years but encouragingly a steady decline in the
yearly mortality over that period.151 A further study
from 2001, showed a mortality rate of 27% by 2001
75 years old, mortality in other age groups remained
static.152 A study from Birmingham in the UK, showed
higher mortality rates in Caucasians than Asians
(median population age of 66 years). Diagnostic delay
was a contributory factor in many of these cases, with
the authors concluding that TB is most likely to be
missed in the elderly Caucasian population.153 Extent
of disease can also contribute to increased mortality
with more elderly patients presenting with dissemi-
nated or miliary disease. A recent study from China
suggested an overall case fatality rate of 5.5%. Of these
deaths 50.5% were attributed to causes other than TB.
Eighty-six per cent of the deaths were among patients
60 years old, with male gender, sputum smear posi-
tivity, comorbidities and advancing age being signifi-
cant independent risk factors for death.154
Non-specific symptoms, such as mild weight loss,
reduced appetite and breathlessness, can be attrib-
uted to age-related change or other diagnoses, such as
COPD or pulmonary fibrosis. For these reasons the
diagnosis may be considerably delayed, leading to
more advanced disease at initial presentation, or an
entirely missed diagnosis, made at post-mortem.135,155
One study showed that initial diagnosis of TB at first
visit was less frequent in the elderly than in the
younger adult group (38.6% vs 47.3%), although
symptoms and signs at first visit were similar in each
of the age groups. Elapsed time from the first visit to
suspicion of TB and initiation of anti-TB treatment
was frequently delayed in elderly patients (mean
22 days, SD 23 days vs 13 days, SD 20 days,
P < 0.05).148
Reports from older studies have shown that a sig-
nificant number of cases of TB in the elderly were
diagnosed at post-mortem. With the declining rates of
post-mortems in the UK and many other countries,
these cases of TB may completely be missed. A Swiss
post-mortem study in the elderly from 1989 found
active TB in 3%.107 A Ghanaian study showed that
mortality was strongly related to age (P < 0.001).156
A UK study showed that elderly patients were over
20 times more likely to be diagnosed with TB at post-
mortem than younger patients, and six times more
likely to die from TB (130). Higher TB-related mortal-
ity (1.3% vs 11.1%, P < 0.05) was noted in the elderly in
Korea.124 A recent Indian study showed mortality rates
of 12.5% in the65-year age group as compared with
5.5% in 50- to 65-year age group.103
Public health aspects
Prevention
Measures to prevent increasing cases of active TB in
the elderly could include poverty reduction, provision
of adequate health care, preventative therapy (for
latent TB), good ventilation in aggregate settings,
such as institutional care, avoidance of overcrowding,
optimal nutrition and improvement of general health
status.
Several studies report increased prevalence in the
elderly living in institutional care (care homes, resi-
dential homes and nursing homes). This is thought to
be due to both a predisposition to reactivation of latent
TB as well as an increased risk of cross-infection from
an index case within the care home environment.157 A
study in Caucasian residents of old age homes in South
Africa showed rates of 798/100 000 population, com-
pared with 16/100 000 in the general population.158 A
study from Hong Kong in 1993 showed rates of 1200–
2600/100 000 in care homes compared with 100–400/
100 000 in the general elderly population. Other
studies have, however, shown no increased risk in the
elderly in such settings.132,159
In the USA in 1984–1985 a study showed an inci-
dence of 39.2/100 000 among nursing home resi-
dents, compared with 21.5/100 000 in those living in
the community. The Centers for Disease Control and
Prevention in the USA has established recommenda-
tions for surveillance, control and reporting of TB in
long-term care facilities.1 All new residents and
employees have an initial TST and then annual
screening. Chest radiography is performed on all
those with a positive TST. As noted earlier TB case
rates are highest in 65-year age group in the USA.
In 1989 the strategic plan for elimination of TB in
the USA stated that ‘control and prevention of TB
among the elderly must be addressed aggressively to
achieve the goal of eliminating TB in the United States
by the year 2010’.160 In the USA, more elderly persons
live in nursing homes than in any other type of resi-
dential institution; approximately 5% of all elderly
persons live in a nursing home. However, elderly
persons represent 88% of the nation’s approximately
1.7 million nursing home residents.161 Such concen-
trations of elderly persons, many of whom have latent
TB and some of whom are immunosuppressed, create
high-risk situations for TB transmission.
The results of a recent prospective observational
study in the USA (entry closed January 2009) are
awaited. This study set out to compare the TST with
IGRA (T-SPOT.TB, Oxford Immunotec, Oxford, UK)
testing for the screening of patients 65 years old in
USA nursing homes.
Screening
The usefulness of TST depends on the prevalence
within and the age of a particular population.
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Universal guidance on screening is not possible as
this will vary depending on the prevalence within a
country. Where the prevalence is high sputum exami-
nation and chest radiography remain the most cost-
effective screening method. Screening using TST,
IGRA, sputum smear and culture, and chest radiogra-
phy may be considered. This screening policy was
advocated in the USA in 1989.160
Methods of screening vary across Europe and
screening of the elderly in long-term facilities only
occurs in 16/50 (32%) of European countries.162
In general the adverse effects of treatment for latent
TB in the elderly outweigh the potential benefits of
disease prevention. If it is believed that the elderly
have an increased susceptibility; surveillance and
screening should be considered to be paramount if
we are to eliminate TB worldwide.1
A study from Hong Kong showed that when screen-
ing an elderly population for TB, low BMI (<18.5 kg/
m2) was associated with the future development of
active TB. If low BMI in an elderly individual can
increase their susceptibility to developing TB, it
should be taken into account in screening pro-
grammes163 A study in 2006 showed that the rates of
active and latent TB in old age homes in Hong Kong
remain high. The average age in the study was
82 years. Patients were screened using interview,
medical record review, two-stage TST and chest radi-
ography with or without sputum microscopy as
required. The estimated prevalence rate of active TB
in the population was 669/100 000 and was notably
significantly higher in men (1101 vs 530/100 000).160
The absolute number of older people in the devel-
oped world continues to increase; TB is likely to
become an increasing problem in this age. It is likely
that it will continue to be a problem in the developing
world. A high index of suspicion is vital. Close thera-
peutic monitoring is necessary. Many advocacy agen-
cies aim to increase the awareness of TB worldwide,
hopefully leading to increased survival worldwide.
More vigorous clinical management and preven-
tion strategies by both the TB control programme and
other public health programmes are essential to
improve TB treatment outcomes especially in devel-
oping countries.164 Uncharacteristic clinical presenta-
tion may occur. Medical and psychosocial aspects of
ageing, comorbidity and misperception of symptoms,
may make the diagnosis of TB difficult in the elderly.
Appropriate investigations and prompt institution of
treatment will help to decrease morbidity and mortal-
ity in the elderly.
CONCLUSION
Tuberculosis in the very young and the elderly poses
problems for the clinician, microbiologist and public
health programme. Presentation may be varied and
diagnosis therefore difficult. Both the young and the
old human frame may be reluctant to divulge its
secrets in the form of positive bacteriology. Treatment
is not often straightforward and drug dosages will
have to be adjusted according to weight, renal func-
tion, liver function and other potentially complicating
factors. Both the very young and the elderly are
subject to increased rates of infection leading to
disease as immunity may be compromised. Doctors
and other health professionals who are to manage
patients at the extremes of life will require special
skills and experience.
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Bioavailabilityof two licensedpaediatric rifampicin suspensions:
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S UMMA R Y
S E T T I NG : To assess the revised World Health Organi-
zation-recommended dose of 10–20 mg/kg rifampicin
(RMP), we studied the steady state pharmacokinetics
of RMP in South African children who received
standard treatment for drug-susceptible tuberculosis
(TB).
OB J E C T I V E : To determine the formulation effect on the
pharmacokinetics of RMP.
DE S I GN : RMP plasma concentrations were character-
ised in 146 children (median age 1.4 years, range 0.2–
10.2). The morning dose on the day of the pharmaco-
kinetic evaluation was administered as one of two RMP
single-drug oral suspensions.
R E SU LT S : While one formulation achieved 2 h concen-
trations in the range of those observed in adults (median
6.54 mg/l, interquartile range [IQR] 4.47–8.84), the other
attained a median bioavailability of only 25% of this, with
a median 2 h concentration of 1.59 mg/l (IQR 0.89–2.38).
CONC LU S I ON : RMP is a key drug for the treatment of
TB. It is critical that the quality of RMP suspensions
used to treat childhood TB is ensured.
K E Y WO R D S : tuberculosis; first-line drug; quality
assurance; children
FEW STUDIES have been conducted in children to
support drug dosing for tuberculosis (TB) or to
evaluate drug formulations.1 Instead, paediatric
doses have generally been extrapolated from those
used in adults. The World Health Organization
(WHO) reviewed the evidence on first-line anti-
tuberculosis drug formulation and dosage in children
and found that rifampicin (RMP) concentrations
were low and varied widely between and within
studies.2,3 Although sampling processes and assay
methods varied across studies, and forms of dosage,
methods of administration and dosing schedules were
not consistently described, experts concluded that the
RMP dose in children needed to be increased to
achieve concentrations comparable to those in adults.
TheWHO accordingly revised its dosing guidelines in
2010, recommending a 50% increase in the dose of
RMP, from 10 (8–12) to 15 (10–20) mg/kg.4 We
evaluated the pharmacokinetics of RMP, isoniazid
(INH), pyrazinamide (PZA) and ethambutol (EMB)
in children with TB at doses consistent with the
revised WHO guidelines. Here we report findings
regarding formulation effects on the pharmacokinet-
ics of RMP.
STUDY POPULATION AND METHODS
Children aged ,12 years diagnosed with drug-
susceptible TB who were receiving RMP, INH and
PZA (with or without EMB or ethionamide) in daily
doses at Red Cross Children’s Hospital, Tygerberg
Hospital and Khayelitsha District Hospital, Cape
Town, South Africa, were enrolled. The children were
treated using fixed-dose combination (FDC) products
available in the public health sector, with doses
approximating the WHO’s 2010 guidelines.4 Chil-
dren underwent pharmacokinetic evaluation after at
least 2 weeks of anti-tuberculosis treatment. On the
day of pharmacokinetic evaluation, single-drug for-
mulations of registered products were administered
by the study team, as FDC products providing doses
in accordance with the revised WHO recommenda-
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tions are not yet available. A granulate preparation of
RMP for suspension (Eremfatw, RIEMSER Arznei-
mittel, Germany, registered for use in several Euro-
pean countries) was reconstituted to a concentration
of 100 mg/5 ml and administered in accurately
measured doses of 10–20 mg/kg using a syringe, or
via a nasogastric tube in very young children. Due to
an interruption in the supply of Eremfat, R-Cinw
suspension (100 mg/5 ml; Aspen Pharmacare, Dur-
ban, South Africa, registered for use in South Africa)
was used in subsequently enrolled children.
Serial 0.6 ml blood samples were drawn to
determine the plasma pharmacokinetics of the anti-
tuberculosis drugs. A pre-dose sample and samples at
2 and 4 h after the dose were drawn in all 146
children. An additional sample was drawn at 8 h in 86
children; in 20 children additional samples were
taken at 1, 6 and 10 h; and in 40 children an
additional sample was drawn at 1, 6 and 8 h after the
dose. The samples were centrifuged to separate the
plasma within 0.5 h of sampling and stored immedi-
ately at708C until analysis.
The study (NCT01637558) protocol was approved
by the Human Research Ethics Committee of the
Faculty of Health Sciences, University of Cape Town,
Cape Town, and the South African Medicines
Control Council, Pretoria, South Africa.
RMP plasma concentrations were determined using
a liquid chromatography–mass spectrometry assay
validated according to Federal Drug Administration
(FDA) and European Medicines Agency (EMA)
guidelines.4–6 The samples were processed with a
protein precipitation extraction method using 20 ll
plasma with 500 ll acetonitrile containing a stable
isotope-labelled internal standard, RMP-D3. Five
microliters of the supernatant were injected onto the
high-performance liquid chromatography column.
Chromatographic separation was achieved on a
Discovery C18, 5 lm, 5034.6 mm analytical column
using acetonitrile, methanol and 0.1% formic acid in
water (6:1:3, v/v/v) as the mobile phase, delivered at a
constant flow rate of 400 ll/min. An AB Sciex API
3000 mass spectrometer (GenTech, Arcade, NY, USA)
was operated at unit resolution in the multiple-
reaction monitoring mode, monitoring the transition
of the protonated molecular ions at m/z 823.4 to the
product ions at m/z 791.4 for RMP and the protonated
molecular ions at m/z 826.5 to the product ions at m/z
794.4 for the internal standard. Electrospray ionisa-
tion was used for ion production. The assay was
validated over the concentration range of 0.117–30 lg/
ml. The combined accuracy and precision statistics of
the limit of quantification, low, medium and high
quality controls (three validation batches, n¼18) were
between 101% and 107%, and 2.7% and 3.7%,
respectively.
A truncated area under the RMP concentration-
time curve to 4 h after the dose (AUC0–4) was
computed as a measure of systemic RMP exposure
using the concentrations from the sampling times
common to all children (pre-dose, 2 and 4 h) in a non-
compartmental analysis. Concentrations below the
limit of quantification of the assay (respectively 95%,
0% and 2% for the pre-dose, 2 h and 4 h
concentrations) were imputed a value of 0.06 mg/l.
Differences between the groups of children receiving
Eremfat and R-Cin RMP suspensions were compared
using the Mann-Whitney U-test. Quantile regression
was used as a robust approach to adjust for the effects
of age, sex, dose per kg of body weight, human
immunodeficiency virus (HIV) status and adminis-
tration by nasogastric tube when evaluating the effect
of formulation on AUC0–4. Each of these variables
was tested separately, and then added to the base
model describing the effect of formulation on the
AUC0–4. Covariate effects with P, 0.2 were retained
in the final model. Non-compartmental analysis and
all statistical analyses were performed using Stata
13.1 (StataCorp LP, College Station, TX, USA).
The RMP content of the Eremfat and R-Cin
formulations was compared using product batches
used during the study. A fresh suspension of Eremfat
was prepared as described in the product insert. The
suspension was shaken well before 200 ll was added
to 40 ml methanol. Similarly, 200 ll of the well-
shaken R-Cin suspension from a freshly opened bottle
was added to 40 ml methanol. The two suspensions
were chromatographed with a gradient high-perfor-
mance liquid chromatography-ultraviolet assay at a
flow rate of 0.4 ml/min. Mobile phase A consisted of
a mixture of 0.1% formic acid in water and
acetonitrile (85:15, v/v), and mobile phase B consist-
ed of 0.1% formic acid in acetonitrile. A mobile phase
gradient was run from 100%A to 100% B over 3 min
and remained at 100% B for another minute before
returning to 100% over 0.5 min. Five microliters
were injected onto a Phenomenex Max-RP 3 l 5032
mm column (Phenomenex, Torrance, CA, USA), and
RMP was detected at a wavelength of 334 nm. A
similar method was used to evaluate the effect of
passage through a nasogastric tube on the RMP
concentrations in a RMP suspension.
RESULTS
Among the 146 children included in the analysis, 92
received Eremfat and 54 received R-Cin formulations
(Table 1). Children receiving R-Cin RMP suspension
were younger (median 0.88 vs. 1.97 years, P ,
0.001), and thus had lower body weight (median 8.37
vs. 11.48 kg, P , 0.001). They also received slightly
higher doses of RMP in mg/kg (median 16.51 vs.
14.95). The children underwent pharmacokinetic
sampling a median of 1.3 months (interquartile range
[IQR] 1.1–1.6) after starting anti-tuberculosis treat-
ment.
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Plasma RMP concentrations by time after dose are
shown in the Figure. The median 2 h concentration
was 6.54 mg/l (IQR 4.47–8.84) in children receiving
Eremfat, higher than the 1.59 mg/l (IQR 0.89–2.38)
for those receiving R-Cin (Figure). The median RMP
AUC0–4 was respectively 16.85 (IQR 11.80–23.24)
and 4.19 (IQR 2.68–6.68) mg.h/l in the groups who
received Eremfat and R-Cin RMP. When stratified by
age, the RMPAUC0–4 remained consistently lower in
children receiving R-Cin than in those who received
Eremfat (Table 2, P , 0.001).
In univariate quantile regression, R-Cin was
associated with a 12.81 mg.h/l (95% confidence
interval [CI]15.39 to10.23) reduction in AUC0–4
compared to Eremfat RMP. Age, sex, HIV status or
administration by nasogastric tube had no impact on
the model describing the effect of formulation on
AUC0–4. In the multivariate model adjusted for the
effect of RMP dose per kg of body weight (AUC0–4
increased by 0.48 mg.h/l, 95%CI 0.03 to 0.10, for
each 1 mg/kg increase in the dose), the strength of
association slightly increased, with administration of
R-Cin being associated with a 13.30 mg.h/l (95%CI
16.40 to10.20) reduction in AUC0–4 compared to
the administration of Eremfat RMP.
The RMP content of the two suspensions from the
respective batches used during the study were
equivalent, with RMP peak areas on the chromato-
gram for Eremfat and R-Cin solutions of respectively
2180 and 2047.
DISCUSSION
Under the National TB Control Programme, dispers-
ible FDCs are used to treat the majority of South
African children with TB. However, commercial
suspensions may be useful in the most vulnerable of
children requiring individualised care, including the
very young or critically ill.
RMP exposures were dependent on the paediatric
product used and were 76% lower among children
who received the R-Cin suspension than in those who
received Eremfat. While the children who received R-
Cin were younger and weighed less, they received, on
average, a higher dose of RMP per kg of body weight,
and the differences in AUC0–4 between the two
groups remained high (79%) even when adjusted
for the effect of dose per kg of body weight.
For adults, a 2 h target RMP concentration of 8–20
mg/l has been proposed,7 and recent studies suggest
that even higher exposures may be more effective.8–10
Despite the administration of a 15 mg/kg dose, as
recommended in the most recent WHO guidelines,
the median 2 h concentration achieved was only 1.59
mg/l (IQR 0.89–2.38) for children receiving R-Cin.
Those receiving Eremfat RMP had a median 2 h
concentration of 6.54 mg/l (IQR 4.47–8.84), in
keeping with concentrations reported in adults with
TB on standard anti-tuberculosis treatment,11 but
lower than the proposed target of 8–20 mg/l for
patients on standard treatment.
Although RMP may be adsorbed to certain plastics,
the results of the multivariate analysis found that
administration by nasogastric tube did not exert a
detectable effect on RMP exposures in the children.
We also measured RMP concentrations in an RMP
suspension passed through a nasogastric tube. Ali-
quots of suspension left to stand for 30 min at room
Table 1 Characteristics of enrolled children, RMP dose per kg of body weight, and administration by nasogastric tube on the day of
pharmacokinetic evaluation by RMP formulation
Formulation
EremfatW RMP (n ¼ 92)
median [IQR]
R-CinW RMP (n ¼ 54)
median [IQR] P value
Age, years 1.97 [0.94–4.37] 0.88 [0.5–2.47] ,0.001
Weight, kg 11.48 [8.27–15.45] 8.37 [5.7–13.3] ,0.001
HIV-infected, n (%)* 5 (5) 6 (11) 0.217
Female, n (%) 43 (47) 17 (31) 0.070
Dose, mg/kg 14.95 [12.20–16.68] 16.51 [14.85–18.67] 0.002
Nasogastric tube, n (%) 14 (15) 26 (48) ,0.001
*At the time of pharmacokinetic sampling, four children had not started antiretroviral treatment, one child was receiving an efavirenz-based regimen and the
remaining children were on lopinavir/ritonavir with two nucleoside reverse transcriptase inhibitors.
RMP¼ rifampicin; IQR¼ interquartile range; HIV¼ human immunodeficiency virus.
Figure Plasma RMP concentrations in 146 children during the
pharmacokinetic sampling interval for children who received
EremfatW RMP (grey diamonds) and R-CinW RMP (black circles).
The dotted line and solid lines track the median splines for the
concentrations after doses of Eremfat and R-Cin, respectively,
over time. RMP¼ rifampicin.
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temperature in three nasogastric tubes were found to
have similar RMP concentrations to a control aliquot
of the suspension (data not shown).
Several reports of substandard and counterfeit RMP-
containing products have been published. In most
instances, these reports are based on in vitro tests such
as the concentration of the active pharmaceutical
ingredient and disintegration.12–14 An analysis of the
RMP concentrations in the two formulations studied
revealed almost identical RMP content. This indicates
that the amount of RMP in R-Cin was adequate, and
that the drug was stable in the suspension.We therefore
hypothesise that the differences observed in bioavail-
ability are due to the mixture of polymorphic forms of
RMP in R-Cin that was not favourable for absorption.
Low RMP concentrations attributed to formulation
effects have been reported in adults with TB.15,16
Production of the active pharmaceutical ingredient
is complex and can lead to forms of the molecule with
variable solubility.17 RMP exists in anhydrous poly-
morphic forms (Form I and Form II), and also in
amorphous form.18 As Form II is metastable, suspen-
sionmy result in phase transition to a more stable form
with subsequent crystal growth. The water solubility
of RMP is reported to vary eight-fold depending on the
crystalline state of the material,19 altered particle size
affects solubility,20 and altered solubility is likely to
affect bioavailability. However, the relationship be-
tween solid-state RMP, dissolution and bioavailability
characteristics is poorly understood. Regulatory au-
thorities, including the FDA and the EMA, would
generally require in vivo bioequivalence testing for a
suspension of a drug such as RMP.21,22 Likewise, in
vivo bioequivalence studies are generally required for
suspensions under the South African Medicines
Control Council (MCC) guidelines. Although the
guidelines state that waivers based on comparative
dissolution studies may be acceptable,23 this condition
should not be applied to a Biopharmaceutics Classi-
fication System Class II drug such as RMP.24 The
methods used to test the active pharmaceutical
ingredient and final product, R-Cin, and the results
of such tests that were used to obtain MCC approval,
are unknown to the investigators, as both the
manufacturer and the regulatory authority regard this
information as confidential.
Our study was not designed to compare the
bioavailability of the formulations used, and the
estimates of the effect of formulation type on the
bioavailability of RMP were limited by a relatively
small sample size for accurate adjustment for poten-
tially confounding factors such as age, weight and
nasogastric tube use. Nor were accurate measures of
disease severity available for inclusion in the multivar-
iate analysis. However, the massive impact of formu-
lation on RMP exposures in these children is clear.
CONCLUSIONS
Our incidental findings reveal extremely low RMP
concentrations in children as a result of very poor
RMP bioavailability in a suspension licensed in South
Africa. The findings raise important questions about
the quality of the RMP-containing formulations
available for children and the procedures in place to
protect children from products that do not deliver
adequate drug exposures.
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R E S U M E
C O N T E X T E : Afin d’e´valuer la dose re´vise´e
recommande´e par l’Organisation Mondiale de la
Sante´ de 10–20 mg/kg de rifampicine (RMP), nous
avons e´tudie´ la pharmacocine´tique stable de la RMP
chez des enfants d’Afrique du Sud qui ont rec¸u un
traitement standard pour une tuberculose (TB)
pharmacosensible.
OB J E C T I F : De´terminer l’effet de la forme gale´nique sur
la pharmacocine´tique de la RMP.
S CH E´MA : Les concentrations plasmatiques de RMP
ont e´te´ mesure´es chez 146 enfants (aˆge me´dian 1,4 ans ;
fourchette 0,2–10,2 ans). La dose matinale le jour de
l’e´valuation pharmacocine´tique a e´te´ administre´e sous
forme de l’une des deux suspensions orales contenant
uniquement de la RMP.
R E´ S U LTAT S : Tandis qu’une formulation a abouti a` une
concentration a` 2 h dans la meˆme fourchette que les
adultes (me´diane 6,54 mg/l ; intervalle interquartile
[IQR] 4,478,84), l’autre a atteint une biodisponibilite´
me´diane de seulement 25% de celle-ci, avec une
concentration me´diane a` 2 h de 1,59 mg/l (IQR 0,89–
2,38).
CONC LU S I ON : La RMP est un me´dicament essentiel
pour le traitement de la TB. Il est crucial que la qualite´
des suspensions de RMP utilise´es pour le traitement des
enfants soit assure´e.
R E S UM E N
MARCO DE R E F E R ENC I A: Con el propo´sito de evaluar
la dosis revisada de 10–20 mg/kg de rifampicina (RMP)
que recomienda la Organizacio´n Mundial de la Salud, se
estudio´ el estado de equilibrio farmacocine´tico en los
nin˜os surafricanos que recibı´an un tratamiento corriente
por tuberculosis (TB) normosensible.
O B J E T I V O S: Determinar el efecto de la forma
farmace´utica en la farmacocine´tica de la RMP.
M E´ T O D O S: Se determinaron las concentraciones
plasma´ticas de RMP en 146 nin˜os (mediana de la edad
1,4 an˜os; intervalo 0,2–10,2). El dı´a de la evaluacio´n
farmacocine´tica la toma matinal se administro´ en una de
dos suspensiones que contienen solo RMP.
R E S U LTA D O S: Con una de las presentaciones se
alcanzaron en 2 h las concentraciones correspondientes
al intervalo observado en los adultos (mediana de 6,54
mg/l; intervalo intercuartil (IQR) 4,47–8,84); con la otra
suspensio´n se obtuvo solo el 25% de esta
biodisponibilidad, con una concentracio´n mediana a
las 2 h de 1,59 mg/l (IQR 0,89–2,38).
CONC LU S I O´ N: La RMP es un medicamento primordial
del tratamiento antituberculoso. Es fundamental
garantizar la calidad de las suspensiones de RMP que
se administran a los nin˜os durante el tratamiento de la
TB.
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